Details of Disease

General Information of Disease (ID: DISH9F1N)

• Disease Name: Carcinoma
• Synonyms: epithelioma; malignant epithelial tumour; malignant epithelial neoplasm; carcinoma, malignant; epithelioma malignant; Other carcinoma; malignant epithelioma; carcinoma; malignant epithelial tumor; epithelial carcinoma
• Disease Class: 2A00-2F9Z: Solid tumour/cancer
• Definition: A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.
• Disease Hierarchy:
  DIS0T594: Epithelial neoplasm
  DISAT1Z9: Advanced cancer
  DISH9F1N: Carcinoma
• ICD Code:
  ICD-11: ICD-11: 2A00-2F9Z
  ICD-10: ICD-10: D00-D09
  ICD-9: ICD-9: 230-234
  Expand ICD-11: 'XH63D2
  Expand ICD-9: 2.30E+14
• Disease Identifiers:
  MONDO ID: MONDO_0004993
  MESH ID: D002277
  UMLS CUI: C0007097
  MedGen ID: 2867
  HPO ID: HP:0030731
  SNOMED CT ID: 1187225007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Carboplatin	DMG281S	Approved	Small molecular drug	[1]
Cisplatin	DMRHGI9	Approved	Small molecular drug	[2]
Darbepoetin alfa	DMMJTYW	Approved	NA	[3]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[4]
Gadopentetate dimeglumine	DMJ62BV	Approved	Small molecular drug	[5]
Gemcitabine	DMSE3I7	Approved	Small molecular drug	[6]
Sorafenib	DMS8IFC	Approved	Small molecular drug	[7]
Vitamin C	DMXJ7O8	Approved	Small molecular drug	[8]
Picibanil	DM10C0L	Phase 4	Small molecular drug	[9]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BMS-986277	DM4RTJJ	Phase 1/2	NA	[10]

This Disease is Treated as An Indication in 4 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Theradigm-HPV	DMMBFEA	Discontinued in Phase 2	NA	[11]
RP-170	DMJ7LQ4	Terminated	Small molecular drug	[12]
TAN-1518A	DMBBG4E	Terminated	NA	[13]
ZK-119010	DMKFYDE	Terminated	Small molecular drug	[14]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 625 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCC1	TTOI92F	Limited	Altered Expression	[15]
ADCY5	TTN64VU	Limited	Biomarker	[16]
ALCAM	TT2AFT6	Limited	Altered Expression	[17]
ALK	TTPMQSO	Limited	Genetic Variation	[18]
ANGPTL4	TTWALY5	Limited	Biomarker	[19]
ANXA8	TTSW16P	Limited	Altered Expression	[20]
ASPH	TT2KHP7	Limited	Genetic Variation	[21]
ATP7B	TTOPO51	Limited	Biomarker	[22]
BMP2	TTP3IGX	Limited	Altered Expression	[23]
CBX7	TTBN3HC	Limited	Biomarker	[24]
CD274	TT8ZLTI	Limited	Altered Expression	[25]
CD40	TT1ERKL	Limited	Biomarker	[26]
CDK2	TT7HF4W	Limited	Biomarker	[27]
CDK4	TT0PG8F	Limited	Biomarker	[28]
CDK5R1	TTBYM6V	Limited	Altered Expression	[29]
CEACAM3	TTPX7I5	Limited	Biomarker	[30]
CEACAM5	TTY6DTE	Limited	Biomarker	[30]
CGA	TTFC29G	Limited	Biomarker	[31]
CGB3	TTUH273	Limited	Biomarker	[31]
CLDN6	TTKSV48	Limited	Altered Expression	[32]
CXCL12	TT4UGTF	Limited	Altered Expression	[33]
CXCR4	TTBID49	Limited	Biomarker	[34]
CYP19A1	TTSZLWK	Limited	Altered Expression	[35]
CYP1B1	TTI84H7	Limited	Biomarker	[36]
CYP2A6	TTAQ6ZW	Limited	Altered Expression	[37]
DIABLO	TTN74LE	Limited	Altered Expression	[38]
DLK1	TTF4AVB	Limited	Altered Expression	[39]
EGF	TTED8JB	Limited	Biomarker	[40]
EPCAM	TTZ8WH4	Limited	Biomarker	[41]
EPHA4	TTG84D3	Limited	Biomarker	[42]
EPHB2	TTKPV6O	Limited	Altered Expression	[43]
ERBB3	TTSINU2	Limited	Genetic Variation	[44]
EZH2	TT9MZCQ	Limited	Altered Expression	[45]
F9	TTFEZ5Q	Limited	Altered Expression	[46]
FGF4	TTCEKVZ	Limited	Altered Expression	[47]
FGF8	TTIUF3J	Limited	Altered Expression	[48]
FGFR3	TTST7KB	Limited	Genetic Variation	[49]
FN1	TTPJ921	Limited	Biomarker	[50]
FOLH1	TT9G4N0	Limited	Biomarker	[51]
FOXM1	TTD3KOX	Limited	Altered Expression	[52]
FURIN	TTH9WF6	Limited	Biomarker	[53]
G6PC	TTBQMJ8	Limited	Biomarker	[54]
GAST	TT4LRVO	Limited	Biomarker	[55]
GCLM	TTNFESW	Limited	Altered Expression	[56]
GDA	TTK4JTZ	Limited	Biomarker	[16]
GGT1	TTZVT7O	Limited	Biomarker	[16]
GHR	TTHJWYD	Limited	Altered Expression	[57]
GHRHR	TTG4R8V	Limited	Altered Expression	[58]
GPRC6A	TTI1PRE	Limited	Genetic Variation	[59]
GREM1	TTOUZN5	Limited	Altered Expression	[60]
GRIA2	TTWM461	Limited	Altered Expression	[61]
GSS	TTVEWR4	Limited	Biomarker	[16]
IGF2	TTE8WGO	Limited	Biomarker	[62]
KIT	TTX41N9	Limited	Altered Expression	[63]
KITLG	TTDJ51N	Limited	Biomarker	[53]
L1CAM	TTC9D3K	Limited	Biomarker	[64]
LGMN	TTPTWV5	Limited	Altered Expression	[65]
LPL	TTOF3WZ	Limited	Biomarker	[66]
MC2R	TTPWFDX	Limited	Altered Expression	[67]
MGMT	TTJ8DV7	Limited	Posttranslational Modification	[68]
MIF	TT6804T	Limited	Biomarker	[16]
MMP11	TTZW4MV	Limited	Biomarker	[69]
MRC1	TTKV8W5	Limited	Biomarker	[70]
MRGPRX1	TTIX6PK	Limited	Genetic Variation	[59]
MTA1	TTO4HUS	Limited	Biomarker	[71]
MTDH	TTH6SA5	Limited	Altered Expression	[72]
MUC16	TTC1PS3	Limited	Biomarker	[73]
MUTYH	TTNB0ZK	Limited	Genetic Variation	[74]
NACC1	TT4AQ5F	Limited	Altered Expression	[75]
NDUFA13	TTRU1NG	Limited	Genetic Variation	[76]
NTSR1	TTTUMEP	Limited	Biomarker	[77]
OXER1	TT7WBSV	Limited	Genetic Variation	[59]
PADI4	TTQHAXM	Limited	Biomarker	[16]
PDCD2	TTYOVWN	Limited	Altered Expression	[78]
PEBP1	TT1BGU8	Limited	Altered Expression	[79]
PHB	TT6U071	Limited	Biomarker	[16]
PIK3CB	TT9H4P3	Limited	Altered Expression	[44]
PLA2G1B	TT9V5JH	Limited	Altered Expression	[80]
PLAUR	TTNOSTX	Limited	Genetic Variation	[81]
PLD2	TTRLMKF	Limited	Altered Expression	[82]
PRKD1	TTSLUMT	Limited	Altered Expression	[83]
PRKDC	TTK3PY9	Limited	Biomarker	[84]
PTBP1	TTWMX0U	Limited	Genetic Variation	[85]
PTPN13	TT405FP	Limited	Biomarker	[86]
RAPGEF3	TTOE7I0	Limited	Altered Expression	[87]
RARB	TTISP28	Limited	Altered Expression	[88]
RASA1	TTPNZ1F	Limited	Genetic Variation	[89]
RHOA	TTP2U16	Limited	Genetic Variation	[90]
ROS1	TTSZ6Y3	Limited	Biomarker	[91]
RPE65	TTBOH16	Limited	Genetic Variation	[92]
RPSA	TTLUW5B	Limited	Genetic Variation	[92]
RUNX3	TTKCVO7	Limited	Biomarker	[93]
S1PR1	TT9JZCK	Limited	Biomarker	[16]
SCARB1	TTRE324	Limited	Biomarker	[16]
SCGB1A1	TTONPVW	Limited	Altered Expression	[94]
SCGB2A2	TT1W3RE	Limited	Altered Expression	[95]
SCN1A	TTANOZH	Limited	Altered Expression	[75]
SDC1	TTYDSVG	Limited	Altered Expression	[96]
SDHD	TTVH9W8	Limited	Genetic Variation	[97]
SGK1	TTTV8EJ	Limited	Biomarker	[98]
SKP2	TT5B2EO	Limited	Biomarker	[99]
SLC26A4	TT7X02I	Limited	Altered Expression	[100]
SNCG	TT5TQNZ	Limited	Biomarker	[53]
SOX2	TTCNOT6	Limited	Genetic Variation	[101]
STAT3	TTHJT3X	Limited	Biomarker	[102]
TACR1	TTZPO1L	Limited	Altered Expression	[103]
TEP1	TTQGAVX	Limited	Altered Expression	[104]
TERF1	TT1Y6J2	Limited	Altered Expression	[104]
TGFA	TTTLQFR	Limited	Biomarker	[105]
TKT	TT04R7I	Limited	Biomarker	[16]
TKTL1	TTNQ1J3	Limited	Altered Expression	[106]
TLN1	TTQSMFG	Limited	Biomarker	[107]
TLR4	TTISGCA	Limited	Altered Expression	[108]
TNKS	TTVUSO7	Limited	Altered Expression	[104]
TPT1	TT3PTB6	Limited	Altered Expression	[29]
TYMS	TTP1UKZ	Limited	Altered Expression	[109]
VCP	TTHNLSB	Limited	Biomarker	[110]
VHL	TTEMWSD	Limited	Biomarker	[111]
XDH	TT7RJY8	Limited	Biomarker	[16]
ANXA5	TT2Z83I	Disputed	Biomarker	[112]
KLK3	TTS78AZ	Disputed	Genetic Variation	[113]
LY96	TT8S9AV	Disputed	Biomarker	[114]
THBD	TTAPV67	Disputed	Altered Expression	[115]
ZWINT	TTWY768	Disputed	Altered Expression	[116]
ADAM8	TTQWYMD	moderate	Altered Expression	[117]
AGXT	TTF5NVW	moderate	Biomarker	[118]
ARG1	TT7ZQEV	moderate	Biomarker	[118]
AXL	TTZPY6J	moderate	Altered Expression	[119]
BAK1	TTFM7V0	moderate	Genetic Variation	[120]
BCL2A1	TTGT9C7	moderate	Altered Expression	[121]
BRD9	TTR7L5Y	moderate	Altered Expression	[122]
C5AR1	TTHXFA1	moderate	Biomarker	[123]
CA2	TTANPDJ	moderate	Altered Expression	[124]
CD200	TT0BE68	moderate	Altered Expression	[125]
CD276	TT6CQUM	moderate	Altered Expression	[126]
CD55	TT5Z9WY	moderate	Biomarker	[127]
CD74	TTCMYP9	moderate	Altered Expression	[128]
CDC20	TTBKFDV	moderate	Altered Expression	[129]
CDH11	TTRGWZC	moderate	Posttranslational Modification	[130]
CDH2	TT1WS0T	moderate	Altered Expression	[131]
CEBPA	TT5LWG1	moderate	Biomarker	[132]
CHEK1	TTTU902	moderate	Altered Expression	[133]
CMA1	TT8VUE0	moderate	Biomarker	[134]
CTAG1A	TTE5ITK	moderate	Altered Expression	[135]
CTCFL	TTY0RZT	moderate	Altered Expression	[136]
CTH	TTLQUZS	moderate	Altered Expression	[137]
CTSD	TTPT2QI	moderate	Biomarker	[138]
CXCR1	TTMWT8Z	moderate	Altered Expression	[139]
DDR1	TTI1FPZ	moderate	Altered Expression	[140]
DLL3	TT1C9K6	moderate	Altered Expression	[141]
DNAJB1	TTPXAWS	moderate	Biomarker	[142]
EGLN1	TT9ISBX	moderate	Altered Expression	[143]
ELAVL1	TTPC9D0	moderate	Biomarker	[144]
EPHA1	TTLFZVU	moderate	Altered Expression	[145]
EPHB1	TT8MDAC	moderate	Biomarker	[146]
EPHB3	TT5LM7U	moderate	Altered Expression	[147]
EPHB6	TTZEMUY	moderate	Altered Expression	[148]
ETS1	TTTGPSD	moderate	Altered Expression	[149]
FABP5	TTNT2S6	moderate	Altered Expression	[150]
FGF7	TTFY134	moderate	Altered Expression	[151]
FOLR1	TTVC37M	moderate	Altered Expression	[152]
FOSL2	TT689IR	moderate	Altered Expression	[153]
FOXC1	TTNT3YA	moderate	Biomarker	[154]
FUT4	TTNV1KZ	moderate	Altered Expression	[155]
GHSR	TTWDC17	moderate	Biomarker	[156]
GLUL	TTURQ2G	moderate	Biomarker	[157]
GRIK2	TT0K5RG	moderate	Biomarker	[158]
HK2	TTK02H8	moderate	Altered Expression	[159]
HLA-G	TTLKFB3	moderate	Altered Expression	[160]
HOXA7	TTMRE4Q	moderate	Biomarker	[161]
HPN	TT25MVL	moderate	Biomarker	[162]
ID1	TTBXVDE	moderate	Biomarker	[163]
IRF8	TTHUBNK	moderate	Posttranslational Modification	[164]
ITGA2	TTSJ542	moderate	Altered Expression	[165]
ITGA5	TTHIZP9	moderate	Biomarker	[166]
ITGAE	TTH0Z37	moderate	Altered Expression	[167]
KCNA5	TTW0CMT	moderate	Altered Expression	[168]
KDM4C	TTV8CRH	moderate	Posttranslational Modification	[169]
KLK2	TTJLNAW	moderate	Altered Expression	[168]
KLK4	TT4319X	moderate	Altered Expression	[170]
LHCGR	TT2O4W9	moderate	Biomarker	[171]
LONP1	TTM1VPZ	moderate	Biomarker	[172]
LOXL2	TTFSUHX	moderate	Altered Expression	[173]
LPAR3	TTE2YJR	moderate	Genetic Variation	[59]
LRP1	TTF2V7I	moderate	Biomarker	[174]
MAGEA2	TTOZT28	moderate	Biomarker	[175]
MAP3K11	TTETX6Q	moderate	Genetic Variation	[176]
MAPKAP1	TTWDKCL	moderate	Altered Expression	[177]
MMP14	TTJ4QE7	moderate	Altered Expression	[178]
MUC17	TTVO0JU	moderate	Genetic Variation	[122]
NAMPT	TTD1WIG	moderate	Posttranslational Modification	[179]
NEDD9	TT1UREA	moderate	Altered Expression	[180]
NOTCH4	TTXDIK2	moderate	Altered Expression	[181]
NPM1	TTHBS98	moderate	Genetic Variation	[182]
NR4A3	TTJQB49	moderate	Biomarker	[183]
NR5A2	TTAU3SY	moderate	Biomarker	[184]
NRG1	TTEH395	moderate	Genetic Variation	[185]
NTRK1	TTTDVOJ	moderate	Biomarker	[186]
PAK1	TTFN95D	moderate	Altered Expression	[187]
PDE5A	TTJ0IQB	moderate	Biomarker	[188]
PKN1	TTSL41O	moderate	Biomarker	[189]
PLK1	TTH4IP0	moderate	Altered Expression	[190]
PLP2	TTK5OG6	moderate	Biomarker	[191]
PMEL	TT8MK59	moderate	Biomarker	[192]
PML	TTLH9NY	moderate	Biomarker	[193]
PPM1D	TTENJAB	moderate	Altered Expression	[194]
PRDX4	TTPBL9I	moderate	Altered Expression	[195]
PROM1	TTXMZ81	moderate	Biomarker	[196]
PRSS1	TT2WR1T	moderate	Genetic Variation	[197]
PTGER4	TT79WV3	moderate	Altered Expression	[198]
RACK1	TTJ10AL	moderate	Altered Expression	[199]
RALBP1	TTVSRUA	moderate	Altered Expression	[200]
RARA	TTW38KT	moderate	Altered Expression	[201]
REG3A	TTL4H8N	moderate	Biomarker	[202]
RET	TT4DXQT	moderate	Altered Expression	[203]
ROR1	TTDEJAU	moderate	Biomarker	[204]
ROR2	TTUDPCI	moderate	Biomarker	[205]
RRM1	TTWP0NS	moderate	Altered Expression	[206]
RSPO3	TT7HJTF	moderate	Biomarker	[207]
SCUBE2	TTWREQP	moderate	Altered Expression	[208]
SENP1	TTW9HY5	moderate	Biomarker	[209]
SERPINB5	TT1KW50	moderate	Altered Expression	[210]
SERPINH1	TTPSWQG	moderate	Altered Expression	[211]
SIK1	TT1H6LC	moderate	Genetic Variation	[212]
SIRT3	TTVZLIJ	moderate	Altered Expression	[213]
SIRT6	TTUXYWF	moderate	Altered Expression	[214]
SLC12A3	TTP362L	moderate	Genetic Variation	[88]
SLC16A1	TTN1J82	moderate	Biomarker	[134]
SLC16A3	TTG6VD5	moderate	Biomarker	[215]
SLC34A2	TTQPZTM	moderate	Biomarker	[216]
SLC38A1	TT1YE9Z	moderate	Altered Expression	[217]
SLC3A2	TT5CZSM	moderate	Altered Expression	[218]
SLC5A2	TTF8JAT	moderate	Genetic Variation	[219]
SLC6A2	TTAWNKZ	moderate	Biomarker	[146]
SLCO1B3	TTU86P0	moderate	Altered Expression	[220]
SPHK2	TTCN0M9	moderate	Altered Expression	[221]
SPN	TTOZAX0	moderate	Altered Expression	[222]
SSTR2	TTZ6T9E	moderate	Biomarker	[223]
ST14	TTPRO7W	moderate	Altered Expression	[224]
ST8SIA4	TTDP8YM	moderate	Altered Expression	[225]
SYK	TT2HUPM	moderate	Posttranslational Modification	[226]
TBL1XR1	TTYXT16	moderate	Biomarker	[227]
TFAP2A	TTDY4BS	moderate	Altered Expression	[228]
TMBIM6	TT7QSMG	moderate	Altered Expression	[229]
TMPRSS11D	TTWHYC8	moderate	Altered Expression	[230]
TMSB4X	TTMVAIU	moderate	Biomarker	[231]
TNFRSF12A	TTKPS7V	moderate	Biomarker	[232]
TNFRSF25	TTDV6BQ	moderate	Biomarker	[233]
TNFSF13	TTOI1RM	moderate	Biomarker	[234]
TRIM59	TT613U4	moderate	Biomarker	[235]
UBE2E2	TTXJEOF	moderate	Biomarker	[236]
USP7	TTXU3EQ	moderate	Altered Expression	[237]
VEGFD	TTOM5H4	moderate	Altered Expression	[238]
XPA	TTGT87E	moderate	Biomarker	[239]
YES1	TT0SQ8J	moderate	Biomarker	[240]
ABCC2	TTFLHJV	Strong	Altered Expression	[241]
ABCC3	TTVLG21	Strong	Genetic Variation	[242]
ACACB	TTY84UG	Strong	Biomarker	[243]
ACKR3	TTRQJTC	Strong	Altered Expression	[244]
ACVR1	TTJNBQA	Strong	Altered Expression	[245]
ADAM9	TTTYQNS	Strong	Altered Expression	[117]
ADM	TTV14YH	Strong	Biomarker	[246]
AFP	TTCFEA1	Strong	Biomarker	[247]
AGR2	TT9K86S	Strong	Altered Expression	[248]
AKR1C3	TT5ZWB6	Strong	Altered Expression	[249]
AKT2	TTH24WI	Strong	Altered Expression	[250]
AKT3	TTO6SGY	Strong	Biomarker	[251]
ALOX15	TTN9T81	Strong	Altered Expression	[124]
ALPI	TTHYMUV	Strong	Altered Expression	[252]
ANXA1	TTUCK4B	Strong	Altered Expression	[253]
ANXA10	TT0NL6U	Strong	Altered Expression	[254]
ANXA2	TT4YANI	Strong	Biomarker	[255]
APEX1	TTHGL48	Strong	Biomarker	[256]
AQP1	TTSF1KH	Strong	Altered Expression	[257]
AQP3	TTLDNMQ	Strong	Altered Expression	[258]
AREG	TT76B3W	Strong	Biomarker	[259]
ASRGL1	TT4WT91	Strong	Altered Expression	[260]
ATR	TT8ZYBQ	Strong	Biomarker	[261]
ATRAID	TTFLIKM	Strong	Altered Expression	[262]
AURKA	TTPS3C0	Strong	Altered Expression	[263]
AZGP1	TTUPYLV	Strong	Biomarker	[264]
BAGE	TTS5GLJ	Strong	Altered Expression	[265]
BBC3	TT7JUKC	Strong	Genetic Variation	[266]
BCHE	TT3MSAO	Strong	Altered Expression	[267]
BCL2L1	TTRE6AX	Strong	Altered Expression	[268]
BGN	TT0JPVF	Strong	Altered Expression	[269]
BIRC2	TTQ5LRD	Strong	Biomarker	[270]
BMI1	TTIPNSR	Strong	Altered Expression	[271]
BRIP1	TTZV7LJ	Strong	Altered Expression	[272]
BSG	TT5UJWD	Strong	Biomarker	[273]
BUB1	TT78309	Strong	Altered Expression	[274]
C1QBP	TTWTD7F	Strong	Altered Expression	[275]
CACNA2D3	TTN7T29	Strong	Altered Expression	[276]
CALCA	TTVSFJW	Strong	Altered Expression	[277]
CALCRL	TTY6O0Q	Strong	Altered Expression	[246]
CAPN2	TTG5QB7	Strong	Altered Expression	[278]
CASP1	TTCQIBE	Strong	Genetic Variation	[279]
CASP10	TTX5HEK	Strong	Genetic Variation	[280]
CASP2	TT12VNG	Strong	Genetic Variation	[281]
CASP5	TTWR48J	Strong	Genetic Variation	[279]
CASP6	TTKW4ML	Strong	Genetic Variation	[282]
CASP7	TTM7Y45	Strong	Genetic Variation	[283]
CBR1	TTVG0SN	Strong	Altered Expression	[284]
CCKBR	TTVFO0U	Strong	Altered Expression	[55]
CCL21	TTLZK1U	Strong	Biomarker	[285]
CCND3	TT1JXNR	Strong	Biomarker	[286]
CD24	TTCTYNP	Strong	Altered Expression	[287]
CD248	TTYJWT7	Strong	Altered Expression	[288]
CD34	TTZAVYN	Strong	Biomarker	[289]
CD36	TTPJMCU	Strong	Altered Expression	[290]
CD40LG	TTIJP3Q	Strong	Biomarker	[26]
CD9	TTZEIBV	Strong	Altered Expression	[291]
CDC25B	TTR0SWN	Strong	Altered Expression	[292]
CDH1	TTLAWO6	Strong	Posttranslational Modification	[293]
CDH3	TTARMD9	Strong	Altered Expression	[294]
CDK1	TTH6V3D	Strong	Biomarker	[295]
CDKL1	TTBTI6P	Strong	Altered Expression	[275]
CDKN1B	TTLGFVW	Strong	Biomarker	[296]
CDKN2C	TTBRUGA	Strong	Genetic Variation	[297]
CEACAM1	TTA9CK4	Strong	Altered Expression	[298]
CEACAM6	TTIGH2W	Strong	Altered Expression	[299]
CEBPB	TTUI35N	Strong	Altered Expression	[300]
CFLAR	TTJZQYH	Strong	Altered Expression	[301]
CHEK2	TT9ABMF	Strong	Biomarker	[302]
CHUK	TT1F8OQ	Strong	Altered Expression	[303]
CLU	TTRL76H	Strong	Biomarker	[304]
COPS5	TTSTNJR	Strong	Biomarker	[305]
CR2	TT0HUN7	Strong	Biomarker	[306]
CRYZ	TTP6UO8	Strong	Genetic Variation	[307]
CSF1	TT0IQER	Strong	Altered Expression	[308]
CSF2	TTNYZG2	Strong	Biomarker	[309]
CSF3	TT5TQ2W	Strong	Therapeutic	[310]
CSK	TTX6F0Q	Strong	Altered Expression	[311]
CTSE	TTLXC4Q	Strong	Altered Expression	[312]
CTSK	TTDZN01	Strong	Altered Expression	[313]
CXCR2	TT30C9G	Strong	Biomarker	[314]
CYP1A2	TTS1DTU	Strong	Genetic Variation	[315]
CYP24A1	TT82UI1	Strong	Altered Expression	[316]
CYP3A5	TTHS0OK	Strong	Altered Expression	[317]
DCLK1	TTOHTCY	Strong	Altered Expression	[318]
DDR2	TTU98HG	Strong	Altered Expression	[140]
DEFB4A	TTIVY12	Strong	Altered Expression	[319]
DICER1	TTTEOPU	Strong	Altered Expression	[320]
DLL4	TTV23LH	Strong	Biomarker	[321]
DNMT1	TT6S2FE	Strong	Altered Expression	[322]
DUSP10	TTF3RJ0	Strong	Altered Expression	[323]
DUT	TTH6MBO	Strong	Altered Expression	[324]
DYRK1B	TTYGQ8A	Strong	Altered Expression	[325]
E2F1	TTASI04	Strong	Altered Expression	[326]
E2F3	TTWIJYH	Strong	Altered Expression	[327]
EHMT2	TTS6RZT	Strong	Altered Expression	[328]
EIF4E	TTZGCP6	Strong	Altered Expression	[329]
EIF4EBP1	TTKGEBL	Strong	Posttranslational Modification	[330]
EML4	TT92GY4	Strong	Biomarker	[331]
EPHA2	TTRJB2G	Strong	Altered Expression	[332]
EPHA5	TTV9KOD	Strong	Altered Expression	[333]
EPHA7	TTAHTVG	Strong	Posttranslational Modification	[334]
EPHB4	TTI4ZX2	Strong	Biomarker	[335]
ERBB4	TTWALCO	Strong	Altered Expression	[336]
EREG	TTYSB89	Strong	Biomarker	[259]
ETS2	TT9AH0M	Strong	Biomarker	[337]
EZR	TTE47YC	Strong	Biomarker	[338]
F11R	TT3C8EG	Strong	Genetic Variation	[339]
F8	TT1290U	Strong	Biomarker	[340]
FABP1	TTIV96N	Strong	Biomarker	[341]
FABP3	TT3TGLR	Strong	Biomarker	[342]
FANCF	TTNZKFJ	Strong	Posttranslational Modification	[343]
FAP	TTGPQ0F	Strong	Biomarker	[344]
FASN	TT7AOUD	Strong	Altered Expression	[345]
FBXW7	TT29KY7	Strong	Altered Expression	[346]
FECH	TTQ6VF4	Strong	Altered Expression	[347]
FGF1	TTMY81X	Strong	Biomarker	[348]
FKBP4	TTHY0FT	Strong	Altered Expression	[275]
FOSL1	TTY8LZG	Strong	Altered Expression	[349]
FOXQ1	TTEJZOL	Strong	Biomarker	[350]
FSCN1	TTTRS9B	Strong	Altered Expression	[351]
FSHR	TTZFDBT	Strong	Altered Expression	[352]
FUT3	TTUPAD7	Strong	Altered Expression	[353]
FZD7	TTUQMO5	Strong	Altered Expression	[354]
GAPDH	TTUGSWA	Strong	Biomarker	[355]
GATA3	TT45KOB	Strong	Altered Expression	[356]
GATA4	TT1VDN2	Strong	Posttranslational Modification	[357]
GGH	TTZJRL0	Strong	Altered Expression	[358]
GJB2	TTRGZX3	Strong	Altered Expression	[359]
GLB1	TTNGJPH	Strong	Altered Expression	[360]
GLI1	TTJOMH6	Strong	Altered Expression	[361]
GLO1	TTV9A7R	Strong	Altered Expression	[362]
GNAQ	TTL1SRG	Strong	Altered Expression	[363]
GNRHR	TT8R70G	Strong	Biomarker	[364]
GPA33	TT96HUR	Strong	Biomarker	[365]
GPR182	TTT23CG	Strong	Altered Expression	[366]
GRB2	TTEYRJ9	Strong	Biomarker	[367]
GRM1	TTVBPDM	Strong	Biomarker	[368]
GRPR	TTC1MVT	Strong	Biomarker	[369]
GSTO1	TTWO3SH	Strong	Genetic Variation	[370]
GUSB	TTHS7CM	Strong	Altered Expression	[371]
HDAC11	TT8K17W	Strong	Altered Expression	[372]
HDAC2	TTSHTOI	Strong	Altered Expression	[373]
HDGF	TTKGV26	Strong	Biomarker	[374]
HMGA2	TTSTVM0	Strong	Altered Expression	[375]
HMGCS2	TTS0EZJ	Strong	Altered Expression	[376]
HNF1A	TT01M3K	Strong	Genetic Variation	[377]
HNF4A	TT2F3CD	Strong	Biomarker	[378]
HOXB13	TTZ6I58	Strong	Genetic Variation	[379]
HRH4	TTXJ178	Strong	Altered Expression	[380]
HSP90B1	TTFPKXQ	Strong	Altered Expression	[381]
HSPA8	TTMQL3K	Strong	Genetic Variation	[382]
IAPP	TTHN8EM	Strong	Altered Expression	[252]
ID2	TTW8A5N	Strong	Altered Expression	[383]
IDO1	TTZJYKH	Strong	Biomarker	[384]
IGFBP3	TTZHNQA	Strong	Genetic Variation	[385]
IGFBP5	TTDWEA8	Strong	Altered Expression	[386]
IGFBP7	TTUQ01B	Strong	Altered Expression	[387]
IL11RA	TTZPLJS	Strong	Biomarker	[388]
IL12RB2	TT4SWR8	Strong	Biomarker	[389]
IL13RA2	TTMPZ7V	Strong	Altered Expression	[390]
IL15	TTJFA35	Strong	Altered Expression	[391]
IL24	TT1EPXZ	Strong	Altered Expression	[392]
IL9	TT0JTFD	Strong	Genetic Variation	[92]
ILK	TT7ALZG	Strong	Altered Expression	[393]
IRS1	TTAJSQ0	Strong	Genetic Variation	[394]
ITGA6	TT165T3	Strong	Altered Expression	[395]
ITGAV	TTT1R2L	Strong	Biomarker	[166]
ITK	TT3C80U	Strong	Altered Expression	[396]
KDM2A	TT8XTY2	Strong	Altered Expression	[397]
KDM3A	TTKXS4A	Strong	Altered Expression	[398]
KDM4A	TTZHPB8	Strong	Biomarker	[399]
KDM5B	TTCLI75	Strong	Biomarker	[400]
KISS1	TTU2O6T	Strong	Biomarker	[401]
KISS1R	TT3KBZY	Strong	Biomarker	[402]
KLK5	TTULSEW	Strong	Biomarker	[403]
KLK6	TTLPF4X	Strong	Altered Expression	[404]
KRT17	TTKV0EC	Strong	Altered Expression	[405]
KRT19	TT3JF9E	Strong	Altered Expression	[406]
LAG3	TTNVXAW	Strong	Biomarker	[407]
LANCL1	TTZW8NS	Strong	Genetic Variation	[92]
LASP1	TTZJA87	Strong	Altered Expression	[408]
LGR4	TTY6C71	Strong	Altered Expression	[409]
LGR5	TTTSGRH	Strong	Biomarker	[410]
LIN28A	TTO50LN	Strong	Biomarker	[411]
LTB	TTHQ6US	Strong	Altered Expression	[275]
LY6K	TT5GKHN	Strong	Biomarker	[412]
LYVE1	TTG8DNU	Strong	Altered Expression	[413]
MAD1L1	TTNE9U7	Strong	Altered Expression	[414]
MAGEA1	TT63M7Q	Strong	Altered Expression	[415]
MAGEA3	TTWSKHD	Strong	Altered Expression	[416]
MALT1	TTCI81G	Strong	Altered Expression	[417]
MAP3K2	TTIX0ZU	Strong	Posttranslational Modification	[418]
MAP3K8	TTGECUM	Strong	Genetic Variation	[419]
MAP4K1	TTSHWUP	Strong	Altered Expression	[420]
MAPK12	TTYT93M	Strong	Altered Expression	[421]
MAPK7	TTU6FSC	Strong	Biomarker	[422]
MARCKS	TTHRM39	Strong	Altered Expression	[423]
MCL1	TTL53M6	Strong	Altered Expression	[424]
MCM7	TT1RM3F	Strong	Altered Expression	[425]
MDM4	TT9OUDQ	Strong	Genetic Variation	[426]
MELTF	TT8OBT3	Strong	Biomarker	[427]
MIA	TT5HNVS	Strong	Genetic Variation	[428]
MLANA	TT362RB	Strong	Biomarker	[429]
MMP1	TTMX39J	Strong	Altered Expression	[430]
MMP10	TTXLEG7	Strong	Altered Expression	[431]
MMP15	TTNSTO3	Strong	Altered Expression	[432]
MMP21	TTYRF5E	Strong	Biomarker	[433]
MMP8	TTGA1IV	Strong	Altered Expression	[434]
MSH2	TTCAWRT	Strong	Genetic Variation	[435]
MSI1	TTSM4BA	Strong	Biomarker	[436]
MSMB	TTYH1ZK	Strong	Posttranslational Modification	[437]
MST1R	TTBQ3OC	Strong	Altered Expression	[438]
MTF1	TTTQDEO	Strong	Altered Expression	[439]
MYB	TT8V13P	Strong	Altered Expression	[440]
MYCN	TT9JBY5	Strong	Biomarker	[441]
MYD88	TTB6Q2O	Strong	Biomarker	[108]
NCAM1	TTVXPHT	Strong	Biomarker	[442]
NCL	TTK1V5Q	Strong	Biomarker	[443]
NCOA3	TT124R0	Strong	Altered Expression	[444]
NES	TTHZ752	Strong	Biomarker	[442]
NFKB2	TTKLNRV	Strong	Altered Expression	[275]
NOTCH3	TTVX7IA	Strong	Biomarker	[445]
NPEPPS	TT371QC	Strong	Genetic Variation	[113]
NPTX2	TTNJ5A6	Strong	Altered Expression	[446]
NR0B1	TTTK36V	Strong	Altered Expression	[447]
NR1H2	TTXA6PH	Strong	Genetic Variation	[448]
NRP2	TTRXUVC	Strong	Biomarker	[449]
NTRK3	TTXABCW	Strong	Altered Expression	[450]
OLFM4	TTK1CX7	Strong	Altered Expression	[451]
OSMR	TTAH0KM	Strong	Posttranslational Modification	[452]
OXTR	TTSCIUP	Strong	Biomarker	[453]
P2RX1	TTJW7B3	Strong	Biomarker	[454]
P2RX3	TT2THBD	Strong	Biomarker	[454]
P2RX4	TT1NLOA	Strong	Biomarker	[454]
P2RY1	TTA93TL	Strong	Biomarker	[454]
P2RY2	TTOZHQC	Strong	Biomarker	[454]
PBK	TTMY6BZ	Strong	Biomarker	[455]
PBRM1	TTH8ZRL	Strong	Altered Expression	[456]
PDK1	TTCZOF2	Strong	Biomarker	[457]
PDXP	TT9UYG4	Strong	Biomarker	[458]
PDZK1	TTDTBLM	Strong	Altered Expression	[459]
PECAM1	TT4EZB2	Strong	Biomarker	[460]
PGC	TT7K6AD	Strong	Altered Expression	[461]
PHGDH	TT8DRCK	Strong	Genetic Variation	[462]
PIGU	TT2LHI6	Strong	Altered Expression	[463]
PIM1	TTTN5QW	Strong	Biomarker	[172]
PINX1	TT4FJ3A	Strong	Biomarker	[464]
PKM	TT4LOT8	Strong	Biomarker	[465]
PLA2G2A	TTO8QRU	Strong	Altered Expression	[80]
PLCG1	TT6T4JI	Strong	Altered Expression	[466]
PLD1	TT3T17P	Strong	Altered Expression	[467]
PLK2	TT976FS	Strong	Biomarker	[468]
PNP	TTMCF1Y	Strong	Biomarker	[469]
POLB	TTA0XPV	Strong	Biomarker	[470]
PPARA	TTJ584C	Strong	Biomarker	[471]
PRDX5	TTLPJWH	Strong	Altered Expression	[472]
PRMT5	TTR1D7X	Strong	Biomarker	[473]
PSEN2	TTWN3F4	Strong	Altered Expression	[474]
PSIP1	TTH9LDP	Strong	Altered Expression	[475]
PSMB6	TT8EPLT	Strong	Biomarker	[476]
PTAFR	TTQL5VC	Strong	Altered Expression	[477]
PTGES	TTYLQ8V	Strong	Altered Expression	[478]
PTP4A2	TT1MHKD	Strong	Biomarker	[479]
PTPRB	TT64I9Q	Strong	Altered Expression	[480]
PTPRJ	TTWMKXP	Strong	Biomarker	[481]
PYGM	TTZHY6R	Strong	Biomarker	[482]
RAD51	TTC0G1L	Strong	Altered Expression	[483]
RBBP9	TTUA38Z	Strong	Altered Expression	[484]
RECK	TTRZBW7	Strong	Altered Expression	[485]
REG4	TTVZEHU	Strong	Altered Expression	[486]
RGS2	TTKB7T3	Strong	Altered Expression	[487]
RHBDF2	TTH1ZOP	Strong	Biomarker	[488]
RNASEL	TT7V0K4	Strong	Genetic Variation	[489]
RNPEP	TTD74YX	Strong	Altered Expression	[490]
RPS6KA6	TT3KYWB	Strong	Altered Expression	[491]
RSF1	TTMP86V	Strong	Altered Expression	[492]
RXRA	TT6PEUO	Strong	Genetic Variation	[493]
SAA1	TTY0DN9	Strong	Altered Expression	[494]
SCD	TT6RIOV	Strong	Biomarker	[53]
SEMA4D	TT5UT28	Strong	Altered Expression	[495]
SIK2	TTCUGZR	Strong	Altered Expression	[496]
SIRT2	TTLKF5M	Strong	Altered Expression	[497]
SLC19A1	TT09I7D	Strong	Altered Expression	[498]
SLC22A1	TTM5Q4V	Strong	Biomarker	[499]
SLC5A4	TTN7Y4P	Strong	Biomarker	[500]
SLC5A5	TTW7HI9	Strong	Biomarker	[501]
SLC6A5	TTI0138	Strong	Biomarker	[502]
SLCO1A2	TTUGD21	Strong	Altered Expression	[503]
SLIT2	TTDWK85	Strong	Altered Expression	[504]
SMAD6	TTON5JB	Strong	Altered Expression	[505]
SMAD7	TT0J32Z	Strong	Altered Expression	[506]
SMARCA4	TTVQEZS	Strong	Biomarker	[507]
SMYD2	TT7YJFO	Strong	Altered Expression	[508]
SMYD3	TTKLJYX	Strong	Biomarker	[418]
SOCS1	TT8COJM	Strong	Altered Expression	[509]
SOCS3	TTI0ME6	Strong	Altered Expression	[509]
SPDEF	TT2ZUPY	Strong	Altered Expression	[510]
SPHK1	TTOHFIY	Strong	Altered Expression	[511]
SRGN	TTCHB06	Strong	Altered Expression	[512]
SSRP1	TTETDKQ	Strong	Biomarker	[513]
SSTR1	TTIND6G	Strong	Altered Expression	[514]
SSTR5	TT2BC4G	Strong	Biomarker	[515]
STEAP2	TTOXF5J	Strong	Altered Expression	[516]
STK33	TTP34DQ	Strong	Biomarker	[517]
STMN1	TT7W5OT	Strong	Biomarker	[518]
STRAP	TT165DP	Strong	Biomarker	[519]
TACR2	TTYO0A3	Strong	Altered Expression	[103]
TAP1	TT7JZI8	Strong	Biomarker	[520]
TDGF1	TTN7HMG	Strong	Altered Expression	[521]
TDO2	TTXNCBV	Strong	Altered Expression	[522]
TENT4A	TT0XZ4Q	Strong	Altered Expression	[523]
TERF2	TT5XSLT	Strong	Biomarker	[524]
TGFBR2	TTZE3P7	Strong	Genetic Variation	[525]
TIAM1	TTNU6I5	Strong	Altered Expression	[526]
TNC	TTUCPMY	Strong	Genetic Variation	[527]
TNFRSF4	TTL31H0	Strong	Biomarker	[528]
TOP2A	TTCGY2K	Strong	Biomarker	[529]
TP53BP1	TTX4UE9	Strong	Altered Expression	[530]
TPBG	TT70MLA	Strong	Altered Expression	[531]
TPO	TT52XDZ	Strong	Altered Expression	[532]
TPX2	TT0PHL4	Strong	Altered Expression	[533]
TRIM27	TTTO3QN	Strong	Altered Expression	[534]
TRPM2	TTEBMN7	Strong	Biomarker	[535]
TRPV6	TTBK14N	Strong	Biomarker	[536]
TSG101	TTHU7JA	Strong	Altered Expression	[537]
TSHR	TT6NYJA	Strong	Altered Expression	[538]
TWIST1	TTX1MY7	Strong	Biomarker	[539]
TYMP	TTO0IB8	Strong	Altered Expression	[540]
UCHL1	TTX9IFP	Strong	Biomarker	[541]
UMPS	TTAFJUD	Strong	Biomarker	[542]
USP14	TTVSYP9	Strong	Genetic Variation	[543]
USP5	TTGYTMA	Strong	Altered Expression	[544]
VDAC1	TTAMKGB	Strong	Altered Expression	[545]
VEGFB	TTPJQHE	Strong	Biomarker	[546]
VEGFC	TT0QUFV	Strong	Altered Expression	[547]
VTCN1	TTCK85E	Strong	Altered Expression	[548]
WNK1	TTJ9UMX	Strong	Altered Expression	[549]
XIAP	TTK3WBU	Strong	Altered Expression	[550]
XPO1	TTCJUR4	Strong	Biomarker	[551]
XRCC5	TTCB9KW	Strong	Altered Expression	[552]
ZEB2	TTT2WK4	Strong	Altered Expression	[539]
ZNF146	TTJD1TI	Strong	Altered Expression	[553]
ZNF217	TTY3BRA	Strong	Biomarker	[554]
ACTG1	TTGAZF9	Definitive	Biomarker	[53]
CD70	TTNCIE0	Definitive	Biomarker	[555]
CLDN18	TT6PKBX	Definitive	Biomarker	[556]
CXCR5	TTIW59R	Definitive	Altered Expression	[557]
CYP26A1	TTD7Q0R	Definitive	Altered Expression	[558]
DNMT3B	TT6VZ78	Definitive	Biomarker	[559]
EIF5A	TTIVCNR	Definitive	Biomarker	[53]
FABP4	TTHWMFZ	Definitive	Biomarker	[53]
HNRNPA1	TTPJ9XK	Definitive	Biomarker	[53]
LAPTM4B	TTEJQT0	Definitive	Biomarker	[560]
MERTK	TTO7LKR	Definitive	Biomarker	[561]
MFGE8	TT1GLAJ	Definitive	Biomarker	[562]
MRC2	TTYVR8M	Definitive	Biomarker	[53]
NTN1	TT0AH4L	Definitive	Altered Expression	[563]
PDGFA	TTSM78N	Definitive	Biomarker	[53]
PRLR	TTBPXMA	Definitive	Biomarker	[564]
PTGS1	TT8NGED	Definitive	Altered Expression	[565]
PTN	TTA9EJK	Definitive	Biomarker	[53]
RBP4	TT0C8BY	Definitive	Biomarker	[53]
S100A6	TT716MY	Definitive	Biomarker	[53]
S100A9	TT0TMQG	Definitive	Biomarker	[566]
SRC	TT6PKBN	Definitive	Altered Expression	[567]
TAGLN	TTDRZ9H	Definitive	Biomarker	[568]
TF	TT8WXAV	Definitive	Biomarker	[53]
TMPRSS2	TT1GM2Z	Definitive	Genetic Variation	[569]
UCP2	TTSC2YM	Definitive	Biomarker	[53]

This Disease Is Related to 15 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC12A2	DTHKL3Q	Limited	Biomarker	[16]
SLC25A10	DTJYKDQ	Limited	Biomarker	[16]
SLC25A3	DTCRIWV	moderate	Biomarker	[570]
SLC26A1	DTJ785O	moderate	Altered Expression	[217]
SLC35A2	DT0567K	moderate	Altered Expression	[571]
ABCD3	DTGLZO4	Strong	Altered Expression	[572]
SLC16A10	DTPAQJO	Strong	Biomarker	[573]
SLC20A1	DTMULXV	Strong	Altered Expression	[574]
SLC22A17	DTXI9E6	Strong	Posttranslational Modification	[575]
SLC25A36	DTANQH4	Strong	Biomarker	[576]
SLC2A2	DTUJPOL	Strong	Biomarker	[577]
SLC30A9	DT2I79L	Strong	Biomarker	[578]
SLC39A1	DTLWPXS	Strong	Altered Expression	[579]
SLC45A3	DTGEFXH	Strong	Biomarker	[580]
SLCO6A1	DTIFXNS	Strong	Biomarker	[236]

This Disease Is Related to 43 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1B10	DEP6GT1	Limited	Biomarker	[581]
ALDH1A1	DE2JP1Y	Limited	Altered Expression	[271]
CYP1A1	DE6OQ3W	Limited	Altered Expression	[582]
EPHX1	DELB4KP	Limited	Biomarker	[16]
NAT2	DER7TA0	Limited	Biomarker	[583]
PSAT1	DEBS17P	Limited	Genetic Variation	[113]
CYP27B1	DE3FYEM	moderate	Altered Expression	[582]
CYP4B1	DEMF740	moderate	Altered Expression	[584]
GLS	DE3E0VT	moderate	Altered Expression	[585]
HPGD	DEHKSC6	moderate	Altered Expression	[586]
HSD3B1	DERDQWN	moderate	Genetic Variation	[587]
P4HA2	DE5EGK0	moderate	Altered Expression	[588]
PTGDS	DER3H9C	moderate	Biomarker	[589]
SAT1	DEMWO83	moderate	Altered Expression	[217]
UGT1A10	DEL5N6Y	moderate	Altered Expression	[571]
UGT1A3	DEF2WXN	moderate	Altered Expression	[571]
UGT1A4	DELOY3P	moderate	Altered Expression	[571]
UGT1A5	DEPF954	moderate	Altered Expression	[571]
UGT1A6	DESD26P	moderate	Altered Expression	[571]
UGT1A7	DEZO4N3	moderate	Altered Expression	[571]
UGT1A8	DE2GB8N	moderate	Altered Expression	[571]
UGT1A9	DE85D2P	moderate	Altered Expression	[571]
ABO	DESIA7R	Strong	Biomarker	[590]
ALDH1A2	DEKN1H4	Strong	Altered Expression	[493]
BAAT	DERA3OF	Strong	Genetic Variation	[591]
CYP3A7	DERD86B	Strong	Altered Expression	[317]
CYP4F3	DEFCMPI	Strong	Genetic Variation	[592]
DCXR	DE3FEV8	Strong	Biomarker	[593]
GGCT	DEKW6PB	Strong	Biomarker	[594]
GSTA4	DEH7XYP	Strong	Altered Expression	[595]
HAGH	DE05IKP	Strong	Altered Expression	[596]
HSD17B12	DE915QP	Strong	Biomarker	[597]
KYAT1	DES9MCU	Strong	Biomarker	[598]
LAP3	DENZF0O	Strong	Altered Expression	[599]
MINPP1	DE5Q1SP	Strong	Biomarker	[600]
NNMT	DECVGJ3	Strong	Biomarker	[601]
PARK7	DEPOVCH	Strong	Altered Expression	[602]
PGPEP1	DEVDR46	Strong	Biomarker	[202]
SCLY	DEH4TD6	Strong	Altered Expression	[603]
SULT2A1	DE0P6LK	Strong	Biomarker	[604]
THOP1	DE95LJC	Strong	Altered Expression	[605]
UGT2B7	DEB3CV1	Strong	Altered Expression	[606]
GSTT1	DE3PKUG	Definitive	Biomarker	[598]

This Disease Is Related to 986 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAMTS18	OTRMFI04	Limited	Biomarker	[607]
AFM	OTPOR8IO	Limited	Biomarker	[608]
AGO1	OTD3R434	Limited	Altered Expression	[609]
ALDH3A1	OTAYZZE6	Limited	Biomarker	[610]
ALDH7A1	OTV57BZD	Limited	Biomarker	[611]
ARL4A	OTAH2GFA	Limited	Biomarker	[612]
BAIAP2L1	OTZ71SK9	Limited	Genetic Variation	[613]
BASP1	OTF4VS5G	Limited	Biomarker	[16]
CA11	OT8RX3AJ	Limited	Altered Expression	[78]
CA8	OT9Y8GA8	Limited	Altered Expression	[78]
CAGE1	OTF3HI3N	Limited	Biomarker	[614]
CASK	OT8EF7ZF	Limited	Biomarker	[16]
CCDC6	OTXRQDYG	Limited	Altered Expression	[46]
CCDC88A	OT3SSYYC	Limited	Genetic Variation	[615]
CCN4	OT69BER9	Limited	Altered Expression	[616]
CD164	OTZ7FIU8	Limited	Altered Expression	[617]
CD226	OT4UG0KB	Limited	Biomarker	[618]
CDKN2B	OTAG24N1	Limited	Genetic Variation	[619]
CDX2	OTCG4TSY	Limited	Biomarker	[620]
CEACAM7	OTKFDTZY	Limited	Biomarker	[30]
CHGA	OTXYX5JH	Limited	Biomarker	[621]
CIB1	OT4BVCRU	Limited	Biomarker	[622]
CIP2A	OTVS2GXA	Limited	Altered Expression	[623]
CIZ1	OT3UKHPI	Limited	Altered Expression	[624]
CKAP4	OTDUC9ME	Limited	Genetic Variation	[92]
CMTM8	OTG28GH2	Limited	Altered Expression	[625]
CNN3	OTJTAXAP	Limited	Biomarker	[16]
COL5A1	OT24078H	Limited	Biomarker	[16]
CORO1A	OTVAZOHC	Limited	Biomarker	[19]
COX2	OTTMVBJJ	Limited	Altered Expression	[626]
CSH1	OT33HTRR	Limited	Biomarker	[627]
CSPP1	OTNX7GD4	Limited	Altered Expression	[628]
CTSZ	OTSCX2LL	Limited	Biomarker	[629]
CUL2	OTPF83PG	Limited	Genetic Variation	[630]
DAP	OT5YLL7E	Limited	Posttranslational Modification	[631]
DBI	OT884QY9	Limited	Biomarker	[16]
DCC	OT2C1SHW	Limited	Posttranslational Modification	[632]
DCTN6	OTI8PIN9	Limited	Biomarker	[633]
DES	OTI09KBW	Limited	Altered Expression	[634]
EEF1A1	OT00THXS	Limited	Biomarker	[16]
EFEMP1	OTZVUOOB	Limited	Biomarker	[16]
EFNA1	OTU2NUA2	Limited	Altered Expression	[635]
ENO1	OTB1KWJS	Limited	Biomarker	[16]
ESPL1	OTMGEVOK	Limited	Biomarker	[636]
ETV4	OT8C98UZ	Limited	Altered Expression	[637]
FBLN2	OTEHR7N7	Limited	Biomarker	[638]
FH	OTEQWU6Q	Limited	Biomarker	[639]
GALNT3	OT7M67WT	Limited	Altered Expression	[640]
GEMIN4	OTX7402E	Limited	Biomarker	[110]
GPR151	OT7EACU6	Limited	Genetic Variation	[59]
GTPBP2	OTOJ1KUA	Limited	Biomarker	[612]
HBA1	OTW2BQF4	Limited	Biomarker	[16]
HBP1	OTDPGGDV	Limited	Biomarker	[641]
HUWE1	OTFH6BJS	Limited	Altered Expression	[526]
ID3	OTUULW5Z	Limited	Biomarker	[16]
IFI27	OTI2XGIT	Limited	Biomarker	[633]
IL6ST	OT1N9C70	Limited	Genetic Variation	[642]
INSIG1	OTZF5X1D	Limited	Biomarker	[16]
INTS6	OT6GDV46	Limited	Altered Expression	[643]
KRT72	OTAXW63A	Limited	Altered Expression	[644]
LEMD1	OTII3FTO	Limited	Biomarker	[645]
LIN7A	OTFL3PUX	Limited	Biomarker	[16]
LZTS1	OTXXL864	Limited	Biomarker	[646]
MAGED2	OTMEWNSE	Limited	Altered Expression	[647]
MAN2C1	OT17VT8D	Limited	Biomarker	[648]
MARCKSL1	OT13J2FM	Limited	Biomarker	[649]
MDH2	OT7364GY	Limited	Biomarker	[16]
MEN1	OTN6U6V0	Limited	Genetic Variation	[650]
MEST	OT8Q4U8Y	Limited	Biomarker	[651]
MGP	OTZWU3FU	Limited	Altered Expression	[652]
MICU1	OTS7N0LE	Limited	Altered Expression	[653]
MRGPRX3	OTRKCCDS	Limited	Genetic Variation	[59]
MRGPRX4	OTOBHZVA	Limited	Genetic Variation	[59]
MRPL28	OT4LUTZU	Limited	Biomarker	[654]
MSH6	OT46FP09	Limited	Biomarker	[655]
MTA2	OTCCYIQJ	Limited	Altered Expression	[656]
MTA3	OTIA6C79	Limited	Altered Expression	[657]
MUC13	OTWKS9MF	Limited	Biomarker	[658]
NEU1	OTH9BY8Y	Limited	Altered Expression	[659]
NEURL1	OT2C4P70	Limited	Altered Expression	[659]
NIN	OTVH3M4Z	Limited	Biomarker	[660]
NKD1	OTY3MO97	Limited	Biomarker	[661]
NSMF	OTLTA24A	Limited	Biomarker	[16]
NXT1	OT0VO6AY	Limited	Biomarker	[654]
OCLN	OTSUTVWL	Limited	Altered Expression	[662]
OXT	OT48M72Z	Limited	Therapeutic	[663]
PDLIM7	OTAZVODU	Limited	Biomarker	[664]
PDZK1IP1	OTWA6M5K	Limited	Altered Expression	[665]
PIGR	OT6GLSUL	Limited	Altered Expression	[666]
PIK3R1	OT5BZ1J9	Limited	Biomarker	[667]
PKP2	OTJOVF68	Limited	Biomarker	[668]
POLH	OTN07WXU	Limited	Biomarker	[612]
POLR2F	OTF9T8I2	Limited	Altered Expression	[669]
PRDX1	OTZ3BEC4	Limited	Altered Expression	[670]
PRDX6	OTS8KC8A	Limited	Altered Expression	[670]
PROS1	OTXQWNOI	Limited	Genetic Variation	[113]
PSMC3IP	OT9UB5UO	Limited	Biomarker	[671]
PSMD2	OT6HZHN7	Limited	Biomarker	[110]
PSMD9	OT6Y5CC3	Limited	Biomarker	[633]
PTCH1	OTMG07H5	Limited	Altered Expression	[672]
PTGES3	OTPPQWI0	Limited	Altered Expression	[29]
RAD50	OTYMU9G1	Limited	Genetic Variation	[673]
RASGRP3	OTEMEV3P	Limited	Biomarker	[674]
RASSF1	OTEZIPB7	Limited	Posttranslational Modification	[675]
RBFOX1	OTFPKEL7	Limited	Biomarker	[612]
RHOBTB2	OT2DATFX	Limited	Altered Expression	[676]
RPA1	OT76POLP	Limited	Biomarker	[677]
RPL6	OTRU71O4	Limited	Biomarker	[16]
RRAS	OTBBF28C	Limited	Altered Expression	[29]
RSPH9	OTRAK1LK	Limited	Biomarker	[612]
SEC14L2	OTJST64D	Limited	Altered Expression	[678]
SGSM3	OTIB1P8A	Limited	Biomarker	[418]
SGTA	OTKOJ3JB	Limited	Biomarker	[679]
SMARCA2	OTSGJ8SV	Limited	Genetic Variation	[680]
SPINT2	OTQV7BKQ	Limited	Biomarker	[53]
STAT5A	OTBSJGN3	Limited	Altered Expression	[681]
TAS2R38	OTX5MM36	Limited	Altered Expression	[46]
TBXT	OTHCO2F0	Limited	Altered Expression	[682]
TFIP11	OT7NVSWU	Limited	Biomarker	[77]
TICAM2	OTK7GIJ5	Limited	Biomarker	[633]
TIMM8A	OTDX9687	Limited	Altered Expression	[683]
TIMP1	OTOXC51H	Limited	Altered Expression	[684]
TIMP3	OTDGQAD1	Limited	Altered Expression	[685]
TLE4	OT4QEH6T	Limited	Biomarker	[16]
TMED10	OTUXSHH7	Limited	Altered Expression	[29]
TMED7	OTONO8E6	Limited	Biomarker	[633]
TP53I3	OTSCM68G	Limited	Biomarker	[19]
TP63	OT0WOOKQ	Limited	Biomarker	[686]
CCNH	OTKDU3SR	Disputed	Biomarker	[687]
CDK2AP2	OTR99SJ8	Disputed	Biomarker	[566]
CTTN	OTJRG4ES	Disputed	Altered Expression	[688]
EGFL8	OTECTJ7K	Disputed	Altered Expression	[689]
HOXA10	OTB6GQ09	Disputed	Altered Expression	[690]
ID4	OTPMJ39I	Disputed	Biomarker	[691]
LAMTOR2	OTHEDISB	Disputed	Biomarker	[566]
LPXN	OTUNV3CK	Disputed	Biomarker	[692]
LSAMP	OTYXVQX2	Disputed	Biomarker	[693]
RASGRF2	OT67DAGF	Disputed	Biomarker	[687]
RPP14	OT4OYFSK	Disputed	Biomarker	[566]
SF3B6	OTPRKS6S	Disputed	Biomarker	[566]
SMARCA1	OT0Y6PTU	Disputed	Genetic Variation	[680]
SPRR3	OTN9QJKG	Disputed	Altered Expression	[694]
THBS2	OTXET551	Disputed	Altered Expression	[695]
ADAM19	OTH88TXU	moderate	Biomarker	[696]
ADAM28	OT3GBVHL	moderate	Biomarker	[697]
ADAMDEC1	OTMT7ZMG	moderate	Altered Expression	[117]
ALDOA	OTWRFTIB	moderate	Biomarker	[698]
ANKRD36B	OT3MW415	moderate	Altered Expression	[699]
APOBEC3B	OTHLNI51	moderate	Genetic Variation	[700]
APTX	OTPAS5G8	moderate	Biomarker	[701]
ARID1B	OTILK3Q7	moderate	Altered Expression	[702]
ARL11	OTF6UDDB	moderate	Biomarker	[703]
ARL2BP	OT7REEDA	moderate	Altered Expression	[704]
ASH1L	OTUT5NLJ	moderate	Altered Expression	[705]
ATF1	OT251CI0	moderate	Genetic Variation	[706]
ATP2A3	OTFYDEES	moderate	Altered Expression	[707]
ATRX	OT77RSQW	moderate	Altered Expression	[62]
AZIN2	OT8OB7CG	moderate	Altered Expression	[531]
BCAM	OTHZOPSD	moderate	Altered Expression	[708]
BHLHE40	OTITX14U	moderate	Biomarker	[709]
BSND	OTYWZWPD	moderate	Altered Expression	[704]
CAP1	OTYM8A2N	moderate	Biomarker	[710]
CASP8AP2	OTTWT68S	moderate	Genetic Variation	[711]
CCAR2	OTLUDG5T	moderate	Biomarker	[712]
CCNG2	OTII38K2	moderate	Biomarker	[713]
CD109	OTDADBM4	moderate	Biomarker	[714]
CD63	OT2UGZA9	moderate	Altered Expression	[715]
CDC6	OTX93FE7	moderate	Altered Expression	[716]
CDCP1	OTD7RRWK	moderate	Biomarker	[717]
CDH17	OT9EV2XK	moderate	Altered Expression	[718]
CDK2AP1	OTNFOHDJ	moderate	Biomarker	[719]
CEBPD	OTNBIPMY	moderate	Biomarker	[720]
CERS2	OTRAHYYP	moderate	Altered Expression	[721]
CHD1	OT9R9G0H	moderate	Biomarker	[569]
CLDN7	OTNE0XHQ	moderate	Altered Expression	[722]
CMTM3	OTS75IGC	moderate	Biomarker	[723]
COX5A	OTP0961M	moderate	Altered Expression	[724]
CPT1A	OTI862QH	moderate	Altered Expression	[725]
CRABP1	OTISDG5X	moderate	Biomarker	[726]
CRABP2	OTY01V9G	moderate	Biomarker	[727]
CTAG1B	OTIQGW6U	moderate	Altered Expression	[135]
CTU1	OTNTM9D1	moderate	Altered Expression	[728]
CUL4A	OTTBV70J	moderate	Altered Expression	[729]
CUL4B	OT2QX4DO	moderate	Altered Expression	[729]
CYLD	OT37FKH0	moderate	Genetic Variation	[730]
DAB2	OTRMQTMZ	moderate	Posttranslational Modification	[731]
DACT2	OTNLCC0K	moderate	Biomarker	[732]
DEDD	OTIL349E	moderate	Biomarker	[733]
DMP1	OTBWBWW7	moderate	Genetic Variation	[734]
DPT	OTINRFC7	moderate	Biomarker	[233]
EHF	OTY6TPWD	moderate	Genetic Variation	[735]
EIF3H	OT61RBF5	moderate	Altered Expression	[736]
EIF4A1	OTMTBX6N	moderate	Altered Expression	[737]
EIF4A2	OT08H03R	moderate	Altered Expression	[737]
EIF6	OTEXMUED	moderate	Altered Expression	[738]
ELF5	OTLRU8YF	moderate	Biomarker	[739]
ENO2	OTRODL0T	moderate	Biomarker	[621]
EPB41L3	OTS6CHG2	moderate	Altered Expression	[740]
FABP7	OTRE2H4G	moderate	Altered Expression	[741]
FBN2	OT3KYJQL	moderate	Altered Expression	[406]
FBXO5	OTTR957W	moderate	Biomarker	[742]
FLCN	OTVM78XM	moderate	Genetic Variation	[743]
FLII	OT7G9JG6	moderate	Altered Expression	[744]
FOXA2	OTJOCVOY	moderate	Altered Expression	[745]
FOXJ1	OT7LLBZ7	moderate	Altered Expression	[746]
FOXO4	OT90X9LN	moderate	Biomarker	[747]
GADL1	OTJM4A0R	moderate	Altered Expression	[531]
GATA5	OTO81B63	moderate	Posttranslational Modification	[357]
GATA6	OTO2BC0F	moderate	Altered Expression	[748]
GCNT1	OTF6OC66	moderate	Altered Expression	[749]
GEMIN2	OT4L6TLL	moderate	Altered Expression	[750]
GOLPH3	OTDLGYM3	moderate	Biomarker	[751]
GOT2	OT6XBWN0	moderate	Altered Expression	[752]
GPRC5A	OTPOCWR7	moderate	Altered Expression	[753]
HACE1	OTEZULKD	moderate	Posttranslational Modification	[754]
HAS2	OTTD3PAL	moderate	Altered Expression	[755]
HHEX	OTLIUVYX	moderate	Altered Expression	[756]
HIC1	OTI9TWY4	moderate	Altered Expression	[757]
HLA-E	OTX1CTFB	moderate	Biomarker	[758]
HOOK2	OTPO4NQV	moderate	Altered Expression	[168]
HOXC8	OTJUYU8J	moderate	Biomarker	[759]
ING5	OTRNNSFM	moderate	Altered Expression	[760]
INHBB	OT2QLD11	moderate	Biomarker	[761]
INPP4B	OTLROA7G	moderate	Altered Expression	[457]
INSM1	OTG8RV8E	moderate	Biomarker	[762]
ITGB4	OT28UK84	moderate	Biomarker	[763]
KDM2B	OTDMCVW7	moderate	Altered Expression	[764]
KIF2A	OT2WQ6QD	moderate	Altered Expression	[168]
KLF6	OTQY9S7F	moderate	Altered Expression	[765]
KLF8	OTUC5CDB	moderate	Altered Expression	[766]
KRT5	OTVGI9HT	moderate	Biomarker	[767]
KRT8	OTTM4X11	moderate	Posttranslational Modification	[768]
LAMA4	OTHI7TA0	moderate	Altered Expression	[769]
LARP6	OTUQ9QS9	moderate	Biomarker	[741]
LATS1	OTOOCG4R	moderate	Posttranslational Modification	[770]
LGR6	OTPZ1PWR	moderate	Genetic Variation	[59]
LHX2	OTK61NP8	moderate	Altered Expression	[771]
LRATD2	OTEZBUUL	moderate	Altered Expression	[772]
LRG1	OTLD0KWA	moderate	Biomarker	[773]
LRP1B	OT4YZG2N	moderate	Biomarker	[774]
LTBP3	OTME98V7	moderate	Biomarker	[775]
LYPLA1	OTENU47T	moderate	Biomarker	[520]
MACC1	OTV3DLX0	moderate	Altered Expression	[776]
MAD2L1	OTXNGZCG	moderate	Biomarker	[129]
MAP1LC3A	OTPMGIU4	moderate	Biomarker	[777]
MCAT	OTH07FIW	moderate	Biomarker	[134]
MCTS1	OT7SAOJP	moderate	Biomarker	[134]
MED15	OT0D0JVD	moderate	Altered Expression	[753]
MRE11	OTGU8TZM	moderate	Genetic Variation	[778]
MXD1	OTS5CTHX	moderate	Biomarker	[779]
MXI1	OTUQ9E0D	moderate	Biomarker	[129]
NAIF1	OT0B3H72	moderate	Biomarker	[780]
NETO2	OT0YAMC0	moderate	Altered Expression	[781]
NEUROD1	OTZQ7QJ2	moderate	Biomarker	[782]
NOB1	OTW0YNSL	moderate	Altered Expression	[783]
NTHL1	OTPQXPT1	moderate	Genetic Variation	[784]
OTX1	OTRGSGH9	moderate	Biomarker	[785]
P2RX5	OTLBR20R	moderate	Biomarker	[454]
P4HB	OTTYNYPF	moderate	Altered Expression	[786]
PCBP1	OTHN0TD7	moderate	Biomarker	[787]
PDHA1	OTGEU8IK	moderate	Altered Expression	[788]
PDS5B	OT3U3X8Z	moderate	Biomarker	[789]
PHF13	OT89FV4A	moderate	Altered Expression	[790]
PHF20	OTCBVH5P	moderate	Genetic Variation	[791]
PLCD1	OT6WFVXZ	moderate	Altered Expression	[792]
POLE	OTFM3MMU	moderate	Genetic Variation	[793]
PSG2	OT2EIXAI	moderate	Biomarker	[30]
PTPA	OTRGFOI7	moderate	Biomarker	[794]
PTPRA	OTZA82J1	moderate	Biomarker	[174]
PTPRU	OTHDO0QG	moderate	Biomarker	[570]
PTTG1	OTIMYS4W	moderate	Biomarker	[795]
RAB1A	OTKPHRD0	moderate	Biomarker	[796]
RAD21	OTQS84ZF	moderate	Biomarker	[797]
RAD51C	OTUD6SY5	moderate	Posttranslational Modification	[798]
RAD52	OT0OTDHI	moderate	Altered Expression	[799]
RAMP3	OTX6XLLM	moderate	Biomarker	[800]
RARRES1	OTETUPP5	moderate	Altered Expression	[753]
RBBP8	OTRHJ3GI	moderate	Altered Expression	[801]
REG1A	OTMHUH1D	moderate	Biomarker	[570]
RHOC	OTOLE1FT	moderate	Altered Expression	[802]
RPL31	OTV9E1OE	moderate	Altered Expression	[803]
RRAD	OTW2O4GD	moderate	Genetic Variation	[804]
RRAS2	OT83NCEB	moderate	Altered Expression	[805]
S100A10	OTI71243	moderate	Altered Expression	[167]
S100A2	OTTGHJ1H	moderate	Altered Expression	[304]
SCAF11	OTX59D0X	moderate	Altered Expression	[750]
SCARA3	OT46I38Y	moderate	Altered Expression	[806]
SCGN	OTGD7SKH	moderate	Biomarker	[621]
SCYL1	OTQ0IN7P	moderate	Altered Expression	[180]
SEL1L	OTC0FB7T	moderate	Altered Expression	[807]
SEMA3B	OTCZCPMS	moderate	Biomarker	[808]
SEMA3F	OTQFMS8S	moderate	Biomarker	[809]
SET	OTGYYQJO	moderate	Genetic Variation	[810]
SFRP1	OT0U9G41	moderate	Biomarker	[811]
SIRT7	OT5M4OT4	moderate	Biomarker	[812]
SLC16A4	OT1YXBKC	moderate	Biomarker	[215]
SMR3B	OTL5HNM8	moderate	Altered Expression	[813]
SOX7	OTOZOFAG	moderate	Altered Expression	[814]
SPINK1	OTSUVAL2	moderate	Altered Expression	[815]
SPRY2	OTH0CRCZ	moderate	Altered Expression	[816]
SRPX2	OT6A63TX	moderate	Altered Expression	[817]
STIL	OT9799VN	moderate	Biomarker	[192]
STK11IP	OTLQ6P8R	moderate	Biomarker	[818]
SUFU	OT0IRYG1	moderate	Altered Expression	[361]
SULT4A1	OT7AL3KJ	moderate	Biomarker	[819]
TBX3	OTM64N7K	moderate	Altered Expression	[820]
TCHP	OTVDMHSY	moderate	Biomarker	[821]
TESC	OTI8C76M	moderate	Genetic Variation	[88]
TET1	OTZDHT1D	moderate	Altered Expression	[822]
TFAP2C	OTUDIW05	moderate	Altered Expression	[823]
TFEB	OTJUJJQY	moderate	Biomarker	[824]
TGFBI	OTR443C5	moderate	Biomarker	[825]
THBS4	OTA1T9KK	moderate	Altered Expression	[826]
TM4SF1	OTY0ECQN	moderate	Altered Expression	[827]
TMEM158	OT0KUBBI	moderate	Biomarker	[828]
TMEM70	OTLTKYXG	moderate	Altered Expression	[236]
TNFAIP6	OT1SLUZH	moderate	Altered Expression	[829]
TNFAIP8L2	OTII0RM0	moderate	Biomarker	[830]
TOPBP1	OT6UPZPD	moderate	Altered Expression	[831]
TRAM1	OT3I0H8E	moderate	Biomarker	[233]
TRAP1	OTNG0L8J	moderate	Altered Expression	[832]
TRIM16	OTLRXYOZ	moderate	Altered Expression	[833]
TSPAN1	OTZQPIYK	moderate	Altered Expression	[834]
AATF	OT1QOKLD	Strong	Altered Expression	[267]
ABI3	OTQTDSHP	Strong	Altered Expression	[835]
ABI3BP	OTW8DN50	Strong	Altered Expression	[835]
ACSL5	OT3L9XO3	Strong	Biomarker	[836]
ACSM1	OT1TS9M9	Strong	Biomarker	[837]
ACTN4	OTCNZAJ5	Strong	Altered Expression	[838]
ADAM12	OTZKOTDB	Strong	Altered Expression	[839]
ADAM15	OTZ7VLTP	Strong	Altered Expression	[840]
ADAMTS8	OT2KFY1S	Strong	Posttranslational Modification	[841]
ADAMTS9	OTV3Q0DS	Strong	Posttranslational Modification	[842]
ADAR	OTQNOHR8	Strong	Genetic Variation	[843]
ADARB1	OTGKSZEV	Strong	Altered Expression	[844]
ADCY10	OTYSTB0R	Strong	Altered Expression	[845]
ADGRG2	OTPAD5S1	Strong	Altered Expression	[846]
AFAP1	OTR473H8	Strong	Altered Expression	[847]
AGO2	OT4JY32Q	Strong	Altered Expression	[848]
AHCYL2	OTGG9KYG	Strong	Biomarker	[849]
AIMP1	OTTA5C3U	Strong	Biomarker	[850]
AKAP12	OTCVRDDX	Strong	Altered Expression	[851]
ALKBH1	OTADGU5D	Strong	Biomarker	[852]
ALKBH2	OTSQW0BG	Strong	Biomarker	[853]
ALKBH8	OTXN70DV	Strong	Altered Expression	[854]
ALPP	OTZU4G9W	Strong	Altered Expression	[252]
AMPD1	OTU17BCI	Strong	Biomarker	[779]
ANGPTL1	OTXIN6V5	Strong	Altered Expression	[855]
ANKRD30A	OTJXYAE5	Strong	Biomarker	[856]
ANP32A	OTRHPFO2	Strong	Altered Expression	[857]
ANP32D	OTAGQSQ6	Strong	Biomarker	[858]
ANTXR1	OT5W1GPC	Strong	Altered Expression	[859]
AP2A1	OTEFZB21	Strong	Altered Expression	[228]
AP5Z1	OTXIPLFH	Strong	Biomarker	[860]
APBA1	OTUH9JPD	Strong	Biomarker	[861]
APBA2	OTXD8ID1	Strong	Biomarker	[862]
APOD	OTT77XW8	Strong	Biomarker	[863]
AQP5	OT77GBY8	Strong	Altered Expression	[257]
ARHGDIA	OTEXWJDO	Strong	Altered Expression	[802]
ARHGDIB	OT9PD6CS	Strong	Altered Expression	[864]
ARHGEF2	OTBQTFRT	Strong	Genetic Variation	[92]
ARID3B	OTUP9MS4	Strong	Altered Expression	[865]
ARID4B	OTYLPILE	Strong	Altered Expression	[866]
ARL6IP5	OTYZ6BEQ	Strong	Genetic Variation	[867]
ARMCX1	OTOGL58Z	Strong	Altered Expression	[868]
ARMCX2	OT9Q95J5	Strong	Altered Expression	[868]
ARMH1	OTTJC0D6	Strong	Genetic Variation	[92]
ASCL1	OTI4X44G	Strong	Biomarker	[869]
ASCL2	OT3D62WB	Strong	Biomarker	[870]
ASH2L	OT3HG324	Strong	Biomarker	[870]
ASPSCR1	OTXTOD10	Strong	Biomarker	[871]
ATAD3B	OTL508AF	Strong	Biomarker	[872]
ATG12	OTJRO09Y	Strong	Genetic Variation	[873]
ATP11A	OT7M9ZDK	Strong	Altered Expression	[874]
ATP13A3	OT5EGV3F	Strong	Altered Expression	[875]
ATP5F1E	OTMPLAIS	Strong	Altered Expression	[876]
ATP5IF1	OTQFD73H	Strong	Biomarker	[53]
ATP6V1E1	OT76J5R9	Strong	Altered Expression	[877]
AXIN1	OTRGZGZ5	Strong	Altered Expression	[878]
AXIN2	OTRMGQNU	Strong	Posttranslational Modification	[879]
B3GAT1	OTXFP98E	Strong	Genetic Variation	[880]
B4GALNT2	OT85V4QV	Strong	Posttranslational Modification	[881]
BAD	OT63ERYM	Strong	Altered Expression	[882]
BAG1	OTRQNIA4	Strong	Altered Expression	[883]
BAG3	OTVXYUDQ	Strong	Altered Expression	[167]
BAMBI	OTCEJ8W5	Strong	Biomarker	[884]
BCL10	OT47MCLI	Strong	Altered Expression	[268]
BCL2L10	OTYXQJ3I	Strong	Altered Expression	[885]
BID	OTOSHSHU	Strong	Genetic Variation	[886]
BLCAP	OTGJVU0C	Strong	Biomarker	[887]
BLM	OTEJOAJX	Strong	Genetic Variation	[888]
BMS1	OTEGQ8ZO	Strong	Biomarker	[243]
BNIP3	OT4SO7J4	Strong	Altered Expression	[167]
BRINP1	OTEUVSCP	Strong	Altered Expression	[889]
BTC	OTW4B2O0	Strong	Biomarker	[890]
BUB1B	OT8KME51	Strong	Biomarker	[779]
BUB3	OTU91HAU	Strong	Altered Expression	[891]
C12orf75	OTFVI3EY	Strong	Altered Expression	[892]
C1GALT1	OT2ZSZ6P	Strong	Biomarker	[893]
C1orf52	OT8RQW3W	Strong	Genetic Variation	[894]
CADM1	OTRWG9QS	Strong	Posttranslational Modification	[895]
CALB2	OTSNMCG9	Strong	Biomarker	[896]
CALM2	OTNYA92F	Strong	Biomarker	[897]
CAMK1D	OTU24HAU	Strong	Altered Expression	[898]
CAMKMT	OTLJBRUW	Strong	Biomarker	[897]
CAPS	OTC9GZ2M	Strong	Biomarker	[899]
CBX5	OT8VYY84	Strong	Altered Expression	[900]
CBX8	OT4U5V1T	Strong	Biomarker	[901]
CCDC136	OTPOV391	Strong	Biomarker	[902]
CCL28	OTY6XNQ7	Strong	Altered Expression	[903]
CCN6	OTRFHQ2Z	Strong	Biomarker	[904]
CCNA1	OTX4HD45	Strong	Biomarker	[905]
CCNB2	OTIEXTDK	Strong	Genetic Variation	[906]
CCNG1	OT17IA9L	Strong	Altered Expression	[907]
CCNL1	OTAJSS3D	Strong	Biomarker	[908]
CD247	OT45FGUX	Strong	Altered Expression	[909]
CD302	OTX580VU	Strong	Altered Expression	[910]
CD68	OTOYEY3J	Strong	Biomarker	[911]
CD82	OTH8MC64	Strong	Altered Expression	[912]
CD99	OTPUZ5DE	Strong	Biomarker	[913]
CDC42	OT5QBC5M	Strong	Genetic Variation	[914]
CDC73	OT6JASZ1	Strong	Biomarker	[915]
CDH13	OTD2CYM5	Strong	Altered Expression	[916]
CDH4	OT8LH3HN	Strong	Posttranslational Modification	[917]
CDK20	OTOLNN68	Strong	Altered Expression	[275]
CDKN2D	OT2TTZPZ	Strong	Altered Expression	[918]
CDKN3	OTBE3H07	Strong	Posttranslational Modification	[919]
CDX1	OTOHTMJE	Strong	Altered Expression	[920]
CEACAM4	OT0C7YUD	Strong	Altered Expression	[921]
CENPK	OTKPUF8K	Strong	Altered Expression	[275]
CFAP97	OT0RSQO4	Strong	Altered Expression	[922]
CFDP1	OTXY7J96	Strong	Biomarker	[110]
CHAF1A	OTXSSY4H	Strong	Biomarker	[923]
CHAF1B	OTOMK4KH	Strong	Biomarker	[923]
CHD5	OTS5EVHH	Strong	Altered Expression	[924]
CHFR	OTRAD2TT	Strong	Posttranslational Modification	[925]
CHPT1	OT4FJ0K3	Strong	Biomarker	[926]
CISH	OT8T5NYL	Strong	Biomarker	[724]
CKS1B	OTNUPLUJ	Strong	Altered Expression	[927]
CKS2	OTPTMHIV	Strong	Biomarker	[928]
CLDN1	OT27KV99	Strong	Biomarker	[929]
CLDN2	OTRF3D6Y	Strong	Altered Expression	[930]
CLDN3	OT71MN9S	Strong	Altered Expression	[931]
CLOCK	OTNEOJY7	Strong	Altered Expression	[932]
CLSPN	OTZZXNDK	Strong	Biomarker	[933]
CNOT7	OTJBKCPI	Strong	Biomarker	[923]
CNOT8	OT6CMCS0	Strong	Biomarker	[923]
COL11A2	OT3BQUBH	Strong	Biomarker	[934]
COL4A2	OTJK1LKN	Strong	Biomarker	[935]
COPS6	OTG9AAG0	Strong	Altered Expression	[936]
COX1	OTG3O9BN	Strong	Altered Expression	[565]
COX3	OTNNGBYJ	Strong	Altered Expression	[937]
COX8A	OTU0NR39	Strong	Biomarker	[938]
CPOX	OTIAY121	Strong	Altered Expression	[939]
CPT2	OTIN6G20	Strong	Biomarker	[926]
CREB3L2	OT09MHV0	Strong	Biomarker	[940]
CREBRF	OT2GK1HI	Strong	Altered Expression	[941]
CREM	OTJIJ5AL	Strong	Biomarker	[942]
CRISP2	OT8HLTV5	Strong	Altered Expression	[943]
CRISP3	OTBSWMPL	Strong	Biomarker	[944]
CRKL	OTOYSD1R	Strong	Altered Expression	[945]
CSMD1	OTIVDSC4	Strong	Biomarker	[946]
CSRNP1	OTDK1FPH	Strong	Altered Expression	[947]
CST6	OTZVHJTF	Strong	Altered Expression	[948]
CT83	OTQEGHAB	Strong	Altered Expression	[949]
CTBP1	OTVYH2DH	Strong	Altered Expression	[950]
CTCF	OT8ZB70U	Strong	Biomarker	[951]
CTHRC1	OTV88X2G	Strong	Altered Expression	[952]
CTNNA1	OTFC725Z	Strong	Genetic Variation	[953]
CTNNA2	OTJ8G92T	Strong	Genetic Variation	[954]
CTNNA3	OT9Z0P1E	Strong	Genetic Variation	[954]
CTNND1	OTUMPSHR	Strong	Biomarker	[955]
CTNND2	OTYKE30Y	Strong	Altered Expression	[956]
CXADR	OT9ZP02A	Strong	Genetic Variation	[957]
CXCL14	OTM189TA	Strong	Biomarker	[958]
CXCL16	OTD49T9R	Strong	Altered Expression	[959]
CXCL5	OTZOUPCA	Strong	Altered Expression	[960]
DACH1	OTMKNAGG	Strong	Altered Expression	[961]
DACT3	OTSNQ55G	Strong	Altered Expression	[962]
DAXX	OTX6O7PL	Strong	Altered Expression	[287]
DBN1	OTZVKG8A	Strong	Biomarker	[963]
DCUN1D1	OT8UJLZU	Strong	Biomarker	[684]
DDX43	OTK1RYSK	Strong	Altered Expression	[964]
DDX53	OTHK3EGZ	Strong	Biomarker	[233]
DEFB1	OT5SV0E4	Strong	Altered Expression	[965]
DHDH	OTKA2AL6	Strong	Biomarker	[966]
DIS3	OT7UPHJS	Strong	Altered Expression	[967]
DLC1	OTP8LMCR	Strong	Altered Expression	[968]
DLEU7	OTVKX1YP	Strong	Genetic Variation	[880]
DMBT1	OTVNU9D9	Strong	Altered Expression	[969]
DMTF1	OTDKO9OO	Strong	Genetic Variation	[970]
DNAJB4	OTUD01BK	Strong	Altered Expression	[971]
DOCK4	OTH3XY8B	Strong	Altered Expression	[946]
DROSHA	OTCE68KZ	Strong	Biomarker	[972]
DSG2	OTJPB2TO	Strong	Altered Expression	[973]
DUOX2	OTU14HCN	Strong	Biomarker	[974]
DUSP4	OT6WAO12	Strong	Biomarker	[975]
DVL2	OTMNYNCM	Strong	Genetic Variation	[976]
DVL3	OTPRROHJ	Strong	Altered Expression	[977]
DYNLL1	OTR69LHT	Strong	Altered Expression	[978]
E2F4	OTB3JFH4	Strong	Genetic Variation	[979]
EBNA1BP2	OTBRVMZH	Strong	Genetic Variation	[92]
EEF1A2	OT9Z23K5	Strong	Altered Expression	[980]
EFNB2	OT0DCUOM	Strong	Altered Expression	[981]
EIF1	OTB4GZ0V	Strong	Altered Expression	[982]
EIF1AX	OTWG2LAB	Strong	Genetic Variation	[983]
EIF2S1	OTM0GDTP	Strong	Altered Expression	[984]
EIF3A	OTFABY9G	Strong	Altered Expression	[982]
EIF3B	OTF67VPH	Strong	Biomarker	[985]
EIF3E	OTI0WG98	Strong	Altered Expression	[643]
EIF3I	OTE07WND	Strong	Biomarker	[982]
EIF4G2	OTEO98CR	Strong	Biomarker	[110]
ELOC	OT0XHHWP	Strong	Genetic Variation	[986]
EMD	OTR8ZANE	Strong	Biomarker	[987]
EML2	OTRX2NTA	Strong	Biomarker	[850]
EML5	OT0EFCPB	Strong	Biomarker	[850]
EMSY	OTBQ3KQE	Strong	Biomarker	[988]
EP400	OTVQ75NX	Strong	Altered Expression	[989]
EPHX3	OTU7LW2F	Strong	Altered Expression	[990]
EPS8	OTZ6ES6V	Strong	Biomarker	[991]
ERP29	OTNKANMH	Strong	Altered Expression	[992]
ETFA	OTXX61VZ	Strong	Biomarker	[993]
ETV5	OTE2OBM4	Strong	Biomarker	[994]
ETV6	OTCZMG61	Strong	Genetic Variation	[186]
EWSR1	OT7SRHV3	Strong	Biomarker	[706]
FAH	OTGZA1YR	Strong	Biomarker	[995]
FANCC	OTTIDM3P	Strong	Genetic Variation	[996]
FBP1	OTQBANEP	Strong	Altered Expression	[997]
FBRS	OTUVH446	Strong	Biomarker	[998]
FBXO8	OTZNGJGW	Strong	Biomarker	[998]
FERMT1	OT626PBA	Strong	Altered Expression	[999]
FEZ1	OTWCXPRE	Strong	Biomarker	[1000]
FGF13	OTHNNVSG	Strong	Genetic Variation	[396]
FGF6	OTRJ679P	Strong	Biomarker	[1001]
FGFBP2	OT3NBPQO	Strong	Altered Expression	[1002]
FLI1	OT0EV3LX	Strong	Altered Expression	[744]
FLNB	OTPCOYL6	Strong	Altered Expression	[1003]
FLNC	OT3F8J6Y	Strong	Posttranslational Modification	[1004]
FLOT2	OTZ0QR5L	Strong	Altered Expression	[1005]
FLVCR1	OT9XCFOC	Strong	Biomarker	[1006]
FOXA1	OTEBY0TD	Strong	Altered Expression	[1007]
FSTL1	OT6KEZUD	Strong	Altered Expression	[892]
FUT1	OTODG57A	Strong	Altered Expression	[1008]
FXYD3	OT9PPRHE	Strong	Altered Expression	[1009]
FXYD5	OT81DIOD	Strong	Altered Expression	[1010]
FZD5	OTXFFY56	Strong	Biomarker	[1011]
GADD45A	OTDRV63V	Strong	Altered Expression	[1012]
GALNT6	OTOQQVH1	Strong	Altered Expression	[1013]
GATA1	OTX1R7O1	Strong	Altered Expression	[1014]
GCA	OTAJ7ZHG	Strong	Biomarker	[1015]
GCFC2	OTC7FRXL	Strong	Altered Expression	[1016]
GDF1	OTZ1VRBH	Strong	Genetic Variation	[1017]
GDI2	OTGLY3I7	Strong	Biomarker	[1018]
GFI1	OT9HB9H8	Strong	Altered Expression	[1019]
GHRH	OT94U6MO	Strong	Biomarker	[1020]
GINS3	OT8NVXTD	Strong	Altered Expression	[1021]
GKN1	OT7ZYFQ9	Strong	Genetic Variation	[1022]
GLYAT	OT3WWYXD	Strong	Biomarker	[1023]
GORASP1	OTQS91S7	Strong	Altered Expression	[549]
GPX2	OTXI2NTI	Strong	Biomarker	[1024]
GPX3	OT6PK94R	Strong	Altered Expression	[167]
GREB1	OTU6ZA26	Strong	Altered Expression	[1025]
GRP	OT8JDFNI	Strong	Biomarker	[1026]
GSC	OT4DH7PR	Strong	Biomarker	[1027]
GSPT1	OT18H1B0	Strong	Altered Expression	[1028]
GSTK1	OTDNGWAF	Strong	Biomarker	[236]
GTF2H4	OTPD1DIU	Strong	Altered Expression	[275]
GZMM	OTEC5CWT	Strong	Biomarker	[1029]
H2AX	OT18UX57	Strong	Biomarker	[62]
H3-3B	OT9XHQ3C	Strong	Biomarker	[53]
H4C1	OTB71W46	Strong	Biomarker	[523]
HAS3	OTPM8IL8	Strong	Altered Expression	[1030]
HHIP	OT77RQYS	Strong	Altered Expression	[1031]
HILPDA	OTEID3ZM	Strong	Altered Expression	[1032]
HLTF	OTRX2OSF	Strong	Biomarker	[1033]
HMMR	OT4M0JTZ	Strong	Altered Expression	[1034]
HNF1B	OTSYIC3T	Strong	Biomarker	[1035]
HOXA4	OTNVTQDT	Strong	Altered Expression	[516]
HOXA9	OTKNK5H0	Strong	Biomarker	[1036]
HOXB1	OTGC0EKI	Strong	Altered Expression	[1037]
HOXB5	OTU74TB8	Strong	Biomarker	[1038]
HOXD10	OT0NOWU2	Strong	Altered Expression	[516]
HSPA14	OTZCA5LK	Strong	Biomarker	[1039]
HSPA1A	OTKGIE76	Strong	Altered Expression	[381]
HSPA2	OTSDET7B	Strong	Biomarker	[475]
HTN3	OTEUXA81	Strong	Biomarker	[604]
HYAL1	OT2SJN0X	Strong	Altered Expression	[1030]
HYAL2	OTTVINXW	Strong	Altered Expression	[1030]
HYAL3	OTG6VUSP	Strong	Altered Expression	[1030]
IARS1	OT9WXH5N	Strong	Biomarker	[408]
IBSP	OT29944Y	Strong	Altered Expression	[437]
IGF2BP1	OT9G360P	Strong	Altered Expression	[1040]
IGF2BP2	OT4ZSEEE	Strong	Biomarker	[1041]
IGFBP4	OT2HZRBD	Strong	Altered Expression	[1042]
IGFBPL1	OTY4HVN8	Strong	Posttranslational Modification	[1043]
IL17C	OTKXIVNQ	Strong	Biomarker	[1044]
ING1	OTEZBRKW	Strong	Altered Expression	[1045]
INHA	OT7HWCO3	Strong	Biomarker	[1046]
INSL3	OT7KUNTE	Strong	Biomarker	[1047]
IQGAP1	OTZRWTGA	Strong	Genetic Variation	[1048]
ISM2	OT4K7KON	Strong	Biomarker	[1049]
ITGA9	OTHN1IKA	Strong	Biomarker	[1050]
ITGAX	OTOGIMHE	Strong	Biomarker	[1051]
ITIH5	OTP46PZM	Strong	Altered Expression	[1052]
ITLN1	OT7ZLJVV	Strong	Altered Expression	[1053]
ITM2A	OT590V63	Strong	Biomarker	[1054]
JUNB	OTG2JXV5	Strong	Biomarker	[1055]
JUND	OTNKACJD	Strong	Biomarker	[1055]
KAT5	OTL7257A	Strong	Biomarker	[1056]
KAT7	OTUN98IC	Strong	Altered Expression	[1057]
KATNB1	OT7CLZKS	Strong	Genetic Variation	[1058]
KIF5B	OTT34MT8	Strong	Biomarker	[1059]
KLF5	OT1ABI9N	Strong	Biomarker	[1060]
KLHL1	OTAX6SAD	Strong	Altered Expression	[241]
KLHL31	OTXZVWDL	Strong	Biomarker	[1061]
KLHL5	OTRDVST4	Strong	Altered Expression	[1061]
KLK13	OT8LOD2U	Strong	Biomarker	[1062]
KRIT1	OT58AP1I	Strong	Biomarker	[897]
KRT14	OTUVZ1DW	Strong	Biomarker	[767]
KRT15	OTS6WLF7	Strong	Altered Expression	[1063]
KRT18	OTVLQFIP	Strong	Biomarker	[1064]
KRT7	OTLT3JFN	Strong	Altered Expression	[603]
LAMB1	OT6J9LJR	Strong	Altered Expression	[1065]
LDHB	OT9B1CT3	Strong	Altered Expression	[1066]
LEF1	OTWS5I5H	Strong	Biomarker	[1067]
LGALS4	OTKQCG0H	Strong	Altered Expression	[1068]
LGALS7	OTMSVI7R	Strong	Altered Expression	[1069]
LGALS8	OT71LJ8T	Strong	Altered Expression	[1070]
LHX6	OT47UQZ5	Strong	Posttranslational Modification	[1071]
LHX8	OT0DFL7C	Strong	Posttranslational Modification	[1072]
LIMS2	OTZ7IIPM	Strong	Altered Expression	[1073]
LIMS3	OTTMS7V8	Strong	Altered Expression	[1073]
LMAN1	OTYHKDEO	Strong	Altered Expression	[1074]
LMLN	OTQF0JPY	Strong	Posttranslational Modification	[437]
LOXL3	OTLLY1QI	Strong	Altered Expression	[173]
LOXL4	OT6XY2JL	Strong	Altered Expression	[172]
LPIN1	OTQ75KF2	Strong	Genetic Variation	[1075]
LRATD1	OT65IL83	Strong	Altered Expression	[1076]
LRCH1	OT0RCL85	Strong	Altered Expression	[967]
LRRC4	OT7XJ70N	Strong	Genetic Variation	[894]
LTBP4	OTC8WL2V	Strong	Altered Expression	[1077]
LUM	OTSRC874	Strong	Altered Expression	[1078]
LXN	OTZQ2M6Y	Strong	Altered Expression	[1079]
LYPD5	OTGP7UKA	Strong	Biomarker	[1080]
LZTS2	OTQFSQEE	Strong	Genetic Variation	[1081]
MAGEB2	OTAGUVU5	Strong	Biomarker	[1082]
MAGED4B	OTO37U7W	Strong	Altered Expression	[415]
MAGT1	OTQSAV5C	Strong	Altered Expression	[252]
MAK16	OTD546E5	Strong	Genetic Variation	[85]
MAL	OTBM30SW	Strong	Posttranslational Modification	[1083]
MAL2	OTVPEI80	Strong	Altered Expression	[1084]
MAP1LC3B	OTUYHB84	Strong	Altered Expression	[1085]
MAP2K4	OTZPZX11	Strong	Genetic Variation	[1086]
MAPK15	OT8SW0L7	Strong	Altered Expression	[1087]
MAPK6	OTDDNF3Q	Strong	Altered Expression	[421]
MAX	OTKZ0YKM	Strong	Biomarker	[132]
MB	OTYWYL2D	Strong	Altered Expression	[1088]
MBD1	OTD19VO6	Strong	Altered Expression	[1089]
MBD4	OTWR9YXE	Strong	Genetic Variation	[1090]
MCC	OTQVI1EM	Strong	Biomarker	[1091]
MCM2	OTGGORIQ	Strong	Altered Expression	[425]
MCM3	OTOOHQPM	Strong	Altered Expression	[1092]
MCPH1	OTYT3TT5	Strong	Altered Expression	[1093]
MDC1	OTEUQH4J	Strong	Biomarker	[1094]
MEF2A	OTV2SF6E	Strong	Altered Expression	[1095]
METTL9	OT3YR9B2	Strong	Biomarker	[202]
MGAT5	OTU4DD4G	Strong	Altered Expression	[1096]
MIP	OTEBLU3E	Strong	Genetic Variation	[1097]
MMP23B	OT2OR6TS	Strong	Biomarker	[433]
MMP25	OT3BG37V	Strong	Biomarker	[1098]
MMP26	OT9O89KU	Strong	Biomarker	[1099]
MMP28	OTHQZXM1	Strong	Altered Expression	[1100]
MOS	OTNMQPFJ	Strong	Genetic Variation	[1101]
MPG	OTAHW80B	Strong	Altered Expression	[1102]
MPST	OTCDPH5D	Strong	Altered Expression	[1103]
MRO	OT5U38CP	Strong	Genetic Variation	[1058]
MRPL41	OTG5URO4	Strong	Genetic Variation	[1104]
MSH3	OTD3YPVL	Strong	Biomarker	[1105]
MST1	OTOC4UNG	Strong	Posttranslational Modification	[437]
MTUS1	OTBPALMU	Strong	Altered Expression	[1106]
MUC21	OTQ8GP5L	Strong	Biomarker	[1107]
MUC3A	OTI4XUDY	Strong	Altered Expression	[1108]
MUC4	OTLT11V1	Strong	Biomarker	[1109]
MUC6	OTPVL723	Strong	Biomarker	[1110]
MUS81	OTVZ4E60	Strong	Altered Expression	[1111]
MVP	OTJGHJRB	Strong	Altered Expression	[1112]
NANOG	OTUEY1FM	Strong	Biomarker	[1113]
NAP1L1	OTI7WBZV	Strong	Biomarker	[1114]
NAPSA	OT6F8IAL	Strong	Biomarker	[1115]
NCOA1	OTLIUJQD	Strong	Altered Expression	[1116]
NCOA6	OTOMIGTV	Strong	Altered Expression	[320]
NCR3LG1	OT15YWU7	Strong	Biomarker	[1117]
NDC80	OTS7D306	Strong	Biomarker	[1118]
NDRG2	OT5L6KD7	Strong	Altered Expression	[1119]
NEIL1	OTHBU5DJ	Strong	Genetic Variation	[1120]
NET1	OTZHNMJV	Strong	Biomarker	[502]
NEU3	OTQ5PQOW	Strong	Altered Expression	[1121]
NFATC1	OT4TMERS	Strong	Biomarker	[1122]
NFIB	OTX94PD0	Strong	Altered Expression	[1123]
NKX2-1	OTCMEJTA	Strong	Altered Expression	[1124]
NLRP2	OTJA81JU	Strong	Altered Expression	[497]
NME2	OTCYGLHV	Strong	Genetic Variation	[1125]
NOLC1	OTKDZU0D	Strong	Biomarker	[1126]
NOX1	OTZPJQCC	Strong	Biomarker	[974]
NPC1	OTRIPICX	Strong	Genetic Variation	[1127]
NRDC	OTWBBCXO	Strong	Altered Expression	[1128]
NSD3	OT3677ZG	Strong	Biomarker	[1129]
NTN4	OTDRRMP3	Strong	Altered Expression	[1130]
NUDT1	OTZSES3W	Strong	Altered Expression	[523]
NUP43	OTDF5K8Y	Strong	Altered Expression	[275]
NXF1	OTEFHXG6	Strong	Altered Expression	[1003]
NXF2	OTJS5KTH	Strong	Biomarker	[1131]
OPTN	OT2UXWH9	Strong	Biomarker	[1114]
ORM1	OTZKSBRE	Strong	Genetic Variation	[1132]
OTX2	OTTV05B1	Strong	Biomarker	[1133]
OVOL2	OTFM1GKF	Strong	Altered Expression	[1134]
P2RX2	OT0LF34A	Strong	Biomarker	[454]
P2RX6	OT1FNTXA	Strong	Biomarker	[454]
PAIP2	OTFNVLSK	Strong	Altered Expression	[1135]
PAX2	OTKP1N8F	Strong	Biomarker	[1136]
PAX7	OTDMQRPO	Strong	Genetic Variation	[577]
PCBP2	OTXCN9CG	Strong	Altered Expression	[1137]
PCDH10	OT2GIT0E	Strong	Biomarker	[1138]
PCDHGC3	OTDXTUMI	Strong	Altered Expression	[1139]
PCLAF	OTMVIOUU	Strong	Altered Expression	[1140]
PCM1	OTFM133C	Strong	Biomarker	[1141]
PDAP1	OTJSWMOD	Strong	Biomarker	[202]
PDCD4	OTZ6NXUX	Strong	Altered Expression	[1142]
PDGFRL	OTJPRECT	Strong	Posttranslational Modification	[1143]
PDIA3	OTHPQ0Q3	Strong	Posttranslational Modification	[1144]
PDS5A	OT34P56Z	Strong	Biomarker	[1145]
PEG10	OTWD2278	Strong	Altered Expression	[1146]
PELP1	OTVXQNOT	Strong	Biomarker	[1147]
PER3	OTVKYVJA	Strong	Altered Expression	[1148]
PFKM	OT1QY9JM	Strong	Biomarker	[1149]
PGK1	OT6V1ICH	Strong	Altered Expression	[1150]
PI3	OT47MTC3	Strong	Altered Expression	[1151]
PIK3C3	OTLUM9L7	Strong	Biomarker	[1152]
PIK3R5	OT4LNXJU	Strong	Biomarker	[1153]
PINK1	OT50NR57	Strong	Altered Expression	[1154]
PIP	OTH719AH	Strong	Altered Expression	[1155]
PIWIL2	OT1PXQIF	Strong	Altered Expression	[1156]
PKHD1	OTAH8SMF	Strong	Genetic Variation	[1157]
PKP3	OTPL1HRB	Strong	Genetic Variation	[1158]
PLA2G6	OT5FL0WU	Strong	Altered Expression	[80]
PLCE1	OTJISZOX	Strong	Altered Expression	[792]
PLPP2	OT0BQAXX	Strong	Altered Expression	[844]
PMS2	OTNLWTMI	Strong	Biomarker	[1159]
PNO1	OT010GIS	Strong	Genetic Variation	[85]
POLD1	OTWO4UCJ	Strong	Genetic Variation	[1160]
POLD2	OTBNASP6	Strong	Biomarker	[1002]
POLK	OTKZ38JH	Strong	Altered Expression	[523]
POLL	OTZ24QGM	Strong	Altered Expression	[523]
POLM	OT0SRIP4	Strong	Biomarker	[1161]
POTEF	OTV3WXYE	Strong	Altered Expression	[1162]
POU1F1	OTXT8A5C	Strong	Altered Expression	[574]
POU2F1	OTK7ELJ0	Strong	Biomarker	[499]
PPFIA1	OTYYFA9C	Strong	Biomarker	[1163]
PPL	OTTM4WDO	Strong	Altered Expression	[1164]
PPP1R13L	OTNCPLWE	Strong	Genetic Variation	[1017]
PPP1R1B	OTSIJMQ9	Strong	Biomarker	[1165]
PPP1R3A	OTJL9VYP	Strong	Genetic Variation	[1166]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[1167]
PPP2R2A	OT9297OG	Strong	Biomarker	[1168]
PPP2R5C	OTF7CGO2	Strong	Genetic Variation	[1169]
PRB1	OTV0SYMD	Strong	Genetic Variation	[1170]
PRDM1	OTQLSVBS	Strong	Biomarker	[1171]
PRDM2	OT8L7CGX	Strong	Genetic Variation	[1172]
PROK1	OT8S7RUG	Strong	Biomarker	[189]
PROX1	OT68R6IO	Strong	Biomarker	[1173]
PRPF38B	OTQLH551	Strong	Biomarker	[502]
PRPS1	OTN3A6CN	Strong	Genetic Variation	[1174]
PRSS55	OTXXWI5Y	Strong	Altered Expression	[943]
PSD4	OTEFB87Z	Strong	Biomarker	[1175]
PSMA5	OT38E6Y1	Strong	Biomarker	[860]
PSMC6	OTG8997V	Strong	Altered Expression	[275]
PSMD7	OT7PZZ4K	Strong	Genetic Variation	[92]
PSMD8	OTY6X27P	Strong	Altered Expression	[877]
PTHLH	OTI1JF13	Strong	Biomarker	[1176]
PTMA	OT2W4T1M	Strong	Altered Expression	[1177]
PTMS	OT9PS4Q0	Strong	Altered Expression	[1177]
PTOV1	OT94WT5X	Strong	Altered Expression	[1178]
PTPN12	OT5WA666	Strong	Biomarker	[1179]
PTPRF	OTH5KF2D	Strong	Altered Expression	[1180]
PTPRM	OTCEL6PN	Strong	Altered Expression	[1181]
PTPRT	OTV5TXNN	Strong	Genetic Variation	[1182]
PXN	OTVMMUOF	Strong	Biomarker	[1183]
QRSL1	OTJDU2UG	Strong	Altered Expression	[1184]
QTRT1	OTC33MCV	Strong	Genetic Variation	[543]
RAB20	OTP9OOVS	Strong	Biomarker	[1185]
RAB3GAP1	OT4DQ8F2	Strong	Biomarker	[1126]
RAB40B	OTCA9ZF5	Strong	Biomarker	[1186]
RABEPK	OTCZSREH	Strong	Genetic Variation	[92]
RAD17	OT1I93DT	Strong	Biomarker	[1187]
RAD18	OTQ9PLNT	Strong	Biomarker	[1161]
RAD54L	OTEGMAKG	Strong	Genetic Variation	[1188]
RAMP1	OT7UT2XB	Strong	Biomarker	[246]
RAMP2	OTGQXLH5	Strong	Biomarker	[990]
RANBP2	OTFG5CVF	Strong	Biomarker	[958]
RAP2B	OTD2NDQP	Strong	Biomarker	[1189]
RB1	OT9VMY7B	Strong	Altered Expression	[1190]
RBBP4	OTG3BT3M	Strong	Altered Expression	[1191]
RBBP6	OTTVG4HU	Strong	Altered Expression	[1192]
RBL2	OTBQSOE6	Strong	Altered Expression	[1193]
RBM17	OT9ROJCL	Strong	Altered Expression	[1194]
RBMS3	OTFSC9MR	Strong	Genetic Variation	[85]
RBP2	OTR8QG5V	Strong	Biomarker	[1195]
RCC1	OT25AGMB	Strong	Biomarker	[1196]
RCHY1	OTAE7504	Strong	Biomarker	[1197]
RDH10	OTL9FSGF	Strong	Altered Expression	[493]
RECQL4	OT59LSW7	Strong	Biomarker	[1198]
RETREG1	OTYOSLZX	Strong	Altered Expression	[1199]
REV3L	OT0OP8EJ	Strong	Altered Expression	[1200]
RFC1	OT3L5PK3	Strong	Biomarker	[498]
RGCC	OTYJMLWM	Strong	Biomarker	[1201]
RHOBTB3	OT1BFKPH	Strong	Altered Expression	[1202]
RIOX2	OT2YFPI2	Strong	Altered Expression	[1203]
RIT2	OTSNYG0D	Strong	Biomarker	[1204]
RMDN3	OTKO7AUM	Strong	Altered Expression	[1205]
RNASE3	OTVE2XD1	Strong	Altered Expression	[1206]
RNASEH2B	OT8KHYFY	Strong	Genetic Variation	[843]
RNASET2	OTWY64L7	Strong	Biomarker	[1207]
RNF41	OTN1DQOY	Strong	Altered Expression	[1208]
RNH1	OT6EC79B	Strong	Genetic Variation	[1017]
RP9	OTGQY66H	Strong	Biomarker	[202]
RPL19	OT33LM66	Strong	Altered Expression	[1209]
RPL29	OTUFIBJL	Strong	Altered Expression	[1031]
RPS27A	OTIIGGZ2	Strong	Altered Expression	[1210]
RPS6	OTT4D1LN	Strong	Biomarker	[1211]
RRBP1	OT4ZTPTM	Strong	Altered Expression	[1212]
S100A5	OTCGGL6K	Strong	Biomarker	[1213]
S100A7	OTJFVJRF	Strong	Altered Expression	[1214]
SAA4	OTCE1WXO	Strong	Altered Expression	[494]
SAGE1	OT4H6FFA	Strong	Altered Expression	[964]
SALL1	OTYYZGLH	Strong	Posttranslational Modification	[179]
SALL4	OTC08PR5	Strong	Biomarker	[411]
SATB2	OT2W80XC	Strong	Altered Expression	[1215]
SBNO1	OTNX3RL0	Strong	Biomarker	[908]
SBNO2	OT1C6J3K	Strong	Biomarker	[908]
SCGB2A1	OT9L87U9	Strong	Biomarker	[1216]
SCO2	OTJQQDRS	Strong	Altered Expression	[540]
SCRT1	OTWTE24S	Strong	Altered Expression	[1217]
SCTR	OTC80IMR	Strong	Biomarker	[1218]
SEC62	OTCWEL5F	Strong	Biomarker	[1219]
SEPTIN10	OTPPNZUA	Strong	Biomarker	[1220]
SEPTIN4	OTD16B30	Strong	Genetic Variation	[1174]
SEPTIN9	OT1VMRFQ	Strong	Altered Expression	[1221]
SERPINB2	OT72QLZB	Strong	Altered Expression	[1222]
SESN2	OT889IXY	Strong	Altered Expression	[1223]
SETDB1	OTWVUA1B	Strong	Biomarker	[1224]
SF1	OTLEDM2S	Strong	Altered Expression	[447]
SFN	OTLJCZ1U	Strong	Biomarker	[1225]
SFRP2	OT8GZ0CA	Strong	Posttranslational Modification	[1226]
SFTPC	OTIZJD09	Strong	Altered Expression	[94]
SH3GLB1	OTAZ5OP8	Strong	Altered Expression	[1227]
SHC1	OT1J5IRN	Strong	Altered Expression	[134]
SHC3	OT305NPA	Strong	Genetic Variation	[1017]
SIGLEC12	OTC36XP9	Strong	Altered Expression	[1228]
SIGLEC9	OTZC7SIM	Strong	Biomarker	[1229]
SIM2	OT0QWHK4	Strong	Biomarker	[1230]
SIX2	OTYOVGSC	Strong	Biomarker	[1231]
SKIL	OTNBXH32	Strong	Biomarker	[908]
SLC25A43	OTY6MWVD	Strong	Altered Expression	[1232]
SLC26A8	OTNCW8RJ	Strong	Biomarker	[573]
SLC49A3	OTVE0LUV	Strong	Biomarker	[1233]
SLC49A4	OTXL3KAM	Strong	Biomarker	[1233]
SMC3	OTWGFRHD	Strong	Altered Expression	[1234]
SMG1	OTTS3SXE	Strong	Altered Expression	[300]
SNAI2	OT7Y8EJ2	Strong	Biomarker	[1235]
SNED1	OTBQVXY5	Strong	Altered Expression	[1236]
SNX1	OTXQSJ1J	Strong	Biomarker	[1237]
SOCS2	OTBPNKJQ	Strong	Altered Expression	[1238]
SOSTDC1	OTAKDNSM	Strong	Biomarker	[1239]
SOX10	OTF25ULQ	Strong	Biomarker	[1240]
SOX11	OT4LG7LA	Strong	Altered Expression	[1241]
SOX9	OTVDJFGN	Strong	Biomarker	[1242]
SPAG8	OTZC5XP9	Strong	Altered Expression	[1243]
SPARCL1	OT74DWMV	Strong	Altered Expression	[1244]
SPEN	OT37A2MD	Strong	Altered Expression	[1245]
SPINT1	OT1CLR5L	Strong	Biomarker	[1246]
SPTA1	OT1YMP65	Strong	Genetic Variation	[1247]
SPZ1	OTQH8HJ5	Strong	Altered Expression	[943]
SRF	OTW18FQN	Strong	Biomarker	[1248]
SRRM2	OTSIMMC9	Strong	Genetic Variation	[85]
SS18	OTDKHN1E	Strong	Biomarker	[913]
ST13	OTNML6UP	Strong	Altered Expression	[1031]
ST3GAL6	OTB17Q43	Strong	Posttranslational Modification	[881]
ST6GAL1	OT7US3NO	Strong	Altered Expression	[1249]
ST7	OTZG8RC6	Strong	Genetic Variation	[1250]
STAG2	OTR6X1Q7	Strong	Altered Expression	[1251]
STARD13	OTB4U1HY	Strong	Biomarker	[910]
STARD8	OTY9IAKW	Strong	Altered Expression	[1252]
STK11	OT1YZSP3	Strong	Altered Expression	[1253]
SUZ12	OT655XF8	Strong	Altered Expression	[1254]
SYCE1L	OTXU44F3	Strong	Altered Expression	[241]
SYP	OTFJKMO4	Strong	Biomarker	[621]
SYT1	OTVTPOI6	Strong	Altered Expression	[549]
TAFA4	OT0RHMNG	Strong	Biomarker	[1255]
TAPBP	OTL81AVZ	Strong	Altered Expression	[1256]
TBPL1	OT4I143E	Strong	Biomarker	[524]
TBX1	OTQLBPRA	Strong	Biomarker	[1257]
TCF21	OT393IMA	Strong	Biomarker	[1154]
TCF7	OT1ID822	Strong	Genetic Variation	[1258]
TDRD9	OTS4UBI8	Strong	Biomarker	[1259]
TFF3	OTJJDRTU	Strong	Biomarker	[1260]
TFG	OT2KJENI	Strong	Biomarker	[1261]
TFPI2	OTZCRWOR	Strong	Posttranslational Modification	[1262]
TG	OT3ELHIJ	Strong	Biomarker	[1124]
TJP2	OTQUY6BV	Strong	Altered Expression	[1263]
TMEM115	OT3OO484	Strong	Altered Expression	[1264]
TMEM132D	OTV6I4Z0	Strong	Biomarker	[1265]
TMEM8B	OTJZWPS6	Strong	Altered Expression	[1266]
TMPO	OTL68EL4	Strong	Biomarker	[1267]
TMPRSS13	OTMAOAP3	Strong	Posttranslational Modification	[437]
TMPRSS3	OT0GTO1Z	Strong	Altered Expression	[1268]
TMSB10	OTLVZ13T	Strong	Altered Expression	[1269]
TNFRSF6B	OTKAN9G7	Strong	Altered Expression	[1270]
TOMM34	OTH6MITE	Strong	Altered Expression	[1271]
TOX	OTE8BL5Z	Strong	Altered Expression	[1272]
TOX4	OTSOXQFN	Strong	Biomarker	[1118]
TP53INP2	OT0GTBXO	Strong	Altered Expression	[463]
TP73	OT0LUO47	Strong	Biomarker	[1273]
TPD52	OTPKSK43	Strong	Altered Expression	[1274]
TPM1	OTD73X6R	Strong	Altered Expression	[1275]
TPM3	OT5RU5G6	Strong	Biomarker	[186]
TRAF1	OTTLM5RU	Strong	Posttranslational Modification	[179]
TRAF4	OTJLRVMC	Strong	Altered Expression	[1276]
TRMT9B	OTU3UPEE	Strong	Altered Expression	[1277]
TRPS1	OT7XPPEL	Strong	Altered Expression	[1184]
TSC1	OTFF4YZ7	Strong	Genetic Variation	[88]
TSC2	OT47LWI9	Strong	Biomarker	[1278]
TSPAN8	OT1F68WQ	Strong	Biomarker	[1279]
TSTD1	OT5DMKFX	Strong	Genetic Variation	[1058]
TTF1	OT4K90WD	Strong	Altered Expression	[1124]
ABI1	OT5H4M62	Definitive	Altered Expression	[1280]
ACSL1	OTB06ESI	Definitive	Biomarker	[53]
ALKBH3	OTS1CD9Z	Definitive	Biomarker	[1281]
ANXA4	OTUCRYXL	Definitive	Biomarker	[53]
ARHGAP24	OTCQCEZS	Definitive	Biomarker	[1273]
ATG9A	OTAZWZH7	Definitive	Biomarker	[1282]
BCAR1	OTKT2C2N	Definitive	Altered Expression	[1283]
CAPZB	OTF1A4N0	Definitive	Biomarker	[53]
CDS1	OT2F591M	Definitive	Biomarker	[53]
CSN2	OT22C0PD	Definitive	Biomarker	[53]
CSN3	OTR61MI8	Definitive	Biomarker	[53]
DSC1	OTNII6GZ	Definitive	Altered Expression	[1284]
DSC2	OTODVH8K	Definitive	Biomarker	[1284]
DUSP6	OT4H6RKW	Definitive	Biomarker	[53]
ERG	OTOTX9VU	Definitive	Altered Expression	[569]
FABP9	OTTAEGAN	Definitive	Biomarker	[1285]
FBLN1	OT5MHHOP	Definitive	Biomarker	[1286]
FOSB	OTW6C05J	Definitive	Biomarker	[1055]
G0S2	OT8FL49L	Definitive	Biomarker	[53]
GATM	OTIJ4Z11	Definitive	Biomarker	[53]
GNAI2	OTTLGRGH	Definitive	Biomarker	[53]
ING3	OTDIJXFP	Definitive	Altered Expression	[1287]
KLLN	OTV3FPH0	Definitive	Altered Expression	[1288]
KRT71	OTI91X9Z	Definitive	Biomarker	[53]
LSR	OTR8Y32X	Definitive	Biomarker	[53]
MPP3	OTNOL0HA	Definitive	Biomarker	[1289]
MPZL1	OTJSUUHR	Definitive	Biomarker	[53]
MYCL	OT1MFQ5U	Definitive	Biomarker	[1290]
NAV3	OT97M1TR	Definitive	Genetic Variation	[1291]
NDN	OTYBYJ82	Definitive	Biomarker	[19]
OPCML	OT93PQ6Y	Definitive	Biomarker	[1292]
PGAM1	OTZ5DB06	Definitive	Biomarker	[53]
PLK3	OT19CT2Z	Definitive	Altered Expression	[1293]
PRDX2	OTLWCY9T	Definitive	Biomarker	[53]
PSMA4	OTAD2XXI	Definitive	Biomarker	[53]
PSME1	OTDHLJWH	Definitive	Biomarker	[53]
RAN	OT2TER5M	Definitive	Biomarker	[53]
RBP1	OTRP1MFC	Definitive	Biomarker	[1294]
RCN1	OT3JBGAG	Definitive	Biomarker	[53]
RPL3	OTX6VXLB	Definitive	Biomarker	[53]
RPS14	OTB90KV5	Definitive	Biomarker	[53]
SELENOP	OT02B8IR	Definitive	Biomarker	[53]
SNAI1	OTDPYAMC	Definitive	Altered Expression	[1295]
SNRPD3	OTZXBQ45	Definitive	Biomarker	[53]
SRSF2	OTVDHO6U	Definitive	Biomarker	[53]
SUB1	OTK71JYU	Definitive	Biomarker	[566]
TCERG1L	OTSBSCLF	Definitive	Biomarker	[1296]
THRSP	OTKYE01L	Definitive	Biomarker	[53]
TLE1	OT50MRZ1	Definitive	Altered Expression	[1297]
TM7SF2	OTILU5S7	Definitive	Altered Expression	[1298]
TMEM37	OT317PEL	Definitive	Biomarker	[19]
TSC22D1	OTN4GFWD	Definitive	Biomarker	[53]

References

• [1] Carboplatin FDA Label
• [2] Cisplatin FDA Label
• [3] DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiother Oncol. 2018 Apr;127(1):12-19.
• [4] Doxorubicin FDA Label
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Gemcitabine FDA Label
• [7] Sorafenib FDA Label
• [8] Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020 Dec;13(6):1010-1021.
• [9] ClinicalTrials.gov (NCT01699347) Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432. U.S. National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013929)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002563)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004281)
• [14] Pharmacological characterization of a novel oestrogen antagonist, ZK 119010, in rats and mice. J Endocrinol. 1991 Sep;130(3):409-14.
• [15] The association of taxane resistance genes with the clinical course of ovarian carcinoma.Genomics. 2013 Aug;102(2):96-101. doi: 10.1016/j.ygeno.2013.03.005. Epub 2013 Mar 28.
• [16] cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.Carcinogenesis. 2002 Oct;23(10):1561-8. doi: 10.1093/carcin/23.10.1561.
• [17] Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.Breast Cancer Res Treat. 2011 Sep;129(2):347-60. doi: 10.1007/s10549-010-1219-y. Epub 2010 Oct 23.
• [18] Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.Mod Pathol. 2019 Apr;32(4):524-531. doi: 10.1038/s41379-018-0173-9. Epub 2018 Nov 6.
• [19] Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas.Cancer Sci. 2011 Jul;102(7):1337-43. doi: 10.1111/j.1349-7006.2011.01955.x. Epub 2011 May 12.
• [20] New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.Am J Surg Pathol. 2008 Feb;32(2):188-96. doi: 10.1097/PAS.0b013e31815701f3.
• [21] Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.J Pathol. 2007 Jul;212(3):287-94. doi: 10.1002/path.2165.
• [22] Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts.Oncol Rep. 2008 Aug;20(2):265-70.
• [23] Switch of the ovarian cancer cell to a calcifying phenotype in the calcification of ovarian cancer.J Cancer. 2018 Feb 28;9(6):1006-1016. doi: 10.7150/jca.22932. eCollection 2018.
• [24] miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.BMC Cancer. 2017 Mar 4;17(1):170. doi: 10.1186/s12885-017-3158-z.
• [25] Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.Virchows Arch. 2019 May;474(5):599-608. doi: 10.1007/s00428-019-02528-6. Epub 2019 Feb 7.
• [26] CD40 Ligand Is Increased in Mast Cells in Psoriasis and Actinic Keratosis but Less So in Epithelial Skin Carcinomas.Cancer Invest. 2017 Mar 16;35(3):143-151. doi: 10.1080/07357907.2017.1289216. Epub 2017 Mar 7.
• [27] Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.Oncotarget. 2015 Sep 22;6(28):24690-8. doi: 10.18632/oncotarget.3992.
• [28] Abemaciclib for the treatment of breast cancer.Expert Opin Pharmacother. 2018 Apr;19(5):517-524. doi: 10.1080/14656566.2018.1448787. Epub 2018 Mar 9.
• [29] Function of HSP90 and p23 in the telomerase complex of thyroid tumors.Pathol Res Pract. 2003;199(9):573-9. doi: 10.1078/0344-0338-00464.
• [30] Use of cholesterol and soluble tumour markers CEA and syndecan-2 in pleural effusions in cases of inconclusive cytology.J Clin Pathol. 2019 Aug;72(8):529-535. doi: 10.1136/jclinpath-2018-205650. Epub 2019 Apr 26.
• [31] Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans.Biol Reprod. 1997 Jan;56(1):67-72. doi: 10.1095/biolreprod56.1.67.
• [32] Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma.Diagn Pathol. 2013 Nov 19;8:190. doi: 10.1186/1746-1596-8-190.
• [33] CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors.BMC Cancer. 2018 Jul 16;18(1):741. doi: 10.1186/s12885-018-4650-9.
• [34] Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells.Oncotarget. 2018 Feb 26;9(24):16996-17013. doi: 10.18632/oncotarget.24580. eCollection 2018 Mar 30.
• [35] Aromatase in human lung carcinoma.Steroids. 2011 Jul;76(8):759-64. doi: 10.1016/j.steroids.2011.02.020. Epub 2011 Mar 8.
• [36] Quinazoline derivatives as selective CYP1B1 inhibitors. Eur J Med Chem. 2017 Apr 21;130:320-327.
• [37] Overexpression of CYP2A6 in human colorectal tumors.Cancer Sci. 2007 Oct;98(10):1582-5. doi: 10.1111/j.1349-7006.2007.00572.x. Epub 2007 Aug 7.
• [38] Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas.Diagn Mol Pathol. 2007 Mar;16(1):1-8. doi: 10.1097/01.pdm.0000213471.92925.51.
• [39] Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice.Oncoimmunology. 2017 Feb 10;6(3):e1290035. doi: 10.1080/2162402X.2017.1290035. eCollection 2017.
• [40] EGF Level in Hepatoid Gland Adenomas and Hepatoid Gland Epitheliomas in Dogs After Administering Tamoxifen.In Vivo. 2018 Sep-Oct;32(5):1175-1181. doi: 10.21873/invivo.11361.
• [41] Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow.Mol Ther Oncolytics. 2019 Mar 23;14:38-56. doi: 10.1016/j.omto.2019.02.004. eCollection 2019 Sep 27.
• [42] Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer.Int J Oncol. 2008 Sep;33(3):573-7.
• [43] Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells.Exp Cell Res. 2014 Jan 15;320(2):233-46. doi: 10.1016/j.yexcr.2013.10.022. Epub 2013 Nov 6.
• [44] Biallelic ERBB3 loss-of-function variants are associated with a novel multisystem syndrome without congenital contracture.Orphanet J Rare Dis. 2019 Nov 21;14(1):265. doi: 10.1186/s13023-019-1241-z.
• [45] Epigenetic dysregulation of key developmental genes in radiation-induced rat mammary carcinomas.Int J Cancer. 2018 Jul 15;143(2):343-354. doi: 10.1002/ijc.31309. Epub 2018 Feb 23.
• [46] Mutual regulation of TGF-1, TRII and ErbB receptors expression in human thyroid carcinomas.Exp Cell Res. 2014 Sep 10;327(1):24-36. doi: 10.1016/j.yexcr.2014.06.012. Epub 2014 Jun 26.
• [47] Prognostic significance of hst-1 gene amplification in primary esophageal carcinomas and its relationship to other prognostic factors.Anticancer Res. 1994 Mar-Apr;14(2B):651-6.
• [48] Predominant expression of fibroblast growth factor (FGF) 8, FGF4, and FGF receptor 1 in nonseminomatous and highly proliferative components of testicular germ cell tumors.Virchows Arch. 2001 Nov;439(5):616-21. doi: 10.1007/s004280100437.
• [49] Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.Mod Pathol. 2019 Oct;32(10):1544-1550. doi: 10.1038/s41379-019-0276-y. Epub 2019 Apr 25.
• [50] Immunoexpression of E-cadherin, P-cadherin and fibronectin in gastric carcinomas.Rom J Morphol Embryol. 2019;60(2):573-579.
• [51] PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.Int J Mol Sci. 2019 Oct 2;20(19):4886. doi: 10.3390/ijms20194886.
• [52] Overexpression of forkhead box protein M1 (FOXM1) plays a critical role in colorectal cancer.Clin Transl Oncol. 2016 May;18(5):527-32. doi: 10.1007/s12094-015-1400-1. Epub 2015 Sep 14.
• [53] Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.Toxicol Pathol. 2005;33(7):768-75. doi: 10.1080/01926230500437027.
• [54] Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease.J Inherit Metab Dis. 2015 May;38(3):521-7. doi: 10.1007/s10545-014-9761-0. Epub 2014 Aug 28.
• [55] Characterization of gastrins and their receptor in solid human gastric adenocarcinomas.Scand J Gastroenterol. 2013 Jun;48(6):688-95. doi: 10.3109/00365521.2013.783101. Epub 2013 Apr 2.
• [56] Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma.Int J Cancer. 2002 Jan 1;97(1):21-7. doi: 10.1002/ijc.1574.
• [57] Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system.Mol Cell Endocrinol. 2002 Nov 29;197(1-2):153-65. doi: 10.1016/s0303-7207(02)00259-9.
• [58] Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer.Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):1-5. doi: 10.1097/PAI.0000000000000622.
• [59] MALT1 is a critical mediator of PAR1-driven NF-B activation and metastasis in multiple tumor types.Oncogene. 2019 Dec;38(49):7384-7398. doi: 10.1038/s41388-019-0958-4. Epub 2019 Aug 16.
• [60] Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation.Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14842-7. doi: 10.1073/pnas.0606857103. Epub 2006 Sep 26.
• [61] Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival.Br J Cancer. 2012 Jun 26;107(1):91-9. doi: 10.1038/bjc.2012.217. Epub 2012 May 29.
• [62] Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma.Am J Surg Pathol. 2018 Feb;42(2):201-213. doi: 10.1097/PAS.0000000000000943.
• [63] KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors.Am J Dermatopathol. 2015 Dec;37(12):898-905. doi: 10.1097/DAD.0000000000000301.
• [64] L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.Anticancer Res. 2019 Jan;39(1):421-424. doi: 10.21873/anticanres.13128.
• [65] Asparaginyl endopeptidase enhances pancreatic ductal adenocarcinoma cell invasion in an exosome-dependent manner and correlates with poor prognosis.Int J Oncol. 2018 May;52(5):1651-1660. doi: 10.3892/ijo.2018.4318. Epub 2018 Mar 15.
• [66] Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.Mod Pathol. 2002 Jan;15(1):35-44. doi: 10.1038/modpathol.3880487.
• [67] Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms.Clin Endocrinol (Oxf). 2001 May;54(5):627-32. doi: 10.1046/j.1365-2265.2001.01253.x.
• [68] Multiple Assays to Determine Methylguanine-Methyltransferase Status in Lung Carcinoids and Correlation with Clinical and Pathological Features.Neuroendocrinology. 2020;110(1-2):1-9. doi: 10.1159/000500158. Epub 2019 Jun 12.
• [69] MMP-11 promoted the oral cancer migration and Fak/Src activation.Oncotarget. 2017 May 16;8(20):32783-32793. doi: 10.18632/oncotarget.15824.
• [70] p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.J Pathol. 2020 Mar;250(3):336-345. doi: 10.1002/path.5375. Epub 2020 Jan 29.
• [71] MTA1 gene silencing inhibits invasion and alters the microRNA expression profile of human lung cancer cells.Oncol Rep. 2012 Jul;28(1):218-24. doi: 10.3892/or.2012.1770. Epub 2012 Apr 20.
• [72] A novel metadherin7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFB-SIRT3 axis.Oncogene. 2020 Mar;39(10):2088-2102. doi: 10.1038/s41388-019-1126-6. Epub 2019 Dec 5.
• [73] Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.Medicine (Baltimore). 2018 Apr;97(16):e0358. doi: 10.1097/MD.0000000000010358.
• [74] Cancer-associated variants and a common polymorphism of MUTYH exhibit reduced repair of oxidative DNA damage using a GFP-based assay in mammalian cells.Carcinogenesis. 2012 Nov;33(11):2301-9. doi: 10.1093/carcin/bgs270. Epub 2012 Aug 26.
• [75] Cancer-related transcription regulator protein NAC1 forms a protein complex with CARM1 for ovarian cancer progression.Oncotarget. 2018 Jun 19;9(47):28408-28420. doi: 10.18632/oncotarget.25400. eCollection 2018 Jun 19.
• [76] Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid.Br J Cancer. 2005 May 23;92(10):1892-8. doi: 10.1038/sj.bjc.6602547.
• [77] Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease.Clin Cancer Res. 2000 Feb;6(2):566-71.
• [78] Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer.Virchows Arch. 2003 Jan;442(1):66-70. doi: 10.1007/s00428-002-0721-y. Epub 2002 Dec 5.
• [79] RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy.PLoS One. 2013;8(3):e59104. doi: 10.1371/journal.pone.0059104. Epub 2013 Mar 19.
• [80] Expression of group XIIA phospholipase A2 in human digestive organs.APMIS. 2014 Dec;122(12):1171-7. doi: 10.1111/apm.12280. Epub 2014 May 26.
• [81] Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group.Am J Pathol. 2009 Jun;174(6):2246-53. doi: 10.2353/ajpath.2009.080785. Epub 2009 May 12.
• [82] Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma.Hum Pathol. 2017 Apr;62:115-121. doi: 10.1016/j.humpath.2016.12.023. Epub 2017 Jan 11.
• [83] Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.Cell Mol Life Sci. 2018 Mar;75(5):939-963. doi: 10.1007/s00018-017-2681-z. Epub 2017 Oct 25.
• [84] Tumor DNA-dependent protein kinase catalytic subunit expression is associated with hepatitis B surface antigen status and tumor progression in patients with hepatocellular carcinoma.Sci Rep. 2018 Oct 9;8(1):15019. doi: 10.1038/s41598-018-33427-6.
• [85] Role of the RNA-binding protein HuR in colon carcinogenesis.Oncogene. 2003 Oct 16;22(46):7146-54. doi: 10.1038/sj.onc.1206862.
• [86] Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.Br J Cancer. 2004 Nov 1;91(9):1718-25. doi: 10.1038/sj.bjc.6602136.
• [87] Expression of the cAMP binding protein EPAC1 in thyroid tumors and growth regulation of thyroid cells and thyroid carcinoma cells by EPAC proteins.Horm Metab Res. 2015 Mar;47(3):200-8. doi: 10.1055/s-0034-1390484. Epub 2014 Nov 5.
• [88] Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor (RAR).Oncogene. 2019 Dec;38(49):7367-7383. doi: 10.1038/s41388-019-0957-5. Epub 2019 Aug 16.
• [89] Mutational signatures and the genomic landscape of betel quid chewing-associated tongue carcinoma.Cancer Med. 2019 Feb;8(2):701-711. doi: 10.1002/cam4.1888. Epub 2019 Jan 22.
• [90] Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes.Histopathology. 2018 Mar;72(4):556-568. doi: 10.1111/his.13383. Epub 2017 Nov 29.
• [91] Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.BMC Gastroenterol. 2019 Feb 4;19(1):21. doi: 10.1186/s12876-019-0942-z.
• [92] RETRACTED ARTICLE: Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases.Mod Pathol. 2019 Feb;32(2):269-279. doi: 10.1038/s41379-018-0123-6. Epub 2018 Sep 26.
• [93] RUNX3 plays a tumor suppressor role by inhibiting cell migration, invasion and angiogenesis in oral squamous cell carcinoma.Oncol Rep. 2017 Oct;38(4):2378-2386. doi: 10.3892/or.2017.5857. Epub 2017 Jul 31.
• [94] Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood.Respir Med. 2005 Sep;99(9):1164-74. doi: 10.1016/j.rmed.2005.02.009.
• [95] Mammaglobin 1 promotes breast cancer malignancy and confers sensitivity to anticancer drugs.Mol Carcinog. 2016 Jul;55(7):1150-62. doi: 10.1002/mc.22358. Epub 2015 Jul 24.
• [96] Association of low Syndecan-1 expression with adverse histopathological parameters in gastric carcinomas.J BUON. 2019 May-Jun;24(3):1106-1112.
• [97] Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas.Genes Chromosomes Cancer. 2002 Jul;34(3):325-32. doi: 10.1002/gcc.10081.
• [98] Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.Int J Cancer. 2005 Dec 10;117(5):738-45. doi: 10.1002/ijc.21270.
• [99] SKP2, positively regulated by circ_ODC1/miR-422a axis, promotes the proliferation of retinoblastoma.J Cell Biochem. 2020 Jan;121(1):322-331. doi: 10.1002/jcb.29177. Epub 2019 Jul 11.
• [100] Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors.Eur J Endocrinol. 2001 Aug;145(2):129-35. doi: 10.1530/eje.0.1450129.
• [101] Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.Virchows Arch. 2019 Oct;475(4):479-488. doi: 10.1007/s00428-019-02647-0. Epub 2019 Aug 27.
• [102] Transcriptomic study of the mechanism of anoikis resistance in head and neck squamous carcinoma.PeerJ. 2019 May 23;7:e6978. doi: 10.7717/peerj.6978. eCollection 2019.
• [103] Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.Biomed Pharmacother. 2018 Dec;108:263-270. doi: 10.1016/j.biopha.2018.09.013. Epub 2018 Sep 14.
• [104] Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas.Int J Oncol. 2001 Sep;19(3):507-12.
• [105] The secretory leukocyte protease inhibitor gene is a target of epidermal growth factor receptor action in endometrial epithelial cells.J Endocrinol. 2005 Jan;184(1):141-51. doi: 10.1677/joe.1.05800.
• [106] TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients.Cancer Biomark. 2015;15(5):591-7. doi: 10.3233/CBM-150499.
• [107] miR-429 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by downregulation of TLN1.Cancer Cell Int. 2019 Apr 30;19:115. doi: 10.1186/s12935-019-0831-0. eCollection 2019.
• [108] The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.PLoS One. 2014 Jun 30;9(6):e100816. doi: 10.1371/journal.pone.0100816. eCollection 2014.
• [109] Immunohistochemical analysis of thymidylate synthase expression in gastric carcinoma: correlation with clinicopathological parameters and survival.Histol Histopathol. 2017 Feb;32(2):193-201. doi: 10.14670/HH-11-784. Epub 2016 May 31.
• [110] Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation.Bioconjug Chem. 1999 Nov-Dec;10(6):1084-9. doi: 10.1021/bc990075w.
• [111] HIF1 Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis.Cell Rep. 2019 Feb 26;26(9):2257-2265.e4. doi: 10.1016/j.celrep.2019.01.106.
• [112] Expression of annexin a5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas.J Clin Gastroenterol. 2009 Oct;43(9):831-7. doi: 10.1097/MCG.0b013e31819cc731.
• [113] Association between interleukin-18 variants and prostate cancer in Slovak population.Neoplasma. 2017;64(1):148-155. doi: 10.4149/neo_2017_119.
• [114] Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma.PLoS One. 2011;6(12):e27399. doi: 10.1371/journal.pone.0027399. Epub 2011 Dec 13.
• [115] Regulation of thrombomodulin expression in prostate cancer cells.Cancer Lett. 2012 Sep 28;322(2):177-84. doi: 10.1016/j.canlet.2012.03.001. Epub 2012 Mar 7.
• [116] Bioinformatic analysis of prognostic value of ZW10 interacting protein in lung cancer.Onco Targets Ther. 2018 Mar 23;11:1683-1695. doi: 10.2147/OTT.S149012. eCollection 2018.
• [117] ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death.Cancer Sci. 2018 Feb;109(2):471-482. doi: 10.1111/cas.13469.
• [118] Alanine-glyoxylate aminotransferase 1 (AGXT1) is a novel marker for hepatocellular carcinomas.Hum Pathol. 2018 Oct;80:76-81. doi: 10.1016/j.humpath.2018.05.025. Epub 2018 Jun 5.
• [119] Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib.Urol Oncol. 2018 Jan;36(1):11.e13-11.e21. doi: 10.1016/j.urolonc.2017.09.003. Epub 2017 Oct 4.
• [120] Genetic alterations in the coding region of the bak gene in uterine cervical carcinoma.Br J Cancer. 2003 May 19;88(10):1584-6. doi: 10.1038/sj.bjc.6600944.
• [121] Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.Endocr Relat Cancer. 2014 Oct;21(5):755-67. doi: 10.1530/ERC-14-0268. Epub 2014 Jul 10.
• [122] Mutation analysis of adenomas and carcinomas of the colon: Early and late drivers.Genes Chromosomes Cancer. 2018 Jul;57(7):366-376. doi: 10.1002/gcc.22539. Epub 2018 Apr 30.
• [123] Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy.Cancer Cell. 2018 Oct 8;34(4):561-578.e6. doi: 10.1016/j.ccell.2018.09.003.
• [124] Substituted (E)-2-(2-benzylidenehydrazinyl)-4-methylthiazole-5-carboxylates as dual inhibitors of 15-lipoxygenase & carbonic anhydrase II: synthesis, biochemical evaluation and docking studies.Biochem Biophys Res Commun. 2017 Jan 1;482(1):176-181. doi: 10.1016/j.bbrc.2016.11.028. Epub 2016 Nov 9.
• [125] CD200 Expression in Neuroendocrine Neoplasms.Am J Clin Pathol. 2017 Sep 1;148(3):236-242. doi: 10.1093/ajcp/aqx071.
• [126] B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.Clin Cancer Res. 2017 Sep 1;23(17):5202-5209. doi: 10.1158/1078-0432.CCR-16-3107. Epub 2017 May 24.
• [127] The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas.Oncol Rep. 2005 Dec;14(6):1413-20.
• [128] CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder.Int J Urol. 2013 Feb;20(2):251-5. doi: 10.1111/j.1442-2042.2012.03128.x. Epub 2012 Aug 21.
• [129] High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer.Virchows Arch. 2013 Nov;463(5):681-7. doi: 10.1007/s00428-013-1473-6. Epub 2013 Aug 31.
• [130] The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/-catenin signaling and silenced in common carcinomas.Oncogene. 2012 Aug 23;31(34):3901-12. doi: 10.1038/onc.2011.541. Epub 2011 Dec 5.
• [131] High-mobility group box 1 is overexpressed in cervical carcinoma and promotes cell invasion and migration invitro.Oncol Rep. 2017 Feb;37(2):831-840. doi: 10.3892/or.2016.5317. Epub 2016 Dec 14.
• [132] Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells.PLoS One. 2015 Nov 11;10(11):e0142229. doi: 10.1371/journal.pone.0142229. eCollection 2015.
• [133] Cellular effects of genotoxic stress and gene silencing of the checkpoint kinases in human oral cells.J Oral Pathol Med. 2009 Aug;38(7):591-6. doi: 10.1111/j.1600-0714.2009.00773.x.
• [134] Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity.Oncotarget. 2012 Nov;3(11):1401-15. doi: 10.18632/oncotarget.688.
• [135] Expression of cancer/testis antigens in salivary gland carcinomas with reference to MAGE-A and NY-ESO-1 expression in adenoid cystic carcinoma.Histopathology. 2017 Aug;71(2):305-315. doi: 10.1111/his.13226. Epub 2017 Jun 2.
• [136] Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.Biochem Pharmacol. 2006 Nov 30;72(11):1577-88. doi: 10.1016/j.bcp.2006.06.020. Epub 2006 Jul 18.
• [137] Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?.J Pathol. 2017 Sep;243(1):26-36. doi: 10.1002/path.4934. Epub 2017 Aug 7.
• [138] Effect of Temperature and pH on the Secondary Structure and Denaturation Process of Jumbo Squid Hepatopancreas Cathepsin D.Protein Pept Lett. 2019;26(7):532-541. doi: 10.2174/0929866526666190405124353.
• [139] Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated.BMC Cancer. 2018 Jul 6;18(1):717. doi: 10.1186/s12885-018-4640-y.
• [140] Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer.Breast Cancer Res Treat. 2015 Feb;150(1):9-18. doi: 10.1007/s10549-015-3285-7. Epub 2015 Feb 10.
• [141] Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.Lung Cancer. 2019 Sep;135:73-79. doi: 10.1016/j.lungcan.2019.07.016. Epub 2019 Jul 17.
• [142] DNAJB1-PRKACA is specific for fibrolamellar carcinoma.Mod Pathol. 2015 Jun;28(6):822-9. doi: 10.1038/modpathol.2015.4. Epub 2015 Feb 20.
• [143] Reduced expression of PHD2 prolyl hydroxylase gene in primary advanced uterine cervical carcinoma.Biomed Pharmacother. 2011 Jul;65(4):298-302. doi: 10.1016/j.biopha.2011.03.005. Epub 2011 May 31.
• [144] Clinical Significance and Biological Role of HuR in Head and Neck Carcinomas.Dis Markers. 2018 Jan 28;2018:4020937. doi: 10.1155/2018/4020937. eCollection 2018.
• [145] Decreased Eph receptorA1 expression is related to grade in ovarian serous carcinoma.Mol Med Rep. 2018 Apr;17(4):5409-5415. doi: 10.3892/mmr.2018.8528. Epub 2018 Jan 31.
• [146] Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5.
• [147] EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas.APMIS. 2017 Feb;125(2):122-127. doi: 10.1111/apm.12646.
• [148] Reduced EphB6 protein in gastric carcinoma and associated lymph nodes suggests EphB6 as a gastric tumor and metastasis inhibitor.Cancer Biomark. 2017 Jul 4;19(3):241-248. doi: 10.3233/CBM-160256.
• [149] Comprehensive gene expression microarray analysis of Ets-1 blockade in PC3 prostate cancer cells and correlations with prostate cancer tissues: Insights into genes involved in the metastatic cascade.Int J Mol Med. 2011 Jun;27(6):811-9. doi: 10.3892/ijmm.2011.652. Epub 2011 Mar 21.
• [150] Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: potential prognostic marker and target for tumourigenicity-suppression.Int J Oncol. 2008 Apr;32(4):767-75.
• [151] FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.J Urol. 2015 Jul;194(1):223-9. doi: 10.1016/j.juro.2015.01.073. Epub 2015 Jan 23.
• [152] Folate receptor- targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study.Oncotarget. 2017 Dec 11;9(1):791-801. doi: 10.18632/oncotarget.23155. eCollection 2018 Jan 2.
• [153] Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility.Breast Cancer Res Treat. 2008 Feb;107(3):337-47. doi: 10.1007/s10549-007-9559-y. Epub 2007 Mar 28.
• [154] Prognostic Significance of FOXC1 in Various Cancers: A Systematic Review and Meta-Analysis.Mol Diagn Ther. 2019 Dec;23(6):695-706. doi: 10.1007/s40291-019-00416-y.
• [155] Differential fucosyltransferase IV expression in squamous carcinoma cells is regulated by promoter methylation.Cell Mol Biol Lett. 2012 Jun;17(2):206-16. doi: 10.2478/s11658-012-0003-x.
• [156] Development of a [(68)Ga]-ghrelin analogue for PET imaging of the ghrelin receptor (GHS-R1a).Medchemcomm. 2018 Sep 17;9(10):1761-1767. doi: 10.1039/c8md00210j. eCollection 2018 Oct 1.
• [157] Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology.Hepatol Int. 2020 Jan;14(1):96-104. doi: 10.1007/s12072-019-10006-z. Epub 2019 Dec 12.
• [158] GRIK2 has a role in the maintenance of urothelial carcinoma stem-like cells, and its expression is associated with poorer prognosis.Oncotarget. 2017 Apr 25;8(17):28826-28839. doi: 10.18632/oncotarget.16259.
• [159] Combination of arsenic trioxide and cisplatin synergistically inhibits both hexokinase activity and viability of Ehrlich ascites carcinoma cells.J Biochem Mol Toxicol. 2019 Aug;33(8):e22350. doi: 10.1002/jbt.22350. Epub 2019 May 31.
• [160] Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness.Histol Histopathol. 2011 Dec;26(12):1487-97. doi: 10.14670/HH-26.1487.
• [161] HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.Reprod Sci. 2007 Sep;14(6):605-14. doi: 10.1177/1933719107307781.
• [162] Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11. doi: 10.1016/j.ajog.2006.10.874.
• [163] Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation.Pathol Oncol Res. 2009 Mar;15(1):91-6. doi: 10.1007/s12253-008-9096-y. Epub 2008 Aug 28.
• [164] Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas.Oncogene. 2008 Sep 4;27(39):5267-76. doi: 10.1038/onc.2008.147. Epub 2008 May 12.
• [165] Integrin 21 decelerates proliferation, but promotes survival and invasion of prostate cancer cells.Oncotarget. 2018 Aug 21;9(65):32435-32447. doi: 10.18632/oncotarget.25945. eCollection 2018 Aug 21.
• [166] An integrin ?KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.Nat Cell Biol. 2014 May;16(5):457-68. doi: 10.1038/ncb2953. Epub 2014 Apr 20.
• [167] Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.Gynecol Oncol. 2015 Oct;139(1):30-9. doi: 10.1016/j.ygyno.2015.07.107. Epub 2015 Jul 29.
• [168] Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma.Oncotarget. 2017 Feb 21;8(8):14133-14146. doi: 10.18632/oncotarget.13044.
• [169] Histone demethylase JMJD2C: epigenetic regulators in tumors.Oncotarget. 2017 Jul 12;8(53):91723-91733. doi: 10.18632/oncotarget.19176. eCollection 2017 Oct 31.
• [170] Clinical significance of kallikrein-related peptidase-4 in oral cancer.Anticancer Res. 2015 Apr;35(4):1861-6.
• [171] Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin.Cancer Chemother Pharmacol. 2011 Oct;68(4):979-90. doi: 10.1007/s00280-011-1573-4. Epub 2011 Feb 16.
• [172] Characterisation of seven newly established head and neck squamous cell carcinoma cell lines.Eur Arch Otorhinolaryngol. 2015 May;272(5):1251-8. doi: 10.1007/s00405-014-3073-8. Epub 2014 May 4.
• [173] Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities.Virchows Arch. 2009 Jan;454(1):71-9. doi: 10.1007/s00428-008-0694-6. Epub 2008 Nov 18.
• [174] Markers of drug resistance in relapsing colon cancer.J Cancer Res Clin Oncol. 2002 Feb;128(2):114-8. doi: 10.1007/s00432-001-0310-5. Epub 2001 Nov 30.
• [175] Findings on Surveillance Imaging After Preoperative Partial Breast Irradiation for Early Stage Breast Cancer.Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1374-1381. doi: 10.1016/j.ijrobp.2018.05.059. Epub 2018 Jun 5.
• [176] Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours.Hum Mol Genet. 2010 Feb 15;19(4):697-706. doi: 10.1093/hmg/ddp536. Epub 2009 Dec 2.
• [177] SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.Surgery. 2014 Dec;156(6):1542-8; discussion 1548-9. doi: 10.1016/j.surg.2014.08.095. Epub 2014 Nov 11.
• [178] Lack of Association between Membrane-Type 1 Matrix Metalloproteinase Expression and Clinically Relevant Molecular or Morphologic Tumor Characteristics at the Leading Edge of Invasive Colorectal Carcinoma.Biomed Res Int. 2015;2015:185404. doi: 10.1155/2015/185404. Epub 2015 May 27.
• [179] miR-181a-2* expression is different amongst carcinomas from the colorectal serrated route.Mutagenesis. 2020 Jul 11;35(3):233-241. doi: 10.1093/mutage/gez039.
• [180] Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.Int J Cancer. 2002 Apr 20;98(6):833-7. doi: 10.1002/ijc.10257.
• [181] Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression.J Clin Invest. 2007 Nov;117(11):3369-82. doi: 10.1172/JCI24311.
• [182] Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.APMIS. 2007 Apr;115(4):341-6. doi: 10.1111/j.1600-0463.2007.apm_592.x.
• [183] Nuclear NR4A3 Immunostaining Is a Specific and Sensitive Novel Marker for Acinic Cell Carcinoma of the Salivary Glands.Am J Surg Pathol. 2019 Sep;43(9):1264-1272. doi: 10.1097/PAS.0000000000001279.
• [184] LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness.Oncotarget. 2017 Jul 28;8(48):83626-83636. doi: 10.18632/oncotarget.18886. eCollection 2017 Oct 13.
• [185] DNA methylation changes in a human cell model of breast cancer progression.Mutat Res. 2010 Jun 1;688(1-2):28-35. doi: 10.1016/j.mrfmmm.2010.02.007. Epub 2010 Mar 1.
• [186] Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.Histopathology. 2019 Jul;75(1):54-62. doi: 10.1111/his.13845. Epub 2019 May 16.
• [187] The frequent co-expression of the oncogenes PIK3CA and PAK1 in oral carcinomas.Oral Oncol. 2011 Mar;47(3):211-6. doi: 10.1016/j.oraloncology.2011.01.003.
• [188] Essential role of the cGMP/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells.Int J Mol Med. 2014 Nov;34(5):1430-8. doi: 10.3892/ijmm.2014.1925. Epub 2014 Sep 8.
• [189] PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.Hum Pathol. 2009 Oct;40(10):1434-40. doi: 10.1016/j.humpath.2009.02.008. Epub 2009 May 7.
• [190] Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.Tumour Biol. 2013 Jun;34(3):1887-94. doi: 10.1007/s13277-013-0732-0. Epub 2013 Mar 14.
• [191] Synthesis, Photochemical and In Vitro Cytotoxic Evaluation of New Iodinated Aminosquaraines as Potential Sensitizers for Photodynamic Therapy.Molecules. 2019 Feb 28;24(5):863. doi: 10.3390/molecules24050863.
• [192] Carcinogenic HPV infection in the cervical squamo-columnar junction.J Pathol. 2015 Jul;236(3):265-71. doi: 10.1002/path.4533. Epub 2015 Apr 27.
• [193] Loss of the promyelocytic leukemia protein in gastric cancer: implications for IP-10 expression and tumor-infiltrating lymphocytes.PLoS One. 2011;6(10):e26264. doi: 10.1371/journal.pone.0026264. Epub 2011 Oct 12.
• [194] PPM1D controls nucleolar formation by up-regulating phosphorylation of nucleophosmin.Sci Rep. 2016 Sep 13;6:33272. doi: 10.1038/srep33272.
• [195] Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis.Transl Oncol. 2019 Mar;12(3):462-474. doi: 10.1016/j.tranon.2018.11.014. Epub 2018 Dec 21.
• [196] Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial.Clin Oral Investig. 2019 Feb;23(2):947-956. doi: 10.1007/s00784-018-2519-6. Epub 2018 Jun 16.
• [197] Characterization of novel genetic alterations in salivary gland secretory carcinoma.Mod Pathol. 2020 Apr;33(4):541-550. doi: 10.1038/s41379-019-0427-1. Epub 2019 Dec 10.
• [198] Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression.Clin Cancer Res. 2002 Apr;8(4):1157-67.
• [199] RACK1 is an organ-specific prognostic predictor in OSCC.Oral Oncol. 2018 Jan;76:22-26. doi: 10.1016/j.oraloncology.2017.10.025. Epub 2017 Nov 29.
• [200] RLIP76 increases apoptosis through Akt/mTOR signaling pathway in gastric cancer.Oncol Rep. 2016 Oct;36(4):2216-24. doi: 10.3892/or.2016.5043. Epub 2016 Aug 25.
• [201] Retinoic Acid Receptor Knockdown Suppresses the Tumorigenicity of Esophageal Carcinoma via Wnt/-catenin Pathway.Dig Dis Sci. 2018 Dec;63(12):3348-3358. doi: 10.1007/s10620-018-5254-6. Epub 2018 Aug 28.
• [202] Detection of human papillomavirus DNA by the hybrid capture assay.Braz J Infect Dis. 2003 Apr;7(2):121-5. doi: 10.1590/s1413-86702003000200004. Epub 2003 Nov 19.
• [203] RET, a targetable driver of pancreatic adenocarcinoma.Int J Cancer. 2019 Jun 15;144(12):3014-3022. doi: 10.1002/ijc.32040. Epub 2019 Jan 11.
• [204] Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.Mol Oncol. 2016 May;10(5):677-92. doi: 10.1016/j.molonc.2015.12.009. Epub 2015 Dec 20.
• [205] Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting -catenin and AKT signaling but frequently methylated in common carcinomas.Cell Mol Life Sci. 2014 Jun;71(11):2179-92. doi: 10.1007/s00018-013-1485-z. Epub 2013 Oct 25.
• [206] RRM1 *151A>T, RRM1 -756T>C, and RRM1 -585T>Gis associated with increased susceptibility of lung cancer in Chinese patients.Cancer Med. 2016 Aug;5(8):2084-90. doi: 10.1002/cam4.703. Epub 2016 Jun 23.
• [207] RSPO fusion transcripts in colorectal cancer in Japanese population.Mol Biol Rep. 2014 Aug;41(8):5375-84. doi: 10.1007/s11033-014-3409-x. Epub 2014 May 22.
• [208] Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.Arterioscler Thromb Vasc Biol. 2018 May;38(5):1202-1215. doi: 10.1161/ATVBAHA.117.310506. Epub 2018 Mar 15.
• [209] SENP1 regulates PTEN stability to dictate prostate cancer development.Oncotarget. 2017 Mar 14;8(11):17651-17664. doi: 10.18632/oncotarget.13283.
• [210] MASPIN tumour-suppressing activity in head and neck squamous cell carcinoma: emerging evidence and therapeutic perspectives.Acta Otolaryngol. 2009 May;129(5):476-80. doi: 10.1080/00016480802256079.
• [211] Heat shock protein 47 regulated by miR-29a to enhance glioma tumor growth and invasion.J Neurooncol. 2014 May;118(1):39-47. doi: 10.1007/s11060-014-1412-7. Epub 2014 Mar 5.
• [212] Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas.J Pathol. 2017 Aug;242(4):400-408. doi: 10.1002/path.4915. Epub 2017 Jun 9.
• [213] SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway.Oncotarget. 2015 Sep 22;6(28):26494-507. doi: 10.18632/oncotarget.4764.
• [214] SIRT6 Is Involved in the Progression of Ovarian Carcinomas via -Catenin-Mediated Epithelial to Mesenchymal Transition.Front Oncol. 2018 Nov 20;8:538. doi: 10.3389/fonc.2018.00538. eCollection 2018.
• [215] Monocarboxylate Transporter 4 (MCT4) Knockout Mice Have Attenuated 4NQO Induced Carcinogenesis; A Role for MCT4 in Driving Oral Squamous Cell Cancer.Front Oncol. 2018 Aug 28;8:324. doi: 10.3389/fonc.2018.00324. eCollection 2018.
• [216] Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion.Oncol Res. 2016 Oct 27;24(6):511-519. doi: 10.3727/096504016X14719078133483.
• [217] GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Cancer Sci. 2007 Oct;98(10):1625-32. doi: 10.1111/j.1349-7006.2007.00578.x. Epub 2007 Aug 16.
• [218] SLC3A2, antigen of mAb 3G9, promotes migration and invasion by upregulating of mucins in gastric cancer.Oncotarget. 2017 Jul 25;8(51):88586-88598. doi: 10.18632/oncotarget.19529. eCollection 2017 Oct 24.
• [219] A Predominant Oxidative Renal Metabolite of Empagliflozin in Male Mice Is Cytotoxic in Mouse Renal Tubular Cells but not Genotoxic.Int J Toxicol. 2017 Nov/Dec;36(6):440-448. doi: 10.1177/1091581817735090. Epub 2017 Nov 12.
• [220] Differences between carcinoma of the cecum and ascending colon: Evidence based on clinical and embryological data.Int J Oncol. 2018 Jul;53(1):87-98. doi: 10.3892/ijo.2018.4366. Epub 2018 Apr 12.
• [221] Sphingosine kinase 2 promotes colorectal cancer cell proliferation and invasion by enhancing MYC expression.Tumour Biol. 2016 Jun;37(6):8455-60. doi: 10.1007/s13277-015-4700-8. Epub 2016 Jan 5.
• [222] Cancer-associated CD43 glycoforms as target of immunotherapy.Mol Cancer Ther. 2014 Mar;13(3):752-62. doi: 10.1158/1535-7163.MCT-13-0651. Epub 2013 Dec 19.
• [223] Preclinical evaluation of a dual sstr2 and integrin (v)(3)-targeted heterodimer [(68)Ga]-NOTA-3PEG(4)-TATE-RGD.Bioorg Med Chem. 2019 Nov 1;27(21):115094. doi: 10.1016/j.bmc.2019.115094. Epub 2019 Sep 9.
• [224] The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma.Cancer. 2003 Nov 1;98(9):1898-904. doi: 10.1002/cncr.11753.
• [225] Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.Oncotarget. 2016 Sep 13;7(37):60074-60086. doi: 10.18632/oncotarget.11054.
• [226] Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.EBioMedicine. 2019 Sep;47:184-194. doi: 10.1016/j.ebiom.2019.08.055. Epub 2019 Sep 3.
• [227] Transducin ()-like 1 X-linked receptor 1 correlates with clinical prognosis and clinicopathological characteristics in human solid carcinomas.Oncotarget. 2017 Jun 27;8(37):61626-61636. doi: 10.18632/oncotarget.18650. eCollection 2017 Sep 22.
• [228] Reduced expression of transcription factor AP-2 is associated with gastric adenocarcinoma prognosis.PLoS One. 2011;6(9):e24897. doi: 10.1371/journal.pone.0024897. Epub 2011 Sep 26.
• [229] Bax inhibitor-1 mediates apoptosis-resistance in human nasopharyngeal carcinoma cells.Mol Cell Biochem. 2010 Jan;333(1-2):1-7. doi: 10.1007/s11010-009-0198-y. Epub 2009 Jul 5.
• [230] Cell Surface Human Airway Trypsin-Like Protease Is Lost During Squamous Cell Carcinogenesis.J Cell Physiol. 2016 Jul;231(7):1476-83. doi: 10.1002/jcp.25173. Epub 2016 Feb 4.
• [231] Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma.Oncogene. 2004 Aug 26;23(39):6666-71. doi: 10.1038/sj.onc.1207888.
• [232] Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis.Front Oncol. 2017 Dec 1;7:283. doi: 10.3389/fonc.2017.00283. eCollection 2017.
• [233] Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation.Oncoimmunology. 2016 Nov 29;6(1):e1261778. doi: 10.1080/2162402X.2016.1261778. eCollection 2017.
• [234] APRIL knockdown suppresses migration and invasion of human colon carcinoma cells.Clin Biochem. 2009 Nov;42(16-17):1694-8. doi: 10.1016/j.clinbiochem.2009.06.019. Epub 2009 Jun 30.
• [235] Silencing Trim59 inhibits invasion/migration and epithelial-to-mesenchymal transition via TGF-/Smad2/3 signaling pathway in bladder cancer cells.Onco Targets Ther. 2017 Mar 9;10:1503-1512. doi: 10.2147/OTT.S130139. eCollection 2017.
• [236] Identification of epigenetically downregulated Tmem70 and Ube2e2 in rat liver after 28-day treatment with hepatocarcinogenic thioacetamide showing gene product downregulation in hepatocellular preneoplastic and neoplastic lesions produced by tumor promotion.Toxicol Lett. 2017 Jan 15;266:13-22. doi: 10.1016/j.toxlet.2016.11.022. Epub 2016 Nov 30.
• [237] The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways.J Pathol. 2006 Apr;208(5):724-32. doi: 10.1002/path.1931.
• [238] Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas.J Clin Pathol. 2004 Aug;57(8):829-34. doi: 10.1136/jcp.2003.015644.
• [239] Disorders of nucleotide excision repair.Handb Clin Neurol. 2013;113:1637-50. doi: 10.1016/B978-0-444-59565-2.00032-0.
• [240] Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30.
• [241] Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas.Eur J Clin Invest. 2008 Feb;38(2):134-42. doi: 10.1111/j.1365-2362.2007.01916.x.
• [242] MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas.Mol Med Rep. 2012 Oct;6(4):705-8. doi: 10.3892/mmr.2012.979. Epub 2012 Jul 5.
• [243] Expression of MAGE-A1 and MAGE-A3 genes in human salivary gland carcinomas.Chin Med J (Engl). 2003 Jun;116(6):897-900.
• [244] Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer.Mol Cancer. 2014 Mar 14;13:58. doi: 10.1186/1476-4598-13-58.
• [245] Recurrent copy number gains of ACVR1 and corresponding transcript overexpression are associated with survival in head and neck squamous cell carcinomas.Histopathology. 2011 Jul;59(1):81-9. doi: 10.1111/j.1365-2559.2011.03885.x. Epub 2011 Jun 13.
• [246] Adrenomedullin (AM) and AM receptor type 2 expression is up-regulated in prostate carcinomas (PC), and AM stimulates in vitro growth of a PC-derived cell line by enhancing proliferation and decreasing apoptosis rates.Int J Oncol. 2004 Dec;25(6):1781-7.
• [247] Fetal-type gastrointestinal adenocarcinoma: a morphologically distinct entity with unfavourable prognosis.J Clin Pathol. 2018 Mar;71(3):221-227. doi: 10.1136/jclinpath-2017-204535. Epub 2017 Aug 16.
• [248] The estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar development.Dev Biol. 2012 Sep 15;369(2):249-60. doi: 10.1016/j.ydbio.2012.06.030. Epub 2012 Jul 20.
• [249] Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress.PLoS One. 2014 Nov 24;9(11):e111911. doi: 10.1371/journal.pone.0111911. eCollection 2014.
• [250] MicroRNAs associated with increased AKT gene number in human lung carcinoma.Hum Pathol. 2016 Oct;56:1-10. doi: 10.1016/j.humpath.2016.04.011. Epub 2016 May 14.
• [251] Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas.Oncology. 2006;70(4):285-9. doi: 10.1159/000096289. Epub 2006 Oct 16.
• [252] Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.Cancer Res. 2003 Jun 15;63(12):3112-20.
• [253] Overexpression of ANXA1 in penile carcinomas positive for high-risk HPVs.PLoS One. 2013;8(1):e53260. doi: 10.1371/journal.pone.0053260. Epub 2013 Jan 14.
• [254] Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.Prostate. 2017 Mar;77(4):337-349. doi: 10.1002/pros.23273. Epub 2016 Nov 8.
• [255] A novel Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level.Mol Cell Endocrinol. 2015 Aug 15;411:75-85. doi: 10.1016/j.mce.2015.04.013. Epub 2015 Apr 24.
• [256] APEX1 Expression as a Potential Diagnostic Biomarker of Clear Cell Renal Cell Carcinoma and Hepatobiliary Carcinomas.J Clin Med. 2019 Aug 1;8(8):1151. doi: 10.3390/jcm8081151.
• [257] Different Prognostic Implications of Aquaporin-1 and Aquaporin-5 Expression among Different Histological Types of Ovarian Carcinoma.Pathol Oncol Res. 2020 Jan;26(1):263-271. doi: 10.1007/s12253-018-0456-y. Epub 2018 Jul 19.
• [258] Assessing the Expression of Aquaporin 3 Antigen-Recognition Sites in Oral Squamous Cell Carcinoma.Appl Immunohistochem Mol Morphol. 2020 Sep;28(8):611-620. doi: 10.1097/PAI.0000000000000802.
• [259] Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.Br J Cancer. 2012 Apr 10;106(8):1406-14. doi: 10.1038/bjc.2012.103.
• [260] Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers.Anticancer Res. 2009 Apr;29(4):951-63.
• [261] 11q21 rearrangement is a frequent and highly specific genetic alteration in mucoepidermoid carcinoma.Diagn Mol Pathol. 2012 Sep;21(3):134-7. doi: 10.1097/PDM.0b013e318255552c.
• [262] Increased expression of apoptosis-related protein 3 is highly associated with tumorigenesis and progression of cervical squamous cell carcinoma.Hum Pathol. 2013 Mar;44(3):388-93. doi: 10.1016/j.humpath.2012.05.028. Epub 2012 Oct 1.
• [263] Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.Hum Pathol. 2013 May;44(5):777-85. doi: 10.1016/j.humpath.2012.08.002. Epub 2012 Oct 29.
• [264] Zinc alpha 2-glycoprotein: a multidisciplinary protein.Mol Cancer Res. 2008 Jun;6(6):892-906. doi: 10.1158/1541-7786.MCR-07-2195.
• [265] New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile.Eur J Hum Genet. 2002 Dec;10(12):833-40. doi: 10.1038/sj.ejhg.5200891.
• [266] Pro-apoptotic PUMA and anti-apoptotic phospho-BAD are highly expressed in colorectal carcinomas.Dig Dis Sci. 2007 Oct;52(10):2751-6. doi: 10.1007/s10620-007-9799-z. Epub 2007 Mar 28.
• [267] Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter.J Biol Chem. 2003 Sep 19;278(38):36496-504. doi: 10.1074/jbc.M306694200. Epub 2003 Jul 7.
• [268] Expression of PCNA, p53, Bax, and Bcl-X in oral poorly differentiated and basaloid squamous cell carcinoma: relationships with prognosis.Head Neck. 2005 Nov;27(11):982-9. doi: 10.1002/hed.20258.
• [269] Characterization of gene expression in major types of salivary gland carcinomas with epithelial differentiation.Cancer Genet Cytogenet. 2005 Jan 15;156(2):104-13. doi: 10.1016/j.cancergencyto.2004.04.016.
• [270] BIRC2 amplification in squamous cell carcinomas of the uterine cervix.Virchows Arch. 2012 Aug;461(2):123-8. doi: 10.1007/s00428-012-1268-1. Epub 2012 Jun 26.
• [271] Cancer stem cell markers ALDH1 and Bmi1 expression in oral erythroplakia revisited: Implication for driving the process of field cancerization.J Oral Pathol Med. 2020 Jan;49(1):96-99. doi: 10.1111/jop.12955. Epub 2019 Sep 5.
• [272] Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.Oncogene. 2008 Jul 10;27(30):4233-41. doi: 10.1038/onc.2008.51. Epub 2008 Mar 17.
• [273] EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.PLoS One. 2013 Sep 20;8(9):e74313. doi: 10.1371/journal.pone.0074313. eCollection 2013.
• [274] BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.Virchows Arch. 2014 Jun;464(6):701-7. doi: 10.1007/s00428-014-1577-7. Epub 2014 Apr 23.
• [275] Overexpression of the Ets-1 transcription factor in human breast cancer.Br J Cancer. 2004 Oct 4;91(7):1308-15. doi: 10.1038/sj.bjc.6602128.
• [276] DNA methylation status is inversely correlated with green tea intake and physical activity in gastric cancer patients.Int J Cancer. 2009 Jun 1;124(11):2677-82. doi: 10.1002/ijc.24231.
• [277] TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor-specific cytotoxic T lymphocytes.Ann N Y Acad Sci. 2013 Apr;1283:75-80. doi: 10.1111/j.1749-6632.2012.06777.x. Epub 2013 Jan 9.
• [278] Overexpression of CAPN2 promotes cell metastasis and proliferation via AKT/mTOR signaling in renal cell carcinoma.Oncotarget. 2017 Oct 26;8(58):97811-97821. doi: 10.18632/oncotarget.22083. eCollection 2017 Nov 17.
• [279] Mutational analysis of caspase 1, 4, and 5 genes in common human cancers.Hum Pathol. 2008 Jun;39(6):895-900. doi: 10.1016/j.humpath.2007.10.015. Epub 2008 Apr 21.
• [280] Mutational analysis of CASP10 gene in colon, breast, lung and hepatocellular carcinomas.Pathology. 2010 Jan;42(1):73-6. doi: 10.3109/00313020903434371.
• [281] Somatic mutations of caspase-2 gene in gastric and colorectal cancers.Pathol Res Pract. 2011 Oct 15;207(10):640-4. doi: 10.1016/j.prp.2011.08.004. Epub 2011 Sep 21.
• [282] Mutational analysis of the CASP6 gene in colorectal and gastric carcinomas.APMIS. 2006 Sep;114(9):646-50. doi: 10.1111/j.1600-0463.2006.apm_417.x.
• [283] Inactivating mutations of CASPASE-7 gene in human cancers.Oncogene. 2003 Sep 11;22(39):8048-52. doi: 10.1038/sj.onc.1206727.
• [284] Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas.Yonsei Med J. 2008 Dec 31;49(6):917-22. doi: 10.3349/ymj.2008.49.6.917.
• [285] Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas.Cell Immunol. 2014 May-Jun;289(1-2):155-61. doi: 10.1016/j.cellimm.2014.03.020. Epub 2014 Apr 18.
• [286] Fluorescence in situ hybridization analysis of CCND3 gene as marker of progression in bladder carcinoma.J Biol Regul Homeost Agents. 2013 Apr-Jun;27(2):559-67.
• [287] Reduced DAXX Expression Is Associated with Reduced CD24 Expression in Colorectal Cancer.Cells. 2019 Oct 12;8(10):1242. doi: 10.3390/cells8101242.
• [288] Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.Clin Cancer Res. 2008 Nov 15;14(22):7223-36. doi: 10.1158/1078-0432.CCR-08-0499.
• [289] Clinicopathological study of role of CD34 expressions in the stroma of premalignant and malignant lesions of uterine cervix.Ann Diagn Pathol. 2019 Feb;38:87-92. doi: 10.1016/j.anndiagpath.2018.11.007. Epub 2018 Nov 29.
• [290] CD36 inhibits -catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis.Nat Commun. 2019 Sep 4;10(1):3981. doi: 10.1038/s41467-019-11662-3.
• [291] Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004 Nov 15;64(22):8397-404. doi: 10.1158/0008-5472.CAN-04-1612.
• [292] Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas.Jpn J Cancer Res. 1997 Oct;88(10):947-52. doi: 10.1111/j.1349-7006.1997.tb00313.x.
• [293] Does hypermethylation of CpG island in the promoter region of the E-cadherin gene increase the risk of lung cancer? A meta-analysis.Thorac Cancer. 2019 Jan;10(1):54-59. doi: 10.1111/1759-7714.12900. Epub 2018 Nov 3.
• [294] CCAAT/enhancer binding protein (C/EBP) isoforms as transcriptional regulators of the pro-invasive CDH3/P-cadherin gene in human breast cancer cells.PLoS One. 2013;8(2):e55749. doi: 10.1371/journal.pone.0055749. Epub 2013 Feb 6.
• [295] Morphologic and Immunohistochemical Appraisal of Primary Gastric Carcinomas.Appl Immunohistochem Mol Morphol. 2018 Nov/Dec;26(10):e107-e115. doi: 10.1097/PAI.0000000000000618.
• [296] Differential roles of Hath1, MUC2 and P27Kip1 in relation with gamma-secretase inhibition in human colonic carcinomas: a translational study.PLoS One. 2013;8(2):e55904. doi: 10.1371/journal.pone.0055904. Epub 2013 Feb 11.
• [297] Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization.PLoS One. 2014 Dec 11;9(12):e114616. doi: 10.1371/journal.pone.0114616. eCollection 2014.
• [298] Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients.Dis Markers. 2018 Jun 28;2018:6714287. doi: 10.1155/2018/6714287. eCollection 2018.
• [299] Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation.Neoplasia. 2002 Mar-Apr;4(2):151-63. doi: 10.1038/sj.neo.7900201.
• [300] NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.Blood. 2006 Sep 15;108(6):2029-36. doi: 10.1182/blood-2005-10-014258. Epub 2006 May 18.
• [301] c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.Urology. 2004 Jun;63(6):1198-204. doi: 10.1016/j.urology.2004.01.007.
• [302] Genes Associated with Human Cancers: Their Expressions, Features, Functions, and Significance.Crit Rev Eukaryot Gene Expr. 2015;25(3):209-38. doi: 10.1615/critreveukaryotgeneexpr.2015013893.
• [303] Opposed expression of IKK: loss in keratinizing carcinomas and gain in non-keratinizing carcinomas.Oncotarget. 2015 Sep 22;6(28):25499-505. doi: 10.18632/oncotarget.4548.
• [304] Altered gene expression in conjunctival squamous cell carcinoma.Mod Pathol. 2016 May;29(5):452-60. doi: 10.1038/modpathol.2016.41. Epub 2016 Feb 26.
• [305] Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma.Endocr Metab Immune Disord Drug Targets. 2019;19(6):826-837. doi: 10.2174/1871530319666190206124120.
• [306] Epstein-Barr virus-associated gastric adenocarcinomas among Koreans.Am J Clin Pathol. 1996 Feb;105(2):174-81. doi: 10.1093/ajcp/105.2.174.
• [307] Association of NQO1 rs1800566 polymorphism and the risk of colorectal cancer: a meta-analysis.Int J Colorectal Dis. 2012 Jul;27(7):885-92. doi: 10.1007/s00384-011-1396-0. Epub 2012 Jan 4.
• [308] CSF-1 Overexpression Predicts Poor Prognosis in Upper Tract Urothelial Carcinomas.Dis Markers. 2019 Aug 21;2019:2724948. doi: 10.1155/2019/2724948. eCollection 2019.
• [309] A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN--2b in patients with CEA-expressing carcinomas.Cancer Immunol Immunother. 2016 Nov;65(11):1353-1364. doi: 10.1007/s00262-016-1893-7. Epub 2016 Aug 31.
• [310] Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression.Cancer Lett. 1996 Dec 20;110(1-2):163-7. doi: 10.1016/s0304-3835(96)04486-2.
• [311] C-terminal Src kinase (Csk)-mediated phosphorylation of eukaryotic elongation factor 2 (eEF2) promotes proteolytic cleavage and nuclear translocation of eEF2.J Biol Chem. 2014 May 2;289(18):12666-78. doi: 10.1074/jbc.M113.546481. Epub 2014 Mar 19.
• [312] Regulation of the human cathepsin E gene by the constitutive androstane receptor.Arch Biochem Biophys. 2007 Nov 1;467(1):132-8. doi: 10.1016/j.abb.2007.08.001. Epub 2007 Aug 19.
• [313] Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.Int J Biol Markers. 2017 May 4;32(2):e243-e247. doi: 10.5301/jbm.5000246.
• [314] Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.JCI Insight. 2019 Apr 4;4(7):e126853. doi: 10.1172/jci.insight.126853. eCollection 2019 Apr 4.
• [315] CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas.Anticancer Res. 2008 Jul-Aug;28(4C):2289-95.
• [316] Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.BMC Cancer. 2010 Sep 11;10:483. doi: 10.1186/1471-2407-10-483.
• [317] Induction of aryl hydrocarbon hydroxylase activity and pulmonary carcinoma.Int J Cancer. 1979 Mar 15;23(3):302-5. doi: 10.1002/ijc.2910230305.
• [318] Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas.Exp Mol Pathol. 2019 Jun;108:164-172. doi: 10.1016/j.yexmp.2019.04.015. Epub 2019 Apr 25.
• [319] Different expression patterns of beta-defensins in human squamous cell carcinomas.Anticancer Res. 2003 Nov-Dec;23(6C):4629-33.
• [320] Low DICER1 expression is associated with poor clinical outcome in adrenocortical carcinoma.Oncotarget. 2015 Sep 8;6(26):22724-33. doi: 10.18632/oncotarget.4261.
• [321] Delta-like 4/Notch pathway is differentially regulated in benign and malignant thyroid tissues.Thyroid. 2011 Dec;21(12):1323-30. doi: 10.1089/thy.2010.0444. Epub 2011 Nov 8.
• [322] Increased DNA methyltransferase 1 protein expression correlates significantly with intestinal histological type and gender in gastric carcinomas.Adv Med Sci. 2015 Mar;60(1):50-7. doi: 10.1016/j.advms.2014.10.002. Epub 2014 Oct 24.
• [323] Novel function of MKP-5/DUSP10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas.Oncol Rep. 2012 Sep;28(3):931-6. doi: 10.3892/or.2012.1862. Epub 2012 Jun 12.
• [324] Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy.Virology. 2005 Jan 20;331(2):269-91. doi: 10.1016/j.virol.2004.09.045.
• [325] Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells.Cancer Res. 2000 Jul 1;60(13):3631-7.
• [326] UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer.Cancer. 2011 Mar 1;117(5):1027-37. doi: 10.1002/cncr.25531. Epub 2010 Nov 8.
• [327] Expression of the E2F family in human gastrointestinal carcinomas.Int J Cancer. 1999 May 17;81(4):535-8. doi: 10.1002/(sici)1097-0215(19990517)81:4<535::aid-ijc5>3.0.co;2-4.
• [328] Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.Neoplasia. 2011 Aug;13(8):676-84. doi: 10.1593/neo.11512.
• [329] Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck.Cancer. 2000 Jun 15;88(12):2803-10. doi: 10.1002/1097-0142(20000615)88:12<2803::aid-cncr20>3.0.co;2-5.
• [330] 4E-BP1, a multifactor regulated multifunctional protein.Cell Cycle. 2016;15(6):781-6. doi: 10.1080/15384101.2016.1151581.
• [331] Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.Clin Respir J. 2018 Feb;12(2):806-810. doi: 10.1111/crj.12550. Epub 2016 Oct 17.
• [332] Prognostic role of EphA2 in various human carcinomas: a meta-analysis of 23 related studies.Growth Factors. 2014 Dec;32(6):247-53. doi: 10.3109/08977194.2014.984806. Epub 2014 Nov 24.
• [333] EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.J Ovarian Res. 2016 Nov 25;9(1):83. doi: 10.1186/s13048-016-0292-1.
• [334] Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features.Int J Cancer. 2009 Jan 1;124(1):88-94. doi: 10.1002/ijc.23890.
• [335] Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.Sci Rep. 2016 Dec 12;6:38792. doi: 10.1038/srep38792.
• [336] Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.J Clin Lab Anal. 2019 Nov;33(9):e22982. doi: 10.1002/jcla.22982. Epub 2019 Jul 29.
• [337] ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.Prostate. 2018 Sep;78(12):896-904. doi: 10.1002/pros.23646. Epub 2018 May 15.
• [338] Role of phospho-ezrin in differentiating thyroid carcinoma.Sci Rep. 2019 Apr 17;9(1):6190. doi: 10.1038/s41598-019-42612-0.
• [339] Multimodal treatment in locally advanced gastric cancer.Updates Surg. 2018 Jun;70(2):173-179. doi: 10.1007/s13304-018-0539-z. Epub 2018 Jun 26.
• [340] CXCL12 chemokine expression and secretion regulates colorectal carcinoma cell anoikis through Bim-mediated intrinsic apoptosis.PLoS One. 2010 Sep 22;5(9):e12895. doi: 10.1371/journal.pone.0012895.
• [341] Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon pathway.Mod Pathol. 2017 Jan;30(1):123-133. doi: 10.1038/modpathol.2016.170. Epub 2016 Sep 30.
• [342] Expression of heart-type fatty acid-binding protein in human gastric carcinoma and its association with tumor aggressiveness, metastasis and poor prognosis.Pathobiology. 2004;71(5):267-73. doi: 10.1159/000080061.
• [343] Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.BMC Cancer. 2015 Oct 5;15:649. doi: 10.1186/s12885-015-1649-3.
• [344] Fibroblast activation proteins- suppress tumor immunity by regulating T cells and tumor-associated macrophages.Exp Mol Pathol. 2018 Feb;104(1):29-37. doi: 10.1016/j.yexmp.2017.12.003. Epub 2017 Dec 19.
• [345] Activation of prolyl hydroxylase-2 for stabilization of mitochondrial stress along with simultaneous downregulation of HIF-1/FASN in ER+breast cancer subtype.Cell Biochem Funct. 2019 Jun;37(4):216-227. doi: 10.1002/cbf.3389. Epub 2019 Apr 5.
• [346] Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.Oncotarget. 2016 Aug 16;7(33):52751-52765. doi: 10.18632/oncotarget.10481.
• [347] Silencing of human ferrochelatase causes abundant protoporphyrin-IX accumulation in colon cancer.FASEB J. 2008 Feb;22(2):500-9. doi: 10.1096/fj.07-8888com. Epub 2007 Sep 17.
• [348] Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma.J Thorac Cardiovasc Surg. 1997 Nov;114(5):838-43. doi: 10.1016/S0022-5223(97)70089-8.
• [349] Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.Oncogene. 2014 Jun 5;33(23):3075-82. doi: 10.1038/onc.2013.278. Epub 2013 Jul 22.
• [350] Melanoma Suppressor Functions of the Carcinoma Oncogene FOXQ1. Cell Rep. 2017 Sep 19;20(12):2820-2832.
• [351] Fascin-1 enhances experimental osteosarcoma tumor formation and metastasis and is related to poor patient outcome.BMC Cancer. 2019 Jan 17;19(1):83. doi: 10.1186/s12885-019-5303-3.
• [352] Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.Int J Cancer. 2003 Jan 20;103(3):328-34. doi: 10.1002/ijc.10848.
• [353] Neutrophil interactions with sialyl Lewis X on human nonsmall cell lung carcinoma cells regulate invasive behavior.Cancer. 2011 Oct 1;117(19):4493-505. doi: 10.1002/cncr.26059. Epub 2011 Mar 22.
• [354] A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals.Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10164-9. doi: 10.1073/pnas.95.17.10164.
• [355] Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target.Expert Opin Ther Targets. 2013 Jun;17(6):681-93. doi: 10.1517/14728222.2013.775253. Epub 2013 Feb 28.
• [356] GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.Mod Pathol. 2019 Apr;32(4):484-489. doi: 10.1038/s41379-018-0167-7. Epub 2018 Nov 2.
• [357] Methylation of GATA-4 and GATA-5 and development of sporadic gastric carcinomas.World J Gastroenterol. 2010 Mar 14;16(10):1201-8. doi: 10.3748/wjg.v16.i10.1201.
• [358] Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin.Oncogene. 2004 Aug 26;23(39):6621-9. doi: 10.1038/sj.onc.1207861.
• [359] Connexin 26 expression correlates with less aggressive phenotype of intestinal type-gastric carcinomas.Int J Mol Med. 2010 May;25(5):709-16. doi: 10.3892/ijmm_00000395.
• [360] Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6/E7 oncogene transcription.J Gen Virol. 2004 Jun;85(Pt 6):1433-1444. doi: 10.1099/vir.0.19317-0.
• [361] Non-canonical Hedgehog signaling activation in ovarian borderline tumors and ovarian carcinomas.Int J Oncol. 2017 Dec;51(6):1869-1877. doi: 10.3892/ijo.2017.4156. Epub 2017 Oct 12.
• [362] Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking.J Comput Aided Mol Des. 2019 Sep;33(9):799-815. doi: 10.1007/s10822-019-00226-8. Epub 2019 Oct 19.
• [363] G protein q exerts expression level-dependent distinct signaling paradigms.Cell Signal. 2019 Jun;58:34-43. doi: 10.1016/j.cellsig.2019.02.006. Epub 2019 Mar 5.
• [364] Intratumoral level of gonadotropin-releasing hormone in ovarian and endometrial cancers.Oncol Rep. 2002 Mar-Apr;9(2):349-52.
• [365] Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin -sarcin.Protein Eng Des Sel. 2012 Aug;25(8):425-35. doi: 10.1093/protein/gzs032. Epub 2012 Jun 19.
• [366] Orphan Gpr182 suppresses ERK-mediated intestinal proliferation during regeneration and adenoma formation. J Clin Invest. 2017 Feb 1;127(2):593-607.
• [367] Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation.Cell. 1998 Dec 11;95(6):793-803. doi: 10.1016/s0092-8674(00)81702-x.
• [368] Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.Oncogene. 2013 Sep 12;32(37):4366-76. doi: 10.1038/onc.2012.471. Epub 2012 Oct 22.
• [369] MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.Bioconjug Chem. 2003 Jul-Aug;14(4):756-63. doi: 10.1021/bc034018l.
• [370] GSTO polymorphism analysis in thyroid nodules suggest that GSTO1 variants do not influence the risk for malignancy.Eur J Cancer Prev. 2005 Jun;14(3):277-80. doi: 10.1097/00008469-200506000-00013.
• [371] Flow cytometric DNA studies in human gastric cancer and polyps.Scand J Gastroenterol. 1987 Dec;22(10):1270-6. doi: 10.3109/00365528708996475.
• [372] HDAC11 is a novel drug target in carcinomas.Int J Cancer. 2013 May 1;132(9):2200-8. doi: 10.1002/ijc.27876. Epub 2012 Oct 25.
• [373] HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers.Cell Mol Life Sci. 2011 Oct;68(19):3261-74. doi: 10.1007/s00018-011-0628-3. Epub 2011 Feb 3.
• [374] Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67.Med Oncol. 2013 Dec;30(4):702. doi: 10.1007/s12032-013-0702-9. Epub 2013 Sep 3.
• [375] Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears.BMC Cancer. 2019 Oct 28;19(1):1010. doi: 10.1186/s12885-019-6154-7.
• [376] Ketogenic HMGCS2 Is a c-Myc target gene expressed in differentiated cells of human colonic epithelium and down-regulated in colon cancer.Mol Cancer Res. 2006 Sep;4(9):645-53. doi: 10.1158/1541-7786.MCR-05-0267. Epub 2006 Aug 28.
• [377] Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA.Hum Pathol. 2019 Jan;83:1-6. doi: 10.1016/j.humpath.2018.08.004. Epub 2018 Aug 17.
• [378] Epigenetic control of HNF-4 in colon carcinoma cells affects MUC4 expression and malignancy.Cell Oncol (Dordr). 2013 Apr;36(2):155-67. doi: 10.1007/s13402-012-0123-3. Epub 2013 Jan 11.
• [379] Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients.PLoS One. 2015 Jul 15;10(7):e0132728. doi: 10.1371/journal.pone.0132728. eCollection 2015.
• [380] Deletion and down-regulation of HRH4 gene in gastric carcinomas: a potential correlation with tumor progression. PLoS One. 2012;7(2):e31207. doi: 10.1371/journal.pone.0031207. Epub 2012 Feb 20.
• [381] HSP72 and gp96 in gastroenterological cancers.Clin Chim Acta. 2013 Feb 18;417:73-9. doi: 10.1016/j.cca.2012.12.017. Epub 2012 Dec 22.
• [382] Intronic polymorphism (1541-1542delGT) of the constitutive heat shock protein 70 gene has functional significance and shows evidence of association with lung cancer risk.Mol Carcinog. 2004 Mar;39(3):155-63. doi: 10.1002/mc.20009.
• [383] Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells.Cancer Res. 2003 Nov 1;63(21):7098-105.
• [384] Prognostic value of tumour-infiltrating CD8+lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?.Cancer Immunol Immunother. 2019 Apr;68(4):563-575. doi: 10.1007/s00262-019-02306-y. Epub 2019 Jan 22.
• [385] Circulating insulin-like growth factor binding protein-3 and risk of gastrointestinal malignant tumors.J Gastroenterol Hepatol. 2019 Dec;34(12):2104-2111. doi: 10.1111/jgh.14753. Epub 2019 Jul 24.
• [386] IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.J Clin Pathol. 2013 Jul;66(7):573-82. doi: 10.1136/jclinpath-2012-201278. Epub 2013 Mar 28.
• [387] Angiomodulin, a marker of cancer vasculature, is upregulated by vascular endothelial growth factor and increases vascular permeability as a ligand of integrin v3.Cancer Med. 2014 Jun;3(3):537-49. doi: 10.1002/cam4.216. Epub 2014 Apr 16.
• [388] Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH.PLoS One. 2007 Aug 22;2(8):e769. doi: 10.1371/journal.pone.0000769.
• [389] IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.PLoS One. 2009 Jul 1;4(7):e6119. doi: 10.1371/journal.pone.0006119.
• [390] Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.Clin Cancer Res. 2011 May 1;17(9):2819-29. doi: 10.1158/1078-0432.CCR-10-2986. Epub 2011 Feb 28.
• [391] An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.Cancer Biother Radiopharm. 2019 Apr;34(3):147-159. doi: 10.1089/cbr.2018.2628. Epub 2019 Jan 2.
• [392] Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.Oncogene. 2005 Jan 20;24(4):585-96. doi: 10.1038/sj.onc.1208183.
• [393] Integrin-linked kinase is overexpressed in laryngeal squamous cell carcinoma and correlates with tumor proliferation, migration and invasion.Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8740-8748. doi: 10.26355/eurrev_201812_16639.
• [394] Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk.Tumour Biol. 2013 Oct;34(5):2929-36. doi: 10.1007/s13277-013-0855-3. Epub 2013 May 25.
• [395] P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.Mod Pathol. 2017 May;30(5):698-709. doi: 10.1038/modpathol.2016.232. Epub 2017 Jan 13.
• [396] Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.Signal Transduct Target Ther. 2017;2:16045-. doi: 10.1038/sigtrans.2016.45. Epub 2017 Mar 17.
• [397] KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state.Cell Cycle. 2008 Nov 15;7(22):3539-47. doi: 10.4161/cc.7.22.7062. Epub 2008 Nov 24.
• [398] The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene.Int J Cancer. 2012 Aug 1;131(3):E179-89. doi: 10.1002/ijc.26501. Epub 2011 Dec 21.
• [399] KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma.Anticancer Res. 2018 Apr;38(4):2295-2302. doi: 10.21873/anticanres.12474.
• [400] Relevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer.Anticancer Res. 2002 Sep-Oct;22(5):2965-9.
• [401] Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma.Anat Rec (Hoboken). 2009 Aug;292(8):1128-34. doi: 10.1002/ar.20950.
• [402] Quantitative reverse transcriptase polymerase chain reaction analysis for KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in hepatocellular carcinoma.J Cancer Res Clin Oncol. 2003 Sep;129(9):531-5. doi: 10.1007/s00432-003-0469-z. Epub 2003 Jul 25.
• [403] Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.Clin Cancer Res. 2003 May;9(5):1710-20.
• [404] A novel protease homolog differentially expressed in breast and ovarian cancer.Mol Med. 1996 Sep;2(5):624-36.
• [405] Keratin 17 in disease pathogenesis: from cancer to dermatoses.J Pathol. 2019 Feb;247(2):158-165. doi: 10.1002/path.5178. Epub 2018 Dec 7.
• [406] The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.BMC Cancer. 2017 Jun 23;17(1):441. doi: 10.1186/s12885-017-3431-1.
• [407] Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.Int J Gynecol Pathol. 2020 Nov;39(6):558-566. doi: 10.1097/PGP.0000000000000657.
• [408] Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma.BMC Cancer. 2007 Oct 23;7:198. doi: 10.1186/1471-2407-7-198.
• [409] Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis.Cancer Res. 2006 Dec 15;66(24):11623-31. doi: 10.1158/0008-5472.CAN-06-2629.
• [410] Prognostic significance of leucine-rich-repeat-containing G-protein-coupled receptor 5, an intestinal stem cell marker, in gastric carcinomas.Gastric Cancer. 2016 Jul;19(3):767-77. doi: 10.1007/s10120-015-0543-7. Epub 2015 Sep 19.
• [411] Expression of RNA-binding protein LIN28 in classic gastric hepatoid carcinomas, gastric fetal type gastrointestinal adenocarcinomas, and hepatocellular carcinomas: An immunohistochemical study with comparison to SALL4, alpha-fetoprotein, glypican-3, and Hep Par1.Pathol Res Pract. 2018 Oct;214(10):1707-1712. doi: 10.1016/j.prp.2018.07.037. Epub 2018 Aug 2.
• [412] Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.Cancer Res. 2007 Dec 15;67(24):11601-11. doi: 10.1158/0008-5472.CAN-07-3243.
• [413] Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression.Radiother Oncol. 2005 Nov;77(2):172-5. doi: 10.1016/j.radonc.2005.09.013. Epub 2005 Oct 17.
• [414] MAD1 (mitotic arrest deficiency 1) is a candidate for a tumor suppressor gene in human stomach.Virchows Arch. 2007 Oct;451(4):771-9. doi: 10.1007/s00428-007-0470-z. Epub 2007 Aug 3.
• [415] Expression of MAGE-1, -2, and -3 genes in gastric carcinomas and cancer cell lines derived from Korean patients.J Korean Med Sci. 2001 Feb;16(1):62-8. doi: 10.3346/jkms.2001.16.1.62.
• [416] A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.J Immunol. 2003 Jul 1;171(1):219-25. doi: 10.4049/jimmunol.171.1.219.
• [417] Proteomic identification of keratin alterations with enhanced proliferation of oral carcinoma cells by loss of mucosa-associated lymphoid tissue 1 expression.Int J Oncol. 2013 Sep;43(3):729-36. doi: 10.3892/ijo.2013.1990. Epub 2013 Jun 25.
• [418] SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.Nature. 2014 Jun 12;510(7504):283-7. doi: 10.1038/nature13320. Epub 2014 May 21.
• [419] Overexpression of the Tpl-2/Cot oncogene in human breast cancer.Oncogene. 1999 Sep 2;18(35):4968-73. doi: 10.1038/sj.onc.1202891.
• [420] hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas.Mol Med Rep. 2012 Jan;5(1):260-5. doi: 10.3892/mmr.2011.621. Epub 2011 Oct 11.
• [421] ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion.J Clin Invest. 2012 May;122(5):1869-80. doi: 10.1172/JCI61492. Epub 2012 Apr 16.
• [422] ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.Neoplasia. 2013 Jun;15(6):649-59. doi: 10.1593/neo.121896.
• [423] Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation.Mol Carcinog. 2010 Feb;49(2):175-82. doi: 10.1002/mc.20587.
• [424] Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells.Cancers (Basel). 2018 Dec 5;10(12):490. doi: 10.3390/cancers10120490.
• [425] MCM-2 expression differentiates potentially malignant verrucous lesions from oral carcinomas.Ann Diagn Pathol. 2018 Jun;34:72-76. doi: 10.1016/j.anndiagpath.2018.03.001. Epub 2018 Mar 13.
• [426] Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.Cancer Res. 2010 Sep 15;70(18):7148-54. doi: 10.1158/0008-5472.CAN-10-1457. Epub 2010 Aug 24.
• [427] Development and activities of a new melphalan prodrug designed for tumor-selective activation.Bioconjug Chem. 1998 Mar-Apr;9(2):255-9. doi: 10.1021/bc970163l.
• [428] Production of parathyroid hormone-related protein in tumour xenografts in nude mice presenting with hypercalcaemia.Br J Cancer. 1991 Feb;63(2):252-6. doi: 10.1038/bjc.1991.59.
• [429] Melan A (A103) is not a marker of mesothelioma.Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):181-4. doi: 10.1097/PAI.0b013e31825e0013.
• [430] Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.Int J Cancer. 2009 Aug 15;125(4):894-901. doi: 10.1002/ijc.24462.
• [431] Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas.Mol Carcinog. 1991;4(6):527-33. doi: 10.1002/mc.2940040617.
• [432] The prognostic value of matrix metalloproteinase-7 and matrix metalloproteinase-15 in acute myeloid leukemia.J Cell Biochem. 2019 Jun;120(6):10613-10624. doi: 10.1002/jcb.28351. Epub 2019 Feb 27.
• [433] Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed during fetal development and in cancer.Gene. 2002 Nov 13;301(1-2):31-41. doi: 10.1016/s0378-1119(02)01088-0.
• [434] Expression and regulation of collagenase-2 (MMP-8) in head and neck squamous cell carcinomas.J Pathol. 2002 May;197(1):72-81. doi: 10.1002/path.1078.
• [435] Multivariate analysis as a method for evaluating the pathogenicity of novel genetic MLH1 variants in patients with colorectal cancer and microsatellite instability.Int J Mol Med. 2015 Aug;36(2):511-7. doi: 10.3892/ijmm.2015.2255. Epub 2015 Jun 19.
• [436] Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas.Int J Colorectal Dis. 2010 Jan;25(1):17-23. doi: 10.1007/s00384-009-0791-2. Epub 2009 Aug 29.
• [437] Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia.Epigenetics. 2012 Nov;7(11):1268-78. doi: 10.4161/epi.22301. Epub 2012 Sep 27.
• [438] Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression.Cancer Res. 2004 Aug 1;64(15):5154-61. doi: 10.1158/0008-5472.CAN-04-0600.
• [439] The metal-responsive transcription factor-1 protein is elevated in human tumors.Cancer Biol Ther. 2010 Mar 15;9(6):469-76. doi: 10.4161/cbt.9.6.10979. Epub 2010 Mar 20.
• [440] GATA3 and MYB Expression in Cutaneous Adnexal Neoplasms.Am J Dermatopathol. 2017 Apr;39(4):279-286. doi: 10.1097/DAD.0000000000000634.
• [441] Understanding the lethal variant of prostate cancer: power of examining extremes.Cancer Discov. 2011 Nov;1(6):466-8. doi: 10.1158/2159-8290.CD-11-0259.
• [442] Immunomorphology and molecular biology of mixed primary liver cancers: is Nestin a marker of intermediate-cell carcinoma?.Histopathology. 2020 Jan;76(2):265-274. doi: 10.1111/his.13966. Epub 2019 Oct 29.
• [443] Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer.J Exp Med. 2002 Oct 21;196(8):1067-78. doi: 10.1084/jem.20011053.
• [444] PTEN suppresses the oncogenic function of AIB1 through decreasing its protein stability via mechanism involving Fbw7 alpha.Mol Cancer. 2013 Mar 21;12:21. doi: 10.1186/1476-4598-12-21.
• [445] Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells.Mod Pathol. 2013 Aug;26(8):1123-31. doi: 10.1038/modpathol.2012.163. Epub 2012 Oct 12.
• [446] Neuronal pentraxin II (NPTX2) is frequently down-regulated by promoter hypermethylation in pancreatic cancers.Dig Dis Sci. 2012 Oct;57(10):2608-14. doi: 10.1007/s10620-012-2202-8. Epub 2012 Jul 18.
• [447] DAX1 Overexpression in Pediatric Adrenocortical Tumors: A Synergic Role with SF1 in Tumorigenesis.Horm Metab Res. 2015 Aug;47(9):656-61. doi: 10.1055/s-0034-1398560. Epub 2015 May 18.
• [448] Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors.Cancer Lett. 2001 Dec 28;174(2):115-25. doi: 10.1016/s0304-3835(01)00690-5.
• [449] VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.Cancer Discov. 2012 Oct;2(10):906-21. doi: 10.1158/2159-8290.CD-12-0085. Epub 2012 Jul 9.
• [450] Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.Virchows Arch. 2020 Feb;476(2):295-305. doi: 10.1007/s00428-019-02640-7. Epub 2019 Aug 19.
• [451] Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma.Clin Cancer Res. 2008 Feb 15;14(4):1041-9. doi: 10.1158/1078-0432.CCR-07-4125.
• [452] Methylation of OSMR gene is frequently observed in non-invasive colorectal cancer.Anticancer Res. 2011 Apr;31(4):1293-5.
• [453] Evidence of oxytocin/oxytocin receptor interplay in human prostate gland and carcinomas.Int J Oncol. 2004 Oct;25(4):899-904.
• [454] Role of purinergic receptors in hepatobiliary carcinoma in Pakistani population: an approach towards proinflammatory role of P2X4 and P2X7 receptors.Purinergic Signal. 2019 Sep;15(3):367-374. doi: 10.1007/s11302-019-09675-0. Epub 2019 Aug 10.
• [455] PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.Cell Death Dis. 2019 Feb 18;10(3):166. doi: 10.1038/s41419-019-1415-6.
• [456] PBRM1 loss is a late event during the development of cholangiocarcinoma.Histopathology. 2017 Sep;71(3):375-382. doi: 10.1111/his.13234. Epub 2017 Jun 22.
• [457] Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas.J Radiat Res. 2017 Mar 1;58(2):183-194. doi: 10.1093/jrr/rrw097.
• [458] Performance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages.BMC Cancer. 2018 Dec 3;18(1):1197. doi: 10.1186/s12885-018-5125-8.
• [459] PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein.Lab Invest. 1999 Sep;79(9):1161-70.
• [460] Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression.Mod Pathol. 2005 Jan;18(1):143-52. doi: 10.1038/modpathol.3800253.
• [461] Expression and prognostic significance of pepsinogen C in gastric carcinoma.Ann Surg Oncol. 2000 Aug;7(7):508-14. doi: 10.1007/s10434-000-0508-9.
• [462] Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation.Cancer Res. 2007 Oct 15;67(20):9721-30. doi: 10.1158/0008-5472.CAN-07-2735.
• [463] CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas.Int J Cancer. 2005 Aug 20;116(2):282-4. doi: 10.1002/ijc.21040.
• [464] The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice.J Clin Invest. 2011 Apr;121(4):1266-82. doi: 10.1172/JCI43452. Epub 2011 Mar 23.
• [465] Role of isoenzyme M2 of pyruvate kinase in urothelial tumorigenesis.Oncotarget. 2016 Apr 26;7(17):23947-60. doi: 10.18632/oncotarget.8114.
• [466] Elevated content of phospholipase C-gamma 1 in colorectal cancer tissues.Cancer. 1994 Jan 1;73(1):36-41. doi: 10.1002/1097-0142(19940101)73:1<36::aid-cncr2820730108>3.0.co;2-5.
• [467] Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling -catenin signaling in cancer-initiating cells.J Exp Med. 2015 Jul 27;212(8):1219-37. doi: 10.1084/jem.20141254. Epub 2015 Jun 29.
• [468] Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis.World J Urol. 2010 Feb;28(1):117-22. doi: 10.1007/s00345-009-0432-y. Epub 2009 Jun 9.
• [469] Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.J Gene Med. 2005 May;7(5):672-80. doi: 10.1002/jgm.701.
• [470] Variant forms of DNA polymerase beta in primary lung carcinomas.DNA Cell Biol. 1999 Jul;18(7):549-54. doi: 10.1089/104454999315097.
• [471] The PPAR-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions.Arch Toxicol. 2018 Jan;92(1):83-119. doi: 10.1007/s00204-017-2094-7. Epub 2017 Dec 2.
• [472] Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma.APMIS. 2004 Feb;112(2):123-32. doi: 10.1111/j.1600-0463.2004.apm1120207.x.
• [473] High nuclear expression of protein arginine methyltransferase-5 is a potentially useful marker to estimate submucosal invasion in endoscopically resected early colorectal carcinoma.Pathol Int. 2015 Oct;65(10):541-8. doi: 10.1111/pin.12338. Epub 2015 Aug 6.
• [474] Expression of pS2 protein and its relation with the Ki-67 proliferative indices and tumor recurrence in superficial bladder carcinomas.Eur Urol. 2001 Aug;40(2):163-8. doi: 10.1159/000049767.
• [475] Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer.Cancer Res. 2007 Mar 15;67(6):2559-67. doi: 10.1158/0008-5472.CAN-06-4121.
• [476] Different pattern of T cell receptor delta gene rearrangement in tumour-infiltrating lymphocytes and peripheral blood in patients with solid tumours.Cancer Immunol Immunother. 1994 Oct;39(4):275-8. doi: 10.1007/BF01525992.
• [477] Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.Cancer Res. 2015 Oct 1;75(19):4198-210. doi: 10.1158/0008-5472.CAN-15-1062. Epub 2015 Sep 10.
• [478] Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma.Auris Nasus Larynx. 2010 Aug;37(4):482-7. doi: 10.1016/j.anl.2009.11.009. Epub 2010 Jan 19.
• [479] Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.Horm Cancer. 2013 Aug;4(4):208-21. doi: 10.1007/s12672-013-0141-2. Epub 2013 Apr 9.
• [480] Implication of a protein-tyrosine-phosphatase in human lung cancer.Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):677-85.
• [481] Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo.Carcinogenesis. 2004 Nov;25(11):2107-14. doi: 10.1093/carcin/bgh224. Epub 2004 Jul 1.
• [482] Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast.Am J Pathol. 1997 Jan;150(1):297-303.
• [483] Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells.Biochem Pharmacol. 2015 Oct 1;97(3):331-40. doi: 10.1016/j.bcp.2015.07.025. Epub 2015 Jul 23.
• [484] Human retinoblastoma binding protein 9, a serine hydrolase implicated in pancreatic cancers.Protein Pept Lett. 2012 Feb;19(2):194-7. doi: 10.2174/092986612799080356.
• [485] Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.Pathobiology. 2011;78(3):123-31. doi: 10.1159/000323563. Epub 2011 May 26.
• [486] The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.BMC Cancer. 2015 Jun 16;15:471. doi: 10.1186/s12885-015-1435-2.
• [487] Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression.Sci Rep. 2018 Nov 22;8(1):17259. doi: 10.1038/s41598-018-35332-4.
• [488] A prognostic gene expression index in ovarian cancer - validation across different independent data sets.J Pathol. 2009 Jun;218(2):273-80. doi: 10.1002/path.2547.
• [489] Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants.J Urol. 2008 Apr;179(4):1344-8. doi: 10.1016/j.juro.2007.11.078. Epub 2008 Mar 4.
• [490] Altered Activity and Expression of Cytosolic Peptidases in Colorectal Cancer.Int J Med Sci. 2015 Jun 2;12(6):458-67. doi: 10.7150/ijms.11808. eCollection 2015.
• [491] Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors.Clin Cancer Res. 2009 Jul 15;15(14):4546-53. doi: 10.1158/1078-0432.CCR-08-3159. Epub 2009 Jul 7.
• [492] Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma.Hum Pathol. 2006 Sep;37(9):1169-75. doi: 10.1016/j.humpath.2006.04.008. Epub 2006 Jul 7.
• [493] Retinoid acid receptor expression is helpful to distinguish between adenoma and well-differentiated carcinoma in the thyroid.Virchows Arch. 2013 Jun;462(6):619-32. doi: 10.1007/s00428-013-1419-z. Epub 2013 May 4.
• [494] Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis.J Histochem Cytochem. 2006 Jan;54(1):63-73. doi: 10.1369/jhc.5A6645.2005. Epub 2005 Aug 22.
• [495] Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity.J Biol Chem. 2009 Nov 13;284(46):32066-74. doi: 10.1074/jbc.M109.057166. Epub 2009 Sep 17.
• [496] SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways.Oncotarget. 2018 Apr 24;9(31):21876-21892. doi: 10.18632/oncotarget.25082. eCollection 2018 Apr 24.
• [497] Expression of MRE11 complex (MRE11, RAD50, NBS1) and hRap1 and its relation with telomere regulation, telomerase activity in human gastric carcinomas.Pathobiology. 2001;69(4):219-24. doi: 10.1159/000055946.
• [498] Expression of RFC/SLC19A1 is associated with tumor type in bladder cancer patients.PLoS One. 2011;6(7):e21820. doi: 10.1371/journal.pone.0021820. Epub 2011 Jul 8.
• [499] OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells.J Pathol. 2005 Dec;207(4):396-401. doi: 10.1002/path.1861.
• [500] Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1.Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2914-9. doi: 10.1073/pnas.95.6.2914.
• [501] Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas.J Endocrinol. 2013 Jan 18;216(2):125-33. doi: 10.1530/JOE-12-0495. Print 2013 Feb.
• [502] Identification of a new proliferation-associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomas.Int J Cancer. 2002 Jun 20;99(6):771-5. doi: 10.1002/ijc.10442.
• [503] Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue.Cancer Biol Ther. 2011 Mar 15;11(6):584-91. doi: 10.4161/cbt.11.6.14533. Epub 2011 Mar 15.
• [504] Activation of Slit2/Robo1 Signaling Promotes Tumor Metastasis in Colorectal Carcinoma through Activation of the TGF-/Smads Pathway.Cells. 2019 Jun 25;8(6):635. doi: 10.3390/cells8060635.
• [505] Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer.Genes Chromosomes Cancer. 1999 Jan;24(1):62-71. doi: 10.1002/(sici)1098-2264(199901)24:1<62::aid-gcc9>3.0.co;2-4.
• [506] A study of Smad4 and Smad7 expression in surgically resected samples of gastric adenocarcinoma and their correlation with clinicopathological parameters and patient survival.J BUON. 2014 Jan-Mar;19(1):221-7.
• [507] Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.Mod Pathol. 2017 Jun;30(6):797-809. doi: 10.1038/modpathol.2017.11. Epub 2017 Mar 3.
• [508] SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.Hum Pathol. 2016 Mar;49:145-55. doi: 10.1016/j.humpath.2015.08.025. Epub 2015 Nov 4.
• [509] Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment.Front Immunol. 2017 Feb 8;8:70. doi: 10.3389/fimmu.2017.00070. eCollection 2017.
• [510] Sam-pointed domain containing Ets transcription factor in luminal breast cancer pathogenesis.Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1899-903. doi: 10.1158/1055-9965.EPI-09-0055.
• [511] Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.Oncotarget. 2016 Jan 19;7(3):3233-44. doi: 10.18632/oncotarget.6564.
• [512] Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines.Biomed Res Int. 2015;2015:690721. doi: 10.1155/2015/690721. Epub 2015 Oct 25.
• [513] High mobility group box associated with cell proliferation appears to play an important role in hepatocellular carcinogenesis in rats and humans.Toxicology. 2009 Jan 31;255(3):160-70. doi: 10.1016/j.tox.2008.10.023. Epub 2008 Nov 11.
• [514] Somatostatin receptor expression in parathyroid neoplasms.Endocr Connect. 2019 Aug;8(8):1213-1223. doi: 10.1530/EC-19-0260.
• [515] Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors.Neuroendocrinology. 2012;95(3):232-47. doi: 10.1159/000330616. Epub 2011 Dec 13.
• [516] Identification of a developmental gene expression signature, including HOX genes, for the normal human colonic crypt stem cell niche: overexpression of the signature parallels stem cell overpopulation during colon tumorigenesis.Stem Cells Dev. 2014 Jan 15;23(2):167-79. doi: 10.1089/scd.2013.0039. Epub 2013 Nov 5.
• [517] Knockdown of human serine/threonine kinase 33 suppresses human small cell lung carcinoma by blocking RPS6/BAD signaling transduction.Neoplasma. 2017;64(6):869-879. doi: 10.4149/neo_2017_608.
• [518] Stathmin Is Required for Normal Mouse Mammary Gland Development and 16HER2-Driven Tumorigenesis.Cancer Res. 2019 Jan 15;79(2):397-409. doi: 10.1158/0008-5472.CAN-18-2488. Epub 2018 Nov 26.
• [519] Structure, molecular dynamics simulation, and docking studies of Dictyostelium discoideum and human STRAPs.J Cell Biochem. 2018 Sep;119(9):7177-7191. doi: 10.1002/jcb.26840. Epub 2018 May 24.
• [520] Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.Clin Transl Oncol. 2017 Aug;19(8):976-988. doi: 10.1007/s12094-017-1629-y. Epub 2017 Feb 21.
• [521] beta-Catenin/TCF/LEF regulate expression of the short form human Cripto-1.Biochem Biophys Res Commun. 2007 Mar 30;355(1):240-4. doi: 10.1016/j.bbrc.2007.01.143. Epub 2007 Feb 2.
• [522] Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers.Cancer Immunol Res. 2020 Jan;8(1):19-31. doi: 10.1158/2326-6066.CIR-19-0040. Epub 2019 Dec 5.
• [523] The absence of Mth1 inactivation and DNA polymerase kappa overexpression in rat mammary carcinomas with frequent A:T to C:G transversions.Jpn J Cancer Res. 2002 May;93(5):501-6. doi: 10.1111/j.1349-7006.2002.tb01284.x.
• [524] Elevated TRF2 in advanced breast cancers with short telomeres.Breast Cancer Res Treat. 2011 Jun;127(3):623-30. doi: 10.1007/s10549-010-0988-7. Epub 2010 Jul 13.
• [525] Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin.BMC Cancer. 2010 Oct 27;10:587. doi: 10.1186/1471-2407-10-587.
• [526] HUWE1 ubiquitylates and degrades the RAC activator TIAM1 promoting cell-cell adhesion disassembly, migration, and invasion.Cell Rep. 2015 Jan 6;10(1):88-102. doi: 10.1016/j.celrep.2014.12.012. Epub 2014 Dec 24.
• [527] Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.J Cancer Res Clin Oncol. 2006 Aug;132(8):537-46. doi: 10.1007/s00432-006-0106-8. Epub 2006 May 31.
• [528] High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.BMC Cancer. 2018 Apr 16;18(1):425. doi: 10.1186/s12885-018-4339-0.
• [529] HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.Pathol Oncol Res. 2018 Jul;24(3):575-581. doi: 10.1007/s12253-017-0260-0. Epub 2017 Jul 28.
• [530] 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12.
• [531] Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.Cancer Med. 2019 Apr;8(4):1793-1805. doi: 10.1002/cam4.2066. Epub 2019 Mar 7.
• [532] Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: strong suppression of peroxidase gene expression.J Pathol. 1996 May;179(1):89-94. doi: 10.1002/(SICI)1096-9896(199605)179:1<89::AID-PATH546>3.0.CO;2-R.
• [533] TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression.Gut. 2012 Nov;61(11):1568-75. doi: 10.1136/gutjnl-2011-301153. Epub 2011 Dec 29.
• [534] RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.Pathol Res Pract. 2009;205(6):403-8. doi: 10.1016/j.prp.2008.12.014. Epub 2009 Feb 20.
• [535] Effect of tumour progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi carcinoma.J Steroid Biochem Mol Biol. 1994 Jul;50(1-2):31-40. doi: 10.1016/0960-0760(94)90169-4.
• [536] In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One. 2013;8(3):e58866.
• [537] Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer.Clin Cancer Res. 2007 Jul 1;13(13):3848-54. doi: 10.1158/1078-0432.CCR-07-0337.
• [538] Expression and activity of g protein-coupled receptor kinases in differentiated thyroid carcinoma.J Clin Endocrinol Metab. 2002 Jul;87(7):3279-86. doi: 10.1210/jcem.87.7.8618.
• [539] Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.Virchows Arch. 2019 Jul;475(1):85-94. doi: 10.1007/s00428-019-02532-w. Epub 2019 Feb 9.
• [540] Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.Int J Oncol. 2003 May;22(5):961-7.
• [541] Inhibition of UCH-L1 Deubiquitinating Activity with Two Forms of LDN-57444 Has Anti-Invasive Effects in Metastatic Carcinoma Cells. Int J Mol Sci. 2019 Jul 31;20(15):3733.
• [542] Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma.Pathol Oncol Res. 2007;13(2):105-13. doi: 10.1007/BF02893485. Epub 2007 Jul 3.
• [543] Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1.Clin Endocrinol (Oxf). 2002 Mar;56(3):341-50. doi: 10.1046/j.1365-2265.2002.01475.x.
• [544] Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2.Aging (Albany NY). 2019 Nov 13;11(21):9778-9793. doi: 10.18632/aging.102425. Epub 2019 Nov 13.
• [545] Low VDAC1 Expression Is Associated with an Aggressive Phenotype and Reduced Overall Patient Survival in Cholangiocellular Carcinoma.Cells. 2019 Jun 4;8(6):539. doi: 10.3390/cells8060539.
• [546] The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.J Pathol. 2003 Jun;200(2):183-94. doi: 10.1002/path.1339.
• [547] Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.Hum Pathol. 2013 Oct;44(10):2204-12. doi: 10.1016/j.humpath.2013.04.014. Epub 2013 Jul 8.
• [548] B7-H4 is Inversely Correlated With T-Cell Infiltration in Clear Cell but Not Serous or Endometrioid Ovarian Cancer.Appl Immunohistochem Mol Morphol. 2019 Aug;27(7):515-522. doi: 10.1097/PAI.0000000000000608.
• [549] ER regulation of NF-kB activation in prostate cancer is mediated by HIF-1.Oncotarget. 2015 Nov 24;6(37):40247-54. doi: 10.18632/oncotarget.5377.
• [550] Site-specific gene expression patterns in oral cancer.Head Face Med. 2017 May 10;13(1):6. doi: 10.1186/s13005-017-0138-0.
• [551] CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas.Med Oncol. 2013 Dec;30(4):726. doi: 10.1007/s12032-013-0726-1. Epub 2013 Sep 12.
• [552] Ku80 is differentially expressed in human lung carcinomas and upregulated in response to irradiation in mice.DNA Cell Biol. 2011 Dec;30(12):987-94. doi: 10.1089/dna.2010.1196. Epub 2011 Jun 11.
• [553] Cloning, characterization, and chromosome assignment of Zfp146 the mouse ortholog of human ZNF146, a gene amplified and overexpressed in pancreatic cancer, and Zfp260 a closely related gene.Cytogenet Cell Genet. 1999;85(3-4):297-300. doi: 10.1159/000015316.
• [554] Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma.Anticancer Res. 2012 Aug;32(8):3091-5.
• [555] CD70 expression in thymic carcinoma.Am J Surg Pathol. 2000 May;24(5):742-6. doi: 10.1097/00000478-200005000-00014.
• [556] Dichotomous roles of claudins as tumor promoters or suppressors: lessons from knockout mice.Cell Mol Life Sci. 2019 Dec;76(23):4663-4672. doi: 10.1007/s00018-019-03238-7. Epub 2019 Jul 23.
• [557] Expression and clinical significance of CXCR5/CXCL13 in human nonsmall cell lung carcinoma.Int J Oncol. 2014 Dec;45(6):2232-40. doi: 10.3892/ijo.2014.2688. Epub 2014 Sep 30.
• [558] The retinoic acid-metabolizing enzyme CYP26A1 upregulates fascin and promotes the malignant behavior of breast carcinoma cells.Oncol Rep. 2015 Aug;34(2):850-8. doi: 10.3892/or.2015.4042. Epub 2015 Jun 8.
• [559] DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.Eur J Cancer. 2011 Aug;47(12):1817-25. doi: 10.1016/j.ejca.2011.02.024. Epub 2011 Mar 31.
• [560] Lentivirus-mediated RNA Interference Targeting LAPTM4B Inhibits Human Ovarian Cancer Cell Invasion In Vitro.Chem Biol Drug Des. 2016 Jan;87(1):121-30. doi: 10.1111/cbdd.12632. Epub 2015 Aug 31.
• [561] Structural insights into the inhibited states of the Mer receptor tyrosine kinase.J Struct Biol. 2009 Feb;165(2):88-96. doi: 10.1016/j.jsb.2008.10.003. Epub 2008 Nov 5.
• [562] Milk fat globule--epidermal growth factor--factor VIII (MFGE8)/lactadherin promotes bladder tumor development.Oncogene. 2011 Feb 10;30(6):642-53. doi: 10.1038/onc.2010.446. Epub 2010 Oct 18.
• [563] Expression of netrin-1 by hypoxia contributes to the invasion and migration of prostate carcinoma cells by regulating YAP activity.Exp Cell Res. 2016 Dec 10;349(2):302-309. doi: 10.1016/j.yexcr.2016.10.023. Epub 2016 Nov 1.
• [564] Proliferation and apoptosis in PhIP-induced rat mammary gland carcinomas with elevated phosphotyrosine-STAT5a.FEBS Lett. 2007 Jan 9;581(1):29-33. doi: 10.1016/j.febslet.2006.11.071. Epub 2006 Dec 5.
• [565] Cyclooxygenase 1 and 2 expressions in the human thyroid gland.Eur Arch Otorhinolaryngol. 2006 Mar;263(3):199-204. doi: 10.1007/s00405-005-0999-x. Epub 2005 Dec 16.
• [566] p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.J Ovarian Res. 2016 Oct 22;9(1):69. doi: 10.1186/s13048-016-0275-2.
• [567] The Differential Impact of SRC Expression on the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma.Cancers (Basel). 2019 Oct 25;11(11):1644. doi: 10.3390/cancers11111644.
• [568] Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma.J Proteome Res. 2009 Dec;8(12):5610-8. doi: 10.1021/pr900705r.
• [569] Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.J Neurooncol. 2019 Apr;142(2):319-325. doi: 10.1007/s11060-019-03099-x. Epub 2019 Jan 17.
• [570] Expression of oxidized protein tyrosine phosphatase and H2AX predicts poor survival of gastric carcinoma patients.BMC Cancer. 2018 Aug 20;18(1):836. doi: 10.1186/s12885-018-4752-4.
• [571] Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas?.Oncotarget. 2017 Jan 10;8(2):3640-3648. doi: 10.18632/oncotarget.12277.
• [572] Impairment of peroxisomal biogenesis in human colon carcinoma.Carcinogenesis. 1999 Jun;20(6):985-9. doi: 10.1093/carcin/20.6.985.
• [573] Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.J Clin Pathol. 2003 Jun;56(6):447-52. doi: 10.1136/jcp.56.6.447.
• [574] Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation.Eur J Endocrinol. 2005 Aug;153(2):335-44. doi: 10.1530/eje.1.01962.
• [575] NGALR is overexpressed and regulated by hypomethylation in esophageal squamous cell carcinoma.Clin Cancer Res. 2008 Dec 1;14(23):7674-81. doi: 10.1158/1078-0432.CCR-08-0420.
• [576] Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.Cancer Chemother Pharmacol. 2003 Sep;52(3):202-8. doi: 10.1007/s00280-003-0639-3. Epub 2003 May 29.
• [577] Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma.Int J Oncol. 2000 Jul;17(1):67-73. doi: 10.3892/ijo.17.1.67.
• [578] The novel human HUEL (C4orf1) protein shares homology with the DNA-binding domain of the XPA DNA repair protein and displays nuclear translocation in a cell cycle-dependent manner.Int J Biochem Cell Biol. 2002 May;34(5):487-504. doi: 10.1016/s1357-2725(01)00156-x.
• [579] Persistent low expression of hZip1 in mucinous carcinomas of the ovary, colon, stomach and lung.J Ovarian Res. 2015 Jun 17;8:40. doi: 10.1186/s13048-015-0169-8.
• [580] Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling.Anticancer Res. 2018 Aug;38(8):4759-4766. doi: 10.21873/anticanres.12784.
• [581] Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.Cancer Biomark. 2016;16(1):127-35. doi: 10.3233/CBM-150548.
• [582] (E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.Bioorg Med Chem Lett. 2017 Dec 15;27(24):5409-5414. doi: 10.1016/j.bmcl.2017.11.009. Epub 2017 Nov 6.
• [583] Genetic aberrations of NAT2 and chromosome 8: their association with progression in transitional cell carcinoma of the urinary bladder.Urol Int. 2001;67(3):235-9. doi: 10.1159/000050995.
• [584] Downregulation of the cytochrome P450 4B1 protein confers a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.APMIS. 2019 Apr;127(4):170-180. doi: 10.1111/apm.12939.
• [585] Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas.Biochem J. 2003 Mar 1;370(Pt 2):403-8. doi: 10.1042/BJ20021360.
• [586] Gene expression changes in patient-matched gastric normal mucosa, adenomas, and carcinomas.Exp Mol Pathol. 2011 Apr;90(2):201-9. doi: 10.1016/j.yexmp.2010.12.004. Epub 2010 Dec 24.
• [587] HSD3B1 as a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumorlike lesions.Am J Surg Pathol. 2008 Feb;32(2):236-42. doi: 10.1097/PAS.0b013e31812e0046.
• [588] Prolyl-4-hydroxylase subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).Br J Cancer. 2018 Dec;119(12):1518-1526. doi: 10.1038/s41416-018-0337-x. Epub 2018 Nov 9.
• [589] Prostaglandin D synthase is a potential novel therapeutic agent for the treatment of gastric carcinomas expressing PPAR.Int J Cancer. 2015 Sep 1;137(5):1235-44. doi: 10.1002/ijc.29392. Epub 2015 Jan 8.
• [590] ABO Blood Group and Endometrial Carcinoma: A Preliminary Single-Center Experience from Saudi Arabia.Cureus. 2017 Dec 18;9(12):e1959. doi: 10.7759/cureus.1959.
• [591] Do microsatellite instability profiles really differ between colorectal and endometrial tumors?.Genes Chromosomes Cancer. 2009 Jul;48(7):552-7. doi: 10.1002/gcc.20664.
• [592] Clinicopathologic features and genetic alterations in endometrioid carcinoma of the uterus with villoglandular differentiation.Am J Clin Pathol. 1999 Mar;111(3):336-42. doi: 10.1093/ajcp/111.3.336.
• [593] Decreased expression of the human carbonyl reductase 2 gene HCR2 in hepatocellular carcinoma.Cell Mol Biol Lett. 2006;11(2):230-41. doi: 10.2478/s11658-006-0022-6.
• [594] Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.Environ Health Perspect. 1991 Jun;93:125-31. doi: 10.1289/ehp.9193125.
• [595] Glutathione S-transferase alpha 4 induction by activator protein 1 in colorectal cancer.Oncogene. 2016 Nov 3;35(44):5795-5806. doi: 10.1038/onc.2016.113. Epub 2016 Apr 11.
• [596] Differing expression of enzymes of the glyoxalase system in superficial and invasive bladder carcinomas.Eur J Cancer. 2002 Sep;38(14):1946-50. doi: 10.1016/s0959-8049(02)00236-8.
• [597] Identification of Hydroxysteroid (17) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.Cancer Immunol Immunother. 2011 Jul;60(7):919-29. doi: 10.1007/s00262-011-1001-y. Epub 2011 Mar 16.
• [598] Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants.Cancer Res. 2010 Aug 15;70(16):6527-36. doi: 10.1158/0008-5472.CAN-09-4167. Epub 2010 Jul 27.
• [599] Inhibition of leucine aminopeptidase 3 suppresses invasion of ovarian cancer cells through down-regulation of fascin and MMP-2/9.Eur J Pharmacol. 2015 Dec 5;768:116-22. doi: 10.1016/j.ejphar.2015.10.039. Epub 2015 Oct 23.
• [600] Cloning and characterization of ectopically expressed transcripts for the actin-binding protein MIPP in mouse mammary carcinomas.Oncogene. 2001 Aug 30;20(38):5366-72. doi: 10.1038/sj.onc.1204701.
• [601] Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization.Breast Cancer Res. 2019 May 17;21(1):64. doi: 10.1186/s13058-019-1150-z.
• [602] Clinical significance of DJ-1 as a secretory molecule: retrospective study of DJ-1 expression at mRNA and protein levels in ductal carcinoma of the breast.Histopathology. 2012 Jul;61(1):69-77. doi: 10.1111/j.1365-2559.2012.04202.x. Epub 2012 Mar 2.
• [603] MAP17 overexpression is a common characteristic of carcinomas.Carcinogenesis. 2007 Aug;28(8):1646-52. doi: 10.1093/carcin/bgm083. Epub 2007 Apr 9.
• [604] D11S146 and BCL1 are physically linked but can be discriminated by their amplification status in human breast cancer.Genomics. 1991 Jun;10(2):410-6. doi: 10.1016/0888-7543(91)90326-a.
• [605] Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.Cancer Res. 2005 Dec 15;65(24):11259-64. doi: 10.1158/0008-5472.CAN-05-2495.
• [606] Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers.Am J Pathol. 2002 Apr;160(4):1467-79. doi: 10.1016/S0002-9440(10)62572-2.
• [607] Epigenetic silencing of ADAMTS18 promotes cell migration and invasion of breast cancer through AKT and NF-B signaling.Cancer Med. 2017 Jun;6(6):1399-1408. doi: 10.1002/cam4.1076. Epub 2017 May 15.
• [608] Afamin promotes glucose metabolism in papillary thyroid carcinoma.Mol Cell Endocrinol. 2016 Oct 15;434:108-15. doi: 10.1016/j.mce.2016.06.013. Epub 2016 Jun 18.
• [609] Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.Hum Pathol. 2012 Nov;43(11):2062-9. doi: 10.1016/j.humpath.2012.02.016. Epub 2012 May 29.
• [610] Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis.Br J Cancer. 2014 May 13;110(10):2593-603. doi: 10.1038/bjc.2014.201. Epub 2014 Apr 24.
• [611] Metabolic control of PPAR activity by aldehyde dehydrogenase regulates invasive cell behavior and predicts survival in hepatocellular and renal clear cell carcinoma.BMC Cancer. 2018 Nov 28;18(1):1180. doi: 10.1186/s12885-018-5061-7.
• [612] High-resolution genomic analysis does not qualify atypical plexus papilloma as a separate entity among choroid plexus tumors.J Neuropathol Exp Neurol. 2015 Feb;74(2):110-20. doi: 10.1097/NEN.0000000000000154.
• [613] A novel somatic FGFR3 mutation in primary lung cancer.Oncol Rep. 2014 Mar;31(3):1219-24. doi: 10.3892/or.2014.2984. Epub 2014 Jan 20.
• [614] High frequency of promoter methylation of the 14-3-3 sigma and CAGE-1 genes, but lack of hypermethylation of the caveolin-1 gene, in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder.Int J Mol Med. 2007 Oct;20(4):557-63.
• [615] Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1).Anticancer Res. 2009 Apr;29(4):1389-93.
• [616] A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma.Oncogene. 2001 Sep 6;20(39):5525-32. doi: 10.1038/sj.onc.1204723.
• [617] The ratio of splicing variants of MGC-24/CD164, a sialomucin, correlates with the metastatic potential of colorectal carcinomas.J Biochem. 2000 Jun;127(6):1103-7. doi: 10.1093/oxfordjournals.jbchem.a022704.
• [618] Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.Clin Cancer Res. 2000 Aug;6(8):3131-8.
• [619] Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma.Am J Pathol. 2002 Oct;161(4):1119-25. doi: 10.1016/S0002-9440(10)64388-X.
• [620] SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.Am J Surg Pathol. 2018 Dec;42(12):1715-1722. doi: 10.1097/PAS.0000000000001159.
• [621] Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation.J Histochem Cytochem. 2017 Dec;65(12):687-703. doi: 10.1369/0022155417733676. Epub 2017 Oct 3.
• [622] Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication.Hum Pathol. 2010 Aug;41(8):1120-7. doi: 10.1016/j.humpath.2010.01.007. Epub 2010 Mar 23.
• [623] CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.Tumour Biol. 2012 Dec;33(6):2299-306. doi: 10.1007/s13277-012-0492-2. Epub 2012 Aug 25.
• [624] Ciz1 promotes tumorigenicity of prostate carcinoma cells.Front Biosci (Landmark Ed). 2015 Jan 1;20(4):705-15. doi: 10.2741/4331.
• [625] CMTM8 is Frequently Downregulated in Multiple Solid Tumors.Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):122-128. doi: 10.1097/PAI.0000000000000274.
• [626] Expression of cyclooxygenase-2 has no impact on survival in adenocarcinoma of the esophagogastric junction but is associated with favourable clinicopathologic features.Histol Histopathol. 2017 Jul;32(7):735-741. doi: 10.14670/HH-11-843. Epub 2016 Nov 17.
• [627] Placental lactogen is expressed but is not translated into protein in breast cancer.PLoS One. 2014 Jan 24;9(1):e87325. doi: 10.1371/journal.pone.0087325. eCollection 2014.
• [628] Nuclear CSPP1 expression defined subtypes of basal-like breast cancer.Br J Cancer. 2014 Jul 15;111(2):326-38. doi: 10.1038/bjc.2014.297. Epub 2014 Jun 5.
• [629] Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia.Prostate. 2004 Jul 1;60(2):109-19. doi: 10.1002/pros.20046.
• [630] Mutational analysis of hypoxia-related genes HIF1alpha and CUL2 in common human cancers.APMIS. 2009 Dec;117(12):880-5. doi: 10.1111/j.1600-0463.2009.02550.x.
• [631] E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases.Oncol Rep. 2006 May;15(5):1125-31.
• [632] Methylation of the DCC gene is lost in advanced gastric cancer.Anticancer Res. 2010 Jan;30(1):107-9.
• [633] Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study.Clin Oral Investig. 2019 Oct;23(10):3801-3809. doi: 10.1007/s00784-019-02809-z. Epub 2019 Jan 23.
• [634] Vimentin regulates differentiation switch via modulation of keratin 14 levels and their expression together correlates with poor prognosis in oral cancer patients.PLoS One. 2017 Feb 22;12(2):e0172559. doi: 10.1371/journal.pone.0172559. eCollection 2017.
• [635] Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.Lung Cancer. 2012 Jun;76(3):431-8. doi: 10.1016/j.lungcan.2011.12.004. Epub 2012 Jan 10.
• [636] Separase is a marker for prognosis and mitotic activity in breast cancer.Br J Cancer. 2017 Oct 24;117(9):1383-1391. doi: 10.1038/bjc.2017.301. Epub 2017 Aug 31.
• [637] The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.Clin Exp Metastasis. 2004;21(3):191-9. doi: 10.1023/b:clin.0000037703.37275.35.
• [638] Interaction between the ADAMTS-12 metalloprotease and fibulin-2 induces tumor-suppressive effects in breast cancer cells.Oncotarget. 2014 Mar 15;5(5):1253-64. doi: 10.18632/oncotarget.1690.
• [639] Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes.Hum Pathol. 2011 Dec;42(12):1979-88. doi: 10.1016/j.humpath.2011.02.026. Epub 2011 Jul 5.
• [640] Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.Clin Cancer Res. 2004 Mar 15;10(6):2090-9. doi: 10.1158/1078-0432.ccr-1024-03.
• [641] HMG-box transcription factor 1: a positive regulator of the G1/S transition through the Cyclin-CDK-CDKI molecular network in nasopharyngeal carcinoma.Cell Death Dis. 2018 Jan 24;9(2):100. doi: 10.1038/s41419-017-0175-4.
• [642] Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a Chinese cohort.Cancer Genet. 2014 Jul-Aug;207(7-8):291-8. doi: 10.1016/j.cancergen.2014.07.003. Epub 2014 Aug 1.
• [643] Reduced expression of INT-6/eIF3-p48 in human tumors.Int J Oncol. 2001 Jan;18(1):175-9. doi: 10.3892/ijo.18.1.175.
• [644] The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells.Toxicol Appl Pharmacol. 2017 Sep 15;331:41-53. doi: 10.1016/j.taap.2017.05.007. Epub 2017 May 10.
• [645] LEM domain containing 1 promotes oral squamous cell carcinoma invasion and endothelial transmigration.Br J Cancer. 2016 Jun 28;115(1):52-8. doi: 10.1038/bjc.2016.167. Epub 2016 Jun 9.
• [646] Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22.Oncogene. 2001 Jul 12;20(31):4169-79. doi: 10.1038/sj.onc.1204539.
• [647] The role of genetic markers--NAP1L1, MAGE-D2, and MTA1--in defining small-intestinal carcinoid neoplasia.Ann Surg Oncol. 2006 Feb;13(2):253-62. doi: 10.1245/ASO.2006.12.011. Epub 2006 Jan 20.
• [648] -Mannosidase 2C1 attenuates PTEN function in prostate cancer cells.Nat Commun. 2011;2:307. doi: 10.1038/ncomms1309.
• [649] c-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cells.Mol Cell Biol. 2012 Sep;32(17):3513-26. doi: 10.1128/MCB.00713-12. Epub 2012 Jul 2.
• [650] Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.J Pathol. 2017 Mar;241(4):488-500. doi: 10.1002/path.4853. Epub 2016 Dec 29.
• [651] Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer.Hum Mol Genet. 2002 Jun 1;11(12):1449-53. doi: 10.1093/hmg/11.12.1449.
• [652] Gene expression profiling to identify markers associated with deregulated hTERT in HPV-transformed keratinocytes and cervical cancer.Int J Cancer. 2008 Feb 15;122(4):877-88. doi: 10.1002/ijc.23210.
• [653] Mitochondrial calcium uniporter activity is dispensable for MDA-MB-231 breast carcinoma cell survival.PLoS One. 2014 May 6;9(5):e96866. doi: 10.1371/journal.pone.0096866. eCollection 2014.
• [654] Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.Eur Urol. 2000 Oct;38(4):475-82. doi: 10.1159/000020327.
• [655] Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.Pathology. 2017 Aug;49(5):457-464. doi: 10.1016/j.pathol.2017.05.004. Epub 2017 Jun 30.
• [656] Reciprocal loop of hypoxia-inducible factor-1 (HIF-1) and metastasis-associated protein 2 (MTA2) contributes to the progression of pancreatic carcinoma by suppressing E-cadherin transcription.J Pathol. 2018 Jul;245(3):349-360. doi: 10.1002/path.5089. Epub 2018 Jun 1.
• [657] The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas.Histol Histopathol. 2010 Nov;25(11):1447-56. doi: 10.14670/HH-25.1447.
• [658] Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases.Clin Chem Lab Med. 2018 Oct 25;56(11):1945-1953. doi: 10.1515/cclm-2018-0139.
• [659] Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.Diagn Pathol. 2018 Mar 12;13(1):19. doi: 10.1186/s13000-018-0696-x.
• [660] Clinical significance of NOB1 expression in breast infiltrating ductal carcinoma.Int J Clin Exp Pathol. 2013 Sep 15;6(10):2137-44. eCollection 2013.
• [661] NKD1 marks intestinal and liver tumors linked to aberrant Wnt signaling.Cell Signal. 2015 Feb;27(2):245-56. doi: 10.1016/j.cellsig.2014.11.008. Epub 2014 Nov 14.
• [662] Occludin is involved in adhesion, apoptosis, differentiation and Ca2+-homeostasis of human keratinocytes: implications for tumorigenesis.PLoS One. 2013;8(2):e55116. doi: 10.1371/journal.pone.0055116. Epub 2013 Feb 4.
• [663] Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas.Int J Cancer. 1996 Jun 11;66(6):817-20. doi: 10.1002/(SICI)1097-0215(19960611)66:6<817::AID-IJC18>3.0.CO;2-#.
• [664] Tetraspanin CD63 Bridges Autophagic and Endosomal Processes To Regulate Exosomal Secretion and Intracellular Signaling of Epstein-Barr Virus LMP1.J Virol. 2018 Feb 12;92(5):e01969-17. doi: 10.1128/JVI.01969-17. Print 2018 Mar 1.
• [665] MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy.Oncotarget. 2018 Aug 31;9(68):32958-32971. doi: 10.18632/oncotarget.26010. eCollection 2018 Aug 31.
• [666] Down-regulation of the polymeric immunoglobulin receptor in non-small cell lung carcinoma: correlation with dysregulated expression of the transcription factors USF and AP2.J Biomed Sci. 2005;12(1):65-77. doi: 10.1007/s11373-004-8185-5.
• [667] Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.Mod Pathol. 2018 Nov;31(11):1661-1674. doi: 10.1038/s41379-018-0081-z. Epub 2018 Jun 26.
• [668] Desmosomal plakophilin 2 as a differentiation marker in normal and malignant tissues.Differentiation. 1999 Jun;64(5):277-90. doi: 10.1046/j.1432-0436.1999.6450277.x.
• [669] POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance?.Anticancer Res. 2008 Mar-Apr;28(2B):1221-7.
• [670] PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.Int J Oncol. 2014 Feb;44(2):548-56. doi: 10.3892/ijo.2013.2208. Epub 2013 Dec 5.
• [671] Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.J Biol Chem. 2013 Nov 15;288(46):33387-97. doi: 10.1074/jbc.M113.485581. Epub 2013 Oct 4.
• [672] Aberrant expression of Sonic hedgehog signaling in Peutz-Jeghers syndrome.Hum Pathol. 2016 Apr;50:153-61. doi: 10.1016/j.humpath.2015.09.044. Epub 2015 Dec 29.
• [673] Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability.Cancer Res. 2001 Jan 1;61(1):36-8. doi: 10.1186/bcr362.
• [674] Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.Prostate Cancer Prostatic Dis. 2014 Jun;17(2):119-25. doi: 10.1038/pcan.2013.51. Epub 2014 Jan 14.
• [675] Association between RASSF1A Promoter Hypermethylation and Oncogenic HPV Infection Status in Invasive Cervical Cancer: a Meta-analysis.Asian Pac J Cancer Prev. 2015;16(14):5749-54. doi: 10.7314/apjcp.2015.16.14.5749.
• [676] A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer.Mol Carcinog. 2010 Mar;49(3):283-9. doi: 10.1002/mc.20598.
• [677] Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway.Biochem Biophys Res Commun. 2018 Apr 6;498(3):424-430. doi: 10.1016/j.bbrc.2018.02.167. Epub 2018 Mar 15.
• [678] Dual expression of alpha-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of alpha-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas.Mod Pathol. 2009 Jun;22(6):770-5. doi: 10.1038/modpathol.2009.24. Epub 2009 Mar 20.
• [679] Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.Horm Cancer. 2013 Jun;4(3):154-64. doi: 10.1007/s12672-013-0135-0. Epub 2013 Feb 27.
• [680] Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.Histopathology. 2017 Feb;70(3):359-366. doi: 10.1111/his.13091. Epub 2016 Nov 16.
• [681] Mammary analogue secretory carcinoma of salivary glands is a lipid-rich tumour, and adipophilin can be valuable in its identification.Histopathology. 2013 Oct;63(4):558-67. doi: 10.1111/his.12192. Epub 2013 Aug 12.
• [682] Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.Clin Cancer Res. 2012 Jul 15;18(14):3868-79. doi: 10.1158/1078-0432.CCR-11-3211. Epub 2012 May 18.
• [683] MicroRNA-133b targets glutathione S-transferase pi expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther. 2015 Sep 16;9:5225-35.
• [684] SCCRO (DCUN1D1) induces extracellular matrix invasion by activating matrix metalloproteinase 2.Clin Cancer Res. 2008 Nov 1;14(21):6780-9. doi: 10.1158/1078-0432.CCR-08-0719.
• [685] Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels.Mol Diagn Ther. 2016 Dec;20(6):603-615. doi: 10.1007/s40291-016-0230-3.
• [686] C-terminal Domain of p63 Binds to p300 to Coactivate -Catenin.Neoplasia. 2019 May;21(5):494-503. doi: 10.1016/j.neo.2019.03.010. Epub 2019 Apr 12.
• [687] Allelic imbalance and altered expression of genes in chromosome 2q11-2q16 from rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.Oncogene. 2003 Feb 27;22(8):1253-60. doi: 10.1038/sj.onc.1206233.
• [688] Cortactin and phosphorylated cortactin tyr(421) and tyr(466) expression in supraglottic laryngeal carcinomas and lymph node metastases.Int J Biol Markers. 2018 Jan;33(1):79-86. doi: 10.5301/ijbm.5000297.
• [689] Down-regulation of EGFL8: a novel biomarker for advanced gastric cancer.Anticancer Res. 2011 Oct;31(10):3377-80.
• [690] Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro.Int J Gynecol Cancer. 2011 Jul;21(5):800-5. doi: 10.1097/IGC.0b013e31821a2584.
• [691] Id4 regulates mammary epithelial cell growth and differentiation and is overexpressed in rat mammary gland carcinomas.Am J Pathol. 2003 Dec;163(6):2495-502. doi: 10.1016/S0002-9440(10)63604-8.
• [692] Leupaxin is expressed in mammary carcinoma and acts as a transcriptional activator of the estrogen receptor .Int J Oncol. 2015 Jul;47(1):106-14. doi: 10.3892/ijo.2015.2988. Epub 2015 May 6.
• [693] Expression of cellular adhesion molecule 'OPCML' is down-regulated in gliomas and other brain tumours.Neuropathol Appl Neurobiol. 2007 Feb;33(1):77-85. doi: 10.1111/j.1365-2990.2006.00786.x.
• [694] Decreased expression of SPRR3 in Chinese human oesophageal cancer.Carcinogenesis. 2000 Dec;21(12):2147-50. doi: 10.1093/carcin/21.12.2147.
• [695] Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma.Oncol Rep. 2009 Aug;22(2):279-83.
• [696] EMT is associated with an epigenetic signature of ECM remodeling genes.Cell Death Dis. 2019 Feb 27;10(3):205. doi: 10.1038/s41419-019-1397-4.
• [697] SOX4, an epithelial-mesenchymal transition inducer, transactivates ADAM28 gene expression and co-localizes with ADAM28 at the invasive front of human breast and lung carcinomas.Pathol Int. 2018 Jun 7. doi: 10.1111/pin.12685. Online ahead of print.
• [698] High expression of fructose-bisphosphate aldolaseA induces progression of renal cell carcinoma.Oncol Rep. 2018 Jun;39(6):2996-3006. doi: 10.3892/or.2018.6378. Epub 2018 Apr 18.
• [699] Clinical application of MAGE A1-6 RT-nested PCR for diagnosis of lung cancer invisible by bronchoscopy.Anticancer Res. 2012 Jan;32(1):163-7.
• [700] Evidence for APOBEC3B mRNA and protein expression in oral squamous cell carcinomas.Exp Mol Pathol. 2016 Dec;101(3):314-319. doi: 10.1016/j.yexmp.2016.11.001. Epub 2016 Nov 4.
• [701] Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma invitro.Int J Oncol. 2017 Apr;50(4):1431-1438. doi: 10.3892/ijo.2017.3891. Epub 2017 Feb 23.
• [702] Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.Mod Pathol. 2016 Dec;29(12):1586-1593. doi: 10.1038/modpathol.2016.156. Epub 2016 Aug 26.
• [703] Tumor suppressor functions of ARLTS1 in lung cancers.Cancer Res. 2007 Aug 15;67(16):7738-45. doi: 10.1158/0008-5472.CAN-07-1481.
• [704] Dissecting the regulation of EBV's BART miRNAs in carcinomas.Virology. 2017 May;505:148-154. doi: 10.1016/j.virol.2017.02.013. Epub 2017 Mar 1.
• [705] miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.J Clin Endocrinol Metab. 2015 Jan;100(1):E59-69. doi: 10.1210/jc.2014-2280.
• [706] EWSR1 translocation in primary hyalinising clear cell carcinoma of the thymus.Histopathology. 2019 Sep;75(3):431-436. doi: 10.1111/his.13890. Epub 2019 Jul 19.
• [707] Aberrant SERCA3 expression is closely linked to pathogenesis, invasion, metastasis, and prognosis of gastric carcinomas.Tumour Biol. 2012 Dec;33(6):1845-54. doi: 10.1007/s13277-012-0444-x. Epub 2012 Sep 5.
• [708] DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer.Blood Cells Mol Dis. 2013 Mar;50(3):161-5. doi: 10.1016/j.bcmd.2012.10.009. Epub 2012 Nov 17.
• [709] DEC1 negatively regulates the expression of DEC2 through binding to the E-box in the proximal promoter.J Biol Chem. 2003 May 9;278(19):16899-907. doi: 10.1074/jbc.M300596200. Epub 2003 Mar 6.
• [710] Cyclase-associated protein 1 is a key negative regulator of milk synthesis and proliferation of bovine mammary epithelial cells.Cell Biochem Funct. 2019 Apr;37(3):185-192. doi: 10.1002/cbf.3387. Epub 2019 Mar 8.
• [711] Immunohistochemical and mutational analysis of FLASH in gastric carcinomas.APMIS. 2007 Aug;115(8):900-5. doi: 10.1111/j.1600-0463.2007.apm_706.x.
• [712] Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas.PLoS One. 2013 Sep 3;8(9):e74738. doi: 10.1371/journal.pone.0074738. eCollection 2013.
• [713] miR-1246 Targets CCNG2 to Enhance Cancer Stemness and Chemoresistance in Oral Carcinomas.Cancers (Basel). 2018 Aug 16;10(8):272. doi: 10.3390/cancers10080272.
• [714] CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells.Pathol Int. 2007 May;57(5):245-50. doi: 10.1111/j.1440-1827.2007.02097.x.
• [715] Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma.World J Surg Oncol. 2011 Apr 27;9:43. doi: 10.1186/1477-7819-9-43.
• [716] Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and precancerous lesions.Anticancer Res. 2008 Nov-Dec;28(6A):3763-9.
• [717] CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.Oncogene. 2016 Sep 8;35(36):4762-72. doi: 10.1038/onc.2016.7. Epub 2016 Feb 15.
• [718] Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/-catenin signaling.PLoS One. 2013;8(3):e56959. doi: 10.1371/journal.pone.0056959. Epub 2013 Mar 15.
• [719] Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.J Clin Pathol. 2012 Sep;65(9):795-801. doi: 10.1136/jclinpath-2012-200893. Epub 2012 Jul 12.
• [720] CCAAT/enhancer binding protein delta (C/EBP) demonstrates a dichotomous role in tumour initiation and promotion of epithelial carcinoma.EBioMedicine. 2019 Jun;44:261-274. doi: 10.1016/j.ebiom.2019.05.002. Epub 2019 May 9.
• [721] Expression profiles of proto-oncogene TWIST1 and tumor metastasis suppressor gene LASS2 in bladder cancer.Cell Mol Biol (Noisy-le-grand). 2018 Aug 30;64(11):66-73.
• [722] Claudin-7 increases chemosensitivity to cisplatin through the upregulation of caspase pathway in human NCI-H522 lung cancer cells.Cancer Sci. 2013 May;104(5):611-8. doi: 10.1111/cas.12135. Epub 2013 Mar 29.
• [723] CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis.PLoS One. 2014 Feb 28;9(2):e88965. doi: 10.1371/journal.pone.0088965. eCollection 2014.
• [724] Expression of methylation-modulated tumor-related genes in endoscopically resected early esophageal squamous neoplasia.Oncol Lett. 2017 Jul;14(1):737-742. doi: 10.3892/ol.2017.6196. Epub 2017 May 17.
• [725] Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer.Oncotarget. 2016 Jan 26;7(4):3832-46. doi: 10.18632/oncotarget.6757.
• [726] DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.Mol Cancer. 2007 Jul 10;6:45. doi: 10.1186/1476-4598-6-45.
• [727] Cellular retinoic acid-binding protein 2 inhibits tumor growth by two distinct mechanisms.J Biol Chem. 2014 Dec 5;289(49):34065-73. doi: 10.1074/jbc.M114.604041. Epub 2014 Oct 15.
• [728] Emerging role of microRNAs in modulating endothelin-1 expression in gastric cancer.Oncol Rep. 2015 Jan;33(1):485-93. doi: 10.3892/or.2014.3598. Epub 2014 Nov 11.
• [729] Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer.J Biol Chem. 2017 Feb 17;292(7):2966-2978. doi: 10.1074/jbc.M116.765230. Epub 2016 Dec 14.
• [730] An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells.Oncogene. 2010 Dec 16;29(50):6522-32. doi: 10.1038/onc.2010.378. Epub 2010 Sep 13.
• [731] Frequent methylation of DAB2, a Wnt pathway antagonist, in oral and oropharyngeal squamous cell carcinomas.Pathol Res Pract. 2018 Feb;214(2):314-317. doi: 10.1016/j.prp.2017.12.010. Epub 2017 Dec 14.
• [732] Prognostic significance of the methylation of Wnt pathway antagonists-CXXC4, DACT2, and the inhibitors of sonic hedgehog signaling-ZIC1, ZIC4, and HHIP in head and neck squamous cell carcinomas.Clin Oral Investig. 2017 Jun;21(5):1777-1788. doi: 10.1007/s00784-016-1946-5. Epub 2016 Aug 23.
• [733] MCL1 and DEDD Promote Urothelial Carcinoma Progression.Mol Cancer Res. 2019 Jun;17(6):1294-1304. doi: 10.1158/1541-7786.MCR-18-0963. Epub 2019 Feb 18.
• [734] Cooperation between Dmp1 loss and cyclin D1 overexpression in breast cancer.Am J Pathol. 2013 Oct;183(4):1339-1350. doi: 10.1016/j.ajpath.2013.06.027. Epub 2013 Aug 11.
• [735] Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.Hum Pathol. 2012 Apr;43(4):496-505. doi: 10.1016/j.humpath.2011.05.023. Epub 2011 Aug 19.
• [736] Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.Br J Cancer. 2004 Mar 8;90(5):1041-6. doi: 10.1038/sj.bjc.6601648.
• [737] Key contribution of eIF4H-mediated translational control in tumor promotion.Oncotarget. 2015 Nov 24;6(37):39924-40. doi: 10.18632/oncotarget.5442.
• [738] Overexpression of p27BBP in head and neck carcinomas and their lymph node metastases.Head Neck. 2004 May;26(5):408-17. doi: 10.1002/hed.10401.
• [739] Effect of the normal mammary differentiation regulator ELF5 upon clinical outcomes of triple negative breast cancers patients.Breast Cancer. 2018 Jul;25(4):489-496. doi: 10.1007/s12282-018-0842-z. Epub 2018 Feb 2.
• [740] DAL-1 attenuates epithelial-to mesenchymal transition in lung cancer.J Exp Clin Cancer Res. 2015 Jan 22;34(1):3. doi: 10.1186/s13046-014-0117-2.
• [741] Functional analysis of fatty acid binding protein 7 and its effect on fatty acid of renal cell carcinoma cell lines.BMC Cancer. 2017 Mar 14;17(1):192. doi: 10.1186/s12885-017-3184-x.
• [742] In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis.Oncogene. 2016 Oct 13;35(41):5446-5455. doi: 10.1038/onc.2016.94. Epub 2016 Apr 11.
• [743] Birt-Hogg-Dub syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.Fam Cancer. 2016 Jan;15(1):127-32. doi: 10.1007/s10689-015-9837-5.
• [744] IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.Hum Pathol. 2018 Nov;81:138-147. doi: 10.1016/j.humpath.2018.07.003. Epub 2018 Jul 18.
• [745] The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.Cancer. 2018 Jan 1;124(1):65-73. doi: 10.1002/cncr.30971. Epub 2017 Sep 21.
• [746] The link between FOXJ1 expression level in bladder carcinoma and tumor recurrence.Oncol Lett. 2018 Feb;15(2):1483-1486. doi: 10.3892/ol.2017.7504. Epub 2017 Nov 29.
• [747] Forkhead box O4 transcription factor in human neoplasms: Cannot afford to lose the novel suppressor.J Cell Physiol. 2019 Jun;234(6):8647-8658. doi: 10.1002/jcp.27853. Epub 2018 Dec 4.
• [748] Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma.Cancer Biol Ther. 2008 Oct;7(10):1593-601. doi: 10.4161/cbt.7.10.6565. Epub 2008 Oct 7.
• [749] C2-O-sLeX glycoproteins are E-selectin ligands that regulate invasion of human colon and hepatic carcinoma cells.PLoS One. 2011 Jan 19;6(1):e16281. doi: 10.1371/journal.pone.0016281.
• [750] Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin.J Pathol. 2007 Apr;211(5):507-515. doi: 10.1002/path.2138.
• [751] Distinct Biochemical Pools of Golgi Phosphoprotein 3 in the Human Breast Cancer Cell Lines MCF7 and MDA-MB-231.PLoS One. 2016 Apr 28;11(4):e0154719. doi: 10.1371/journal.pone.0154719. eCollection 2016.
• [752] Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.Mod Pathol. 2016 Jun;29(6):607-15. doi: 10.1038/modpathol.2016.59. Epub 2016 Mar 25.
• [753] Expression and mutation analysis of TIG1 (tazarotene-induced gene 1) in human gastric cancer.Oncol Res. 2009;17(11-12):571-80. doi: 10.3727/096504009789745584.
• [754] Methylation of HACE1 in gastric carcinoma.Anticancer Res. 2009 Jun;29(6):2231-3.
• [755] Hyaluronic acid synthase 2 promotes malignant phenotypes of colorectal cancer cells through transforming growth factor beta signaling.Cancer Sci. 2019 Jul;110(7):2226-2236. doi: 10.1111/cas.14070. Epub 2019 Jun 12.
• [756] HEX, PAX-8 and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism.Clin Endocrinol (Oxf). 2006 Apr;64(4):398-404. doi: 10.1111/j.1365-2265.2006.02477.x.
• [757] Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification.J Clin Endocrinol Metab. 2012 Jul;97(7):E1307-15. doi: 10.1210/jc.2011-3136. Epub 2012 Apr 27.
• [758] Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8(+) Tumor-Infiltrating T Lymphocyte Responses.Cancer Immunol Res. 2019 Aug;7(8):1293-1306. doi: 10.1158/2326-6066.CIR-18-0885. Epub 2019 Jun 18.
• [759] Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma.Br J Cancer. 2011 Jul 12;105(2):288-95. doi: 10.1038/bjc.2011.217. Epub 2011 Jun 28.
• [760] The altered expression of ING5 protein is involved in gastric carcinogenesis and subsequent progression.Hum Pathol. 2011 Jan;42(1):25-35. doi: 10.1016/j.humpath.2010.05.024. Epub 2010 Nov 9.
• [761] Immunolabeling of the inhibin-A and -B subunit in normal and malignant human cervical tissue and cervical cancer cell lines.Int J Gynecol Cancer. 2010 Oct;20(7):1117-24. doi: 10.1111/IGC.0b013e3181ef10aa.
• [762] INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity.Am J Surg Pathol. 2017 Nov;41(11):1561-1569. doi: 10.1097/PAS.0000000000000916.
• [763] ITGB4 is a novel prognostic factor in colon cancer.J Cancer. 2019 Aug 28;10(21):5223-5233. doi: 10.7150/jca.29269. eCollection 2019.
• [764] HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.Oncogene. 2018 Mar;37(12):1654-1668. doi: 10.1038/s41388-017-0083-1. Epub 2018 Jan 16.
• [765] E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor.Oncogene. 2006 Sep 28;25(44):6026-31. doi: 10.1038/sj.onc.1209611. Epub 2006 May 15.
• [766] The level of Krppel-like factor 8 expression predicts prognosis and metastasis in various carcinomas.Medicine (Baltimore). 2019 May;98(18):e15519. doi: 10.1097/MD.0000000000015519.
• [767] Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.Ann Diagn Pathol. 2019 Dec;43:151397. doi: 10.1016/j.anndiagpath.2019.08.001. Epub 2019 Aug 3.
• [768] Quantitative phosphoproteomic analysis reveals system-wide signaling pathways regulated by site-specific phosphorylation of Keratin-8 in skin squamous cell carcinoma derived cell line.Proteomics. 2017 Apr;17(7). doi: 10.1002/pmic.201600254.
• [769] Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer.Nat Cell Biol. 2015 May;17(5):651-64. doi: 10.1038/ncb3148. Epub 2015 Apr 13.
• [770] Hypermethylation of promoter region of LATS1--a CDK interacting protein in oral squamous cell carcinomas--a pilot study in India.Asian Pac J Cancer Prev. 2015;16(4):1599-603. doi: 10.7314/apjcp.2015.16.4.1599.
• [771] Magnifying glass on spiradenoma and cylindroma histogenesis and tumorigenesis using systematic transcriptome analysis.Ann Diagn Pathol. 2019 Aug;41:14-23. doi: 10.1016/j.anndiagpath.2019.04.015. Epub 2019 May 5.
• [772] Upregulation of FAM84B during prostate cancer progression.Oncotarget. 2017 Mar 21;8(12):19218-19235. doi: 10.18632/oncotarget.15168.
• [773] Electrochemical peptide sensor for diagnosing adenoma-carcinoma transition in colon cancer.Biosens Bioelectron. 2017 Dec 15;98:330-337. doi: 10.1016/j.bios.2017.07.013. Epub 2017 Jul 6.
• [774] Nuclear localization of LDL receptor-related protein 1B in mammary gland carcinogenesis.J Mol Med (Berl). 2019 Feb;97(2):257-268. doi: 10.1007/s00109-018-01732-2. Epub 2019 Jan 3.
• [775] LTBP3 promotes early metastatic events during cancer cell dissemination.Oncogene. 2018 Apr;37(14):1815-1829. doi: 10.1038/s41388-017-0075-1. Epub 2018 Jan 19.
• [776] Prognostic value and clinical pathology of MACC-1 and c-MET expression in gastric carcinoma.Pathol Oncol Res. 2013 Oct;19(4):821-32. doi: 10.1007/s12253-013-9650-0. Epub 2013 Jul 1.
• [777] Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.J Gynecol Oncol. 2017 May;28(3):e33. doi: 10.3802/jgo.2017.28.e33. Epub 2017 Feb 13.
• [778] Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract.Oncogene. 2006 Mar 30;25(14):2113-8. doi: 10.1038/sj.onc.1209229.
• [779] Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas.Cell Oncol. 2008;30(5):389-95. doi: 10.3233/clo-2008-0439.
• [780] NAIF1 suppresses osteosarcoma progression and is regulated by miR-128.Cell Biochem Funct. 2018 Dec;36(8):443-449. doi: 10.1002/cbf.3365. Epub 2018 Nov 8.
• [781] NETO2 promotes invasion and metastasis of gastric cancer cells via activation of PI3K/Akt/NF-B/Snail axis and predicts outcome of the patients.Cell Death Dis. 2019 Feb 15;10(3):162. doi: 10.1038/s41419-019-1388-5.
• [782] NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM.Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6524-9. doi: 10.1073/pnas.1303932110. Epub 2013 Apr 3.
• [783] Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma.Int J Clin Exp Pathol. 2013 Oct 15;6(11):2300-11. eCollection 2013.
• [784] Defective repair capacity of variant proteins of the DNA glycosylase NTHL1 for 5-hydroxyuracil, an oxidation product of cytosine.Free Radic Biol Med. 2019 Feb 1;131:264-273. doi: 10.1016/j.freeradbiomed.2018.12.010. Epub 2018 Dec 12.
• [785] OTX1 and OTX2 as possible molecular markers of sinonasal carcinomas and olfactory neuroblastomas.Eur J Histochem. 2017 Feb 9;61(1):2730. doi: 10.4081/ejh.2017.2730.
• [786] From structure to redox: The diverse functional roles of disulfides and implications in disease.Proteomics. 2017 Mar;17(6):10.1002/pmic.201600391. doi: 10.1002/pmic.201600391.
• [787] PCBP1 depletion promotes tumorigenesis through attenuation of p27(Kip1) mRNA stability and translation.J Exp Clin Cancer Res. 2018 Aug 7;37(1):187. doi: 10.1186/s13046-018-0840-1.
• [788] Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers.Oncotarget. 2017 Feb 21;8(8):13344-13356. doi: 10.18632/oncotarget.14527.
• [789] Cohesin subunits, STAG1 and STAG2, and cohesin regulatory factor, PDS5b, in oral squamous cells carcinomas.J Oral Pathol Med. 2017 Mar;46(3):188-193. doi: 10.1111/jop.12474. Epub 2016 Jun 24.
• [790] SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancer.Int J Cancer. 2005 Sep 10;116(4):547-54. doi: 10.1002/ijc.20912.
• [791] Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: a case report.BMC Cancer. 2019 Jun 17;19(1):592. doi: 10.1186/s12885-019-5780-4.
• [792] Phospholipase C isozymes are deregulated in colorectal cancer--insights gained from gene set enrichment analysis of the transcriptome.PLoS One. 2011;6(9):e24419. doi: 10.1371/journal.pone.0024419. Epub 2011 Sep 1.
• [793] Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.Hum Pathol. 2018 Feb;72:100-106. doi: 10.1016/j.humpath.2017.11.006. Epub 2017 Nov 11.
• [794] Protein Phosphatase 2A: More Than a Passenger in the Regulation of Epithelial Cell-Cell Junctions.Front Cell Dev Biol. 2019 Mar 6;7:30. doi: 10.3389/fcell.2019.00030. eCollection 2019.
• [795] Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma.Br J Cancer. 2006 Jun 5;94(11):1672-7. doi: 10.1038/sj.bjc.6603155.
• [796] Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.Radiother Oncol. 2018 Sep;128(3):557-563. doi: 10.1016/j.radonc.2018.06.008. Epub 2018 Jun 18.
• [797] Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.Breast Cancer Res. 2011 Jan 21;13(1):R9. doi: 10.1186/bcr2814.
• [798] Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.Gynecol Oncol. 2018 Feb;148(2):281-285. doi: 10.1016/j.ygyno.2017.12.004. Epub 2017 Dec 9.
• [799] Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.PLoS One. 2016 Jan 19;11(1):e0147230. doi: 10.1371/journal.pone.0147230. eCollection 2016.
• [800] Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2.FASEB J. 2011 Jan;25(1):55-65. doi: 10.1096/fj.10-162677. Epub 2010 Aug 27.
• [801] Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases.Anticancer Res. 2002 Jul-Aug;22(4):1949-57.
• [802] Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.Hum Pathol. 2011 Jun;42(6):833-9. doi: 10.1016/j.humpath.2010.08.022. Epub 2011 Jan 3.
• [803] Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway.PLoS One. 2014 Oct 6;9(10):e108743. doi: 10.1371/journal.pone.0108743. eCollection 2014.
• [804] Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.J Gynecol Oncol. 2017 Jul;28(4):e39. doi: 10.3802/jgo.2017.28.e39.
• [805] R-RAS2 overexpression in tumors of the human central nervous system.Mol Cancer. 2013 Oct 23;12(1):127. doi: 10.1186/1476-4598-12-127.
• [806] SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.Hum Pathol. 2012 May;43(5):669-74. doi: 10.1016/j.humpath.2011.06.003. Epub 2011 Aug 19.
• [807] SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo.Oncogene. 2003 Sep 25;22(41):6359-68. doi: 10.1038/sj.onc.1206665.
• [808] MiR-6872 host gene SEMA3B and its antisense lncRNA SEMA3B-AS1 function synergistically to suppress gastric cardia adenocarcinoma progression.Gastric Cancer. 2019 Jul;22(4):705-722. doi: 10.1007/s10120-019-00924-0. Epub 2019 Jan 17.
• [809] Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas.Hum Pathol. 2006 Nov;37(11):1414-25. doi: 10.1016/j.humpath.2006.04.031. Epub 2006 Sep 28.
• [810] Morphologic correlates of molecular alterations in extrauterine Mllerian carcinomas.Mod Pathol. 2016 Aug;29(8):893-903. doi: 10.1038/modpathol.2016.82. Epub 2016 May 6.
• [811] Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer.Lab Invest. 2004 Apr;84(4):465-78. doi: 10.1038/labinvest.3700068.
• [812] Sirtuin 7 promotes colorectal carcinoma proliferation and invasion through the inhibition of E-cadherin.Exp Ther Med. 2018 Mar;15(3):2333-2342. doi: 10.3892/etm.2017.5673. Epub 2017 Dec 22.
• [813] PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis.Anticancer Agents Med Chem. 2011 Jan;11(1):99-108. doi: 10.2174/187152011794941145.
• [814] Clinical signicance and prognostic value of SOX7 expression in liver and pancreatic carcinoma.Mol Med Rep. 2017 Jul;16(1):499-506. doi: 10.3892/mmr.2017.6660. Epub 2017 May 31.
• [815] Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2.Am J Physiol Renal Physiol. 2013 Aug 1;305(3):F382-9. doi: 10.1152/ajprenal.00357.2012. Epub 2013 May 22.
• [816] SPROUTY2 is a -catenin and FOXO3a target gene indicative of poor prognosis in colon cancer.Oncogene. 2014 Apr 10;33(15):1975-85. doi: 10.1038/onc.2013.140. Epub 2013 Apr 29.
• [817] O-glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype.EBioMedicine. 2019 Feb;40:349-362. doi: 10.1016/j.ebiom.2019.01.017. Epub 2019 Jan 17.
• [818] STRAD in Peutz-Jeghers syndrome and sporadic cancers.J Clin Pathol. 2005 Oct;58(10):1091-5. doi: 10.1136/jcp.2005.026013.
• [819] Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits.Histopathology. 2019 Jan;74(2):300-310. doi: 10.1111/his.13733. Epub 2018 Nov 11.
• [820] The T-Box transcription factor 3 in development and cancer.Biosci Trends. 2017 Jul 24;11(3):254-266. doi: 10.5582/bst.2017.01043. Epub 2017 Jun 4.
• [821] The VHL/HIF axis in clear cell renal carcinoma.Semin Cancer Biol. 2013 Feb;23(1):18-25. doi: 10.1016/j.semcancer.2012.06.001. Epub 2012 Jun 13.
• [822] Cytosine 5-hydroxymethylation regulates VHL gene expression in renal clear cell carcinoma.Oncotarget. 2017 Jul 7;8(38):63780-63787. doi: 10.18632/oncotarget.19070. eCollection 2017 Sep 8.
• [823] Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma.Am J Pathol. 2002 Oct;161(4):1315-23. doi: 10.1016/S0002-9440(10)64408-2.
• [824] Uncommon and recently described renal carcinomas.Mod Pathol. 2009 Jun;22 Suppl 2:S2-S23. doi: 10.1038/modpathol.2009.70.
• [825] Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor--induced expression in urothelial carcinoma.Cancer Sci. 2018 Apr;109(4):980-987. doi: 10.1111/cas.13403. Epub 2018 Feb 20.
• [826] The clinicopathological significance of Thrombospondin-4 expression in the tumor microenvironment of gastric cancer.PLoS One. 2019 Nov 8;14(11):e0224727. doi: 10.1371/journal.pone.0224727. eCollection 2019.
• [827] Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer.Cancer Med. 2018 Jun;7(6):2592-2600. doi: 10.1002/cam4.1494. Epub 2018 Apr 17.
• [828] TMEM158 promotes pancreatic cancer aggressiveness by activation of TGF1 and PI3K/AKT signaling pathway.J Cell Physiol. 2020 Mar;235(3):2761-2775. doi: 10.1002/jcp.29181. Epub 2019 Sep 17.
• [829] High TNFAIP6 level is associated with poor prognosis of urothelial carcinomas.Urol Oncol. 2019 Apr;37(4):293.e11-293.e24. doi: 10.1016/j.urolonc.2018.12.009. Epub 2018 Dec 27.
• [830] TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/-catenin pathway.J Transl Med. 2018 Jan 17;16(1):7. doi: 10.1186/s12967-018-1383-0.
• [831] Topoisomerase II-binding protein 1 activates expression of E2F1 and p73 in HPV-positive cells for genome amplification upon epithelial differentiation.Oncogene. 2019 Apr;38(17):3274-3287. doi: 10.1038/s41388-018-0633-1. Epub 2019 Jan 10.
• [832] TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma.Oncotarget. 2017 Mar 28;8(13):21229-21240. doi: 10.18632/oncotarget.15070.
• [833] Tripartite motif 16 suppresses breast cancer stem cell properties through regulation of Gli-1 degradation via the ubiquitin-proteasome pathway.Oncol Rep. 2016 Feb;35(2):1204-12. doi: 10.3892/or.2015.4437. Epub 2015 Nov 18.
• [834] Silencing Tspan1 inhibits migration and invasion, and induces the apoptosis of human pancreatic cancer cells.Mol Med Rep. 2018 Sep;18(3):3280-3288. doi: 10.3892/mmr.2018.9331. Epub 2018 Jul 27.
• [835] ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence.BMC Cancer. 2011 Jan 11;11:11. doi: 10.1186/1471-2407-11-11.
• [836] Levels of acyl-coenzyme A synthetase 5 in urothelial cells and corresponding neoplasias reflect cellular differentiation.Histol Histopathol. 2013 Mar;28(3):353-64. doi: 10.14670/HH-28.353.
• [837] New network topology approaches reveal differential correlation patterns in breast cancer.BMC Syst Biol. 2013 Aug 15;7:78. doi: 10.1186/1752-0509-7-78.
• [838] Actinin-4 as a Diagnostic Biomarker in Serum of Breast Cancer Patients.Med Sci Monit. 2019 May 4;25:3298-3302. doi: 10.12659/MSM.912404.
• [839] ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling.Hepatology. 2003 May;37(5):1056-66. doi: 10.1053/jhep.2003.50205.
• [840] ADAM15 to 51 integrin switch in colon carcinoma cells: a late event in cancer progression associated with tumor dedifferentiation and poor prognosis.Int J Cancer. 2012 Jan 15;130(2):278-87. doi: 10.1002/ijc.25891. Epub 2011 Nov 9.
• [841] The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation.Mol Cancer Res. 2014 Feb;12(2):228-38. doi: 10.1158/1541-7786.MCR-13-0195. Epub 2013 Nov 1.
• [842] The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer.J Cell Mol Med. 2018 Feb;22(2):1257-1271. doi: 10.1111/jcmm.13404. Epub 2017 Nov 29.
• [843] Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis.Acta Neuropathol. 2017 Dec;134(6):905-922. doi: 10.1007/s00401-017-1774-y. Epub 2017 Oct 13.
• [844] Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets.Mol Cancer Ther. 2009 Jan;8(1):249-60. doi: 10.1158/1535-7163.MCT-08-0636.
• [845] Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes.Oncotarget. 2015 Jul 10;6(19):17342-53. doi: 10.18632/oncotarget.3944.
• [846] G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1.J Pathol. 2013 May;230(1):70-81. doi: 10.1002/path.4170. Epub 2013 Mar 14.
• [847] AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.J Clin Invest. 2007 Oct;117(10):2962-73. doi: 10.1172/JCI30710.
• [848] Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.Int J Mol Sci. 2018 May 31;19(6):1622. doi: 10.3390/ijms19061622.
• [849] New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas.Oncol Rep. 2006 Sep;16(3):603-8. doi: 10.3892/or.16.3.603.
• [850] Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells.J Exp Med. 1999 Aug 2;190(3):341-54. doi: 10.1084/jem.190.3.341.
• [851] The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.Cancer Res. 2001 Jul 15;61(14):5644-51.
• [852] Blood group ABH-related antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas.Int J Cancer. 1989 May 15;43(5):774-80. doi: 10.1002/ijc.2910430505.
• [853] ALKBH2, a novel AlkB homologue, contributes to human bladder cancer progression by regulating MUC1 expression.Cancer Sci. 2013 Mar;104(3):321-7. doi: 10.1111/cas.12089. Epub 2013 Feb 14.
• [854] A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression.Cancer Res. 2009 Apr 1;69(7):3157-64. doi: 10.1158/0008-5472.CAN-08-3530. Epub 2009 Mar 17.
• [855] Angioarrestin mRNA expression in early-stage lung cancers.Eur J Surg Oncol. 2003 Oct;29(8):649-53. doi: 10.1016/s0748-7983(03)00106-9.
• [856] Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5.Pathol Oncol Res. 2018 Apr;24(2):259-267. doi: 10.1007/s12253-017-0246-y. Epub 2017 May 3.
• [857] Involvement of hepatopoietin Cn in the development of human hepatocellular carcinoma.Clin Exp Metastasis. 2010 Dec;27(8):571-80. doi: 10.1007/s10585-010-9346-8. Epub 2010 Aug 4.
• [858] Expression of pp32 gene family members in breast cancer.Breast Cancer Res Treat. 2001 Jul;68(1):65-73. doi: 10.1023/a:1017919507109.
• [859] Expression of Tumour Endothelial Marker 8 in Canine Mammary Gland Tumour Cells.J Comp Pathol. 2019 Nov;173:30-40. doi: 10.1016/j.jcpa.2019.10.001. Epub 2019 Nov 4.
• [860] Expression of the opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor in head and neck squamous cell carcinoma.Laryngoscope. 1997 Mar;107(3):335-9. doi: 10.1097/00005537-199703000-00011.
• [861] Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas.Gastroenterology. 2003 May;124(5):1300-10. doi: 10.1016/s0016-5085(03)00278-6.
• [862] Role of DNA methylation in the development of Epstein-Barr virus-associated gastric carcinoma.J Med Virol. 2013 Jan;85(1):121-7. doi: 10.1002/jmv.23405. Epub 2012 Oct 16.
• [863] Identification of apolipoprotein D as a novel inhibitor of osteopontin-induced neoplastic transformation.Int J Oncol. 2006 Dec;29(6):1591-9.
• [864] Changes in gene expression during progression of ovarian carcinoma.Cancer Genet Cytogenet. 2001 Jul 1;128(1):1-6. doi: 10.1016/s0165-4608(01)00386-7.
• [865] Differential expression of ARID3B in normal adult tissue and carcinomas.Gene. 2014 Jun 10;543(1):174-80. doi: 10.1016/j.gene.2014.04.007. Epub 2014 Apr 3.
• [866] RBP1L1, a retinoblastoma-binding protein-related gene encoding an antigenic epitope abundantly expressed in human carcinomas and normal testis.J Natl Cancer Inst. 2001 Aug 1;93(15):1159-65. doi: 10.1093/jnci/93.15.1159.
• [867] Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.BMC Cancer. 2015 Apr 30;15:331. doi: 10.1186/s12885-015-1364-0.
• [868] ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas.Biochem Biophys Res Commun. 2001 Jan 12;280(1):340-7. doi: 10.1006/bbrc.2000.4125.
• [869] Human achaete-scute homolog-1 expression in neuroendocrine breast carcinoma.Virchows Arch. 2012 Apr;460(4):415-21. doi: 10.1007/s00428-012-1223-1. Epub 2012 Mar 16.
• [870] H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1.Hum Pathol. 2010 Feb;41(2):181-9. doi: 10.1016/j.humpath.2009.08.007. Epub 2009 Nov 6.
• [871] Bilateral renal tumors; conventional clear cell carcinoma and contralateral t(6;11)/t(X;17)-like tumor Histomorphologic, immunohistochemical, ultrastructural and molecular genetic studies including the report of a novel mutation in the VHL gene.Ann Diagn Pathol. 2011 Oct;15(5):362-9. doi: 10.1016/j.anndiagpath.2010.05.004. Epub 2010 Aug 14.
• [872] Molecular characterization of the tumor-associated antigen AAA-TOB3.Cell Mol Life Sci. 2006 Sep;63(18):2162-74. doi: 10.1007/s00018-006-6200-x.
• [873] Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability.J Pathol. 2009 Apr;217(5):702-6. doi: 10.1002/path.2509.
• [874] Post-transcriptional regulation of the mitochondrial H(+)-ATP synthase: a key regulator of the metabolic phenotype in cancer.Biochim Biophys Acta. 2011 Jun;1807(6):543-51. doi: 10.1016/j.bbabio.2010.10.016. Epub 2010 Oct 27.
• [875] Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis.Genes Chromosomes Cancer. 2013 Jan;52(1):56-68. doi: 10.1002/gcc.22006. Epub 2012 Sep 14.
• [876] The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response.Mol Cell. 2012 Mar 30;45(6):731-42. doi: 10.1016/j.molcel.2012.01.008. Epub 2012 Feb 16.
• [877] Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger?.Br J Cancer. 2003 Jul 7;89(1):113-9. doi: 10.1038/sj.bjc.6601027.
• [878] Verification of predicted alternatively spliced Wnt genes reveals two new splice variants (CTNNB1 and LRP5) and altered Axin-1 expression during tumour progression.BMC Genomics. 2006 Jun 13;7:148. doi: 10.1186/1471-2164-7-148.
• [879] DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability.BMC Cancer. 2014 Jun 25;14:466. doi: 10.1186/1471-2407-14-466.
• [880] Neuroendocrine marker expression in thyroid epithelial tumors.Endocr Pathol. 2001 Fall;12(3):291-9. doi: 10.1385/ep:12:3:291.
• [881] DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer.Gastroenterology. 2008 Jul;135(1):142-151.e3. doi: 10.1053/j.gastro.2008.03.031. Epub 2008 Mar 21.
• [882] Immunohistochemical analysis of phospho-BAD protein and mutational analysis of BAD gene in gastric carcinomas.APMIS. 2007 Aug;115(8):976-81. doi: 10.1111/j.1600-0463.2007.apm_804.x.
• [883] Nuclear or cytoplasmic localization of Bag-1 distinctly correlates with pathologic behavior and outcome of gastric carcinomas.Hum Pathol. 2010 May;41(5):724-36. doi: 10.1016/j.humpath.2009.10.017. Epub 2010 Jan 25.
• [884] A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.Gastroenterology. 2009 Jul;137(1):165-75. doi: 10.1053/j.gastro.2009.03.041. Epub 2009 Mar 26.
• [885] Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10.Cancer Res. 2018 Mar 15;78(6):1404-1417. doi: 10.1158/0008-5472.CAN-17-0846. Epub 2018 Jan 12.
• [886] Inactivating mutation of the pro-apoptotic gene BID in gastric cancer. J Pathol. 2004 Apr;202(4):439-45. doi: 10.1002/path.1532.
• [887] A-to-I RNA editing of BLCAP lost the inhibition to STAT3 activation in cervical cancer.Oncotarget. 2017 Jun 13;8(24):39417-39429. doi: 10.18632/oncotarget.17034.
• [888] Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.Hum Pathol. 2018 Dec;82:20-31. doi: 10.1016/j.humpath.2018.06.024. Epub 2018 Jun 26.
• [889] The Expression of SIRT1 and DBC1 in Laryngeal and Hypopharyngeal Carcinomas.PLoS One. 2013 Jun 21;8(6):e66975. doi: 10.1371/journal.pone.0066975. Print 2013.
• [890] Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells.J Cell Physiol. 1998 Aug;176(2):383-91. doi: 10.1002/(SICI)1097-4652(199808)176:2<383::AID-JCP17>3.0.CO;2-4.
• [891] Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer--association with tumour cell proliferation.J Pathol. 2003 May;200(1):16-22. doi: 10.1002/path.1324.
• [892] Cloning of the mRNA of overexpression in colon carcinoma-1: a sequence overexpressed in a subset of colon carcinomas.Cancer Genet Cytogenet. 2002 Feb;133(1):55-60. doi: 10.1016/s0165-4608(01)00634-3.
• [893] Relevance of Gal-GalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients.Breast Cancer Res Treat. 2015 Jun;151(3):515-28. doi: 10.1007/s10549-015-3425-0. Epub 2015 May 15.
• [894] Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.J Pathol. 2007 Aug;212(4):395-401. doi: 10.1002/path.2186.
• [895] Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.Oncogene. 2006 Feb 9;25(6):959-68. doi: 10.1038/sj.onc.1209115.
• [896] A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract.Am J Surg Pathol. 2018 Dec;42(12):1596-1606. doi: 10.1097/PAS.0000000000001142.
• [897] Expression and prognostic value of L1-CAM in breast cancer.Oncol Rep. 2009 Nov;22(5):1109-17. doi: 10.3892/or_00000543.
• [898] CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer.Mol Oncol. 2008 Dec;2(4):327-39. doi: 10.1016/j.molonc.2008.09.004. Epub 2008 Oct 2.
• [899] Overexpression of calcyphosine is associated with poor prognosis in esophageal squamous cell carcinoma.Oncol Lett. 2017 Nov;14(5):6231-6237. doi: 10.3892/ol.2017.6973. Epub 2017 Sep 15.
• [900] Heterochromatin protein 1 expression is reduced in human thyroid malignancy.Lab Invest. 2014 Jul;94(7):788-95. doi: 10.1038/labinvest.2014.68. Epub 2014 May 19.
• [901] CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma.Cell Death Dis. 2019 Jan 18;10(2):52. doi: 10.1038/s41419-018-1288-0.
• [902] Expression of tumor related gene NAG6 in gastric cancer and restriction fragment length polymorphism analysis.World J Gastroenterol. 2004 May 1;10(9):1361-4. doi: 10.3748/wjg.v10.i9.1361.
• [903] Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue.Gastroenterology. 2003 Jul;125(1):98-106. doi: 10.1016/s0016-5085(03)00697-8.
• [904] Matricellular CCN6 (WISP3) protein: a tumor suppressor for mammary metaplastic carcinomas.J Cell Commun Signal. 2018 Mar;12(1):13-19. doi: 10.1007/s12079-018-0451-9. Epub 2018 Jan 22.
• [905] TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors.J Transl Med. 2013 Dec 20;11:316. doi: 10.1186/1479-5876-11-316.
• [906] Tumour suppressor gene expression correlates with gastric cancer prognosis.J Pathol. 2003 May;200(1):39-46. doi: 10.1002/path.1288.
• [907] Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.Cancer Res. 2007 Jul 1;67(13):6092-9. doi: 10.1158/0008-5472.CAN-06-4607.
• [908] Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC).Br J Cancer. 2005 Feb 28;92(4):770-4. doi: 10.1038/sj.bjc.6602400.
• [909] CD3-zetachain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients.Cancer. 2002 Mar 1;94(5):1437-42. doi: 10.1002/cncr.10346.
• [910] Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.Clin Cancer Res. 2006 Mar 1;12(5):1412-9. doi: 10.1158/1078-0432.CCR-05-1906.
• [911] Mast cells co-expressing CD68 and inorganic polyphosphate are linked with colorectal cancer.PLoS One. 2018 Mar 15;13(3):e0193089. doi: 10.1371/journal.pone.0193089. eCollection 2018.
• [912] Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer.Cancer Sci. 2009 Sep;100(9):1767-71. doi: 10.1111/j.1349-7006.2009.01231.x. Epub 2009 May 27.
• [913] Expression of TLE-1 and CD99 in Carcinoma: Pitfalls in Diagnosis of Synovial Sarcoma.Appl Immunohistochem Mol Morphol. 2018 Jul;26(6):368-373. doi: 10.1097/PAI.0000000000000436.
• [914] Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors.Nat Genet. 2014 Jun;46(6):613-7. doi: 10.1038/ng.2956. Epub 2014 Apr 20.
• [915] Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.Mod Pathol. 2019 Jul;32(8):1082-1094. doi: 10.1038/s41379-019-0252-6. Epub 2019 Mar 28.
• [916] BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells.Lab Invest. 2012 Dec;92(12):1788-800. doi: 10.1038/labinvest.2012.140. Epub 2012 Oct 15.
• [917] Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.Cancer Res. 2004 Nov 15;64(22):8156-9. doi: 10.1158/0008-5472.CAN-04-3000.
• [918] p19(INK4d) mRNA and protein expression as new prognostic factors in ovarian cancer patients.Cancer Biol Ther. 2013 Oct 1;14(10):973-81. doi: 10.4161/cbt.25966. Epub 2013 Aug 14.
• [919] Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4990-5. doi: 10.1073/pnas.101617298. Epub 2001 Apr 17.
• [920] CDX1 expression is reduced in colorectal carcinoma and is associated with promoter hypermethylation.J Pathol. 2004 Nov;204(3):289-95. doi: 10.1002/path.1641.
• [921] Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross-reacting antigen in colorectal carcinomas. Comparative analysis by northern blot and in situ hybridization.Am J Pathol. 1997 Aug;151(2):521-30.
• [922] Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.Horm Cancer. 2018 Oct;9(5):338-348. doi: 10.1007/s12672-018-0339-4. Epub 2018 Jun 28.
• [923] Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours.Histopathology. 2010 Nov;57(5):716-24. doi: 10.1111/j.1365-2559.2010.03681.x.
• [924] Distinct high-profile methylated genes in colorectal cancer.PLoS One. 2009 Sep 11;4(9):e7012. doi: 10.1371/journal.pone.0007012.
• [925] Aberrant methylation of the CHFR gene in digestive tract cancer.Anticancer Res. 2006 May-Jun;26(3A):1791-5.
• [926] Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation?.Cancer Biol Ther. 2007 Oct;6(10):1606-13. doi: 10.4161/cbt.6.10.4742. Epub 2007 Jul 13.
• [927] Increased expression of Cks1 protein is associated with lymph node metastasis and poor prognosis in nasopharyngeal carcinoma.Diagn Pathol. 2017 Jan 7;12(1):2. doi: 10.1186/s13000-016-0589-9.
• [928] Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma.Liver Int. 2010 Jan;30(1):119-25. doi: 10.1111/j.1478-3231.2009.02106.x. Epub 2009 Oct 21.
• [929] Reexpression of the TJ protein CLDN1 induces apoptosis in breast tumor spheroids.Int J Cancer. 2004 Jan 20;108(3):374-83. doi: 10.1002/ijc.11571.
• [930] Differential expression of claudin-2 in normal human tissues and gastrointestinal carcinomas.Virchows Arch. 2006 Apr;448(4):428-34. doi: 10.1007/s00428-005-0120-2. Epub 2005 Nov 17.
• [931] Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.Histol Histopathol. 2007 Nov;22(11):1185-95. doi: 10.14670/HH-22.1185.
• [932] Expression of circadian clock genes in human colorectal adenoma and carcinoma.Oncol Lett. 2017 Nov;14(5):5319-5325. doi: 10.3892/ol.2017.6876. Epub 2017 Sep 4.
• [933] Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix.J Transl Med. 2012 Jun 25;10:132. doi: 10.1186/1479-5876-10-132.
• [934] Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.Int J Cancer. 2019 Sep 1;145(5):1209-1220. doi: 10.1002/ijc.32143. Epub 2019 Feb 23.
• [935] Canstatin gene electrotransfer combined with radiotherapy: preclinical trials for cancer treatment.Gene Ther. 2008 Nov;15(21):1436-45. doi: 10.1038/gt.2008.100. Epub 2008 Jun 12.
• [936] The prognostic value of CSN6 expression in upper tract urothelial carcinomas.Kaohsiung J Med Sci. 2019 Sep;35(9):559-565. doi: 10.1002/kjm2.12104. Epub 2019 Jul 24.
• [937] Expression of mitochondrial cytochrome c oxidase in human colonic cell differentiation, transformation, and risk for colonic cancer.Cancer Res. 1990 Mar 1;50(5):1596-600.
• [938] Neoangiogenesis of gastric submucosa-invasive adenocarcinoma.Oncol Lett. 2018 Sep;16(3):3895-3900. doi: 10.3892/ol.2018.9116. Epub 2018 Jul 10.
• [939] Expression of coproporphyrinogen oxidase is associated with detection of upper gastrointestinal carcinomas by 5-aminolevulinic acid-mediated photodynamic diagnosis.Photodiagnosis Photodyn Ther. 2017 Sep;19:15-21. doi: 10.1016/j.pdpdt.2017.04.003. Epub 2017 Apr 14.
• [940] CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis.Cancer Res. 2008 Sep 1;68(17):7156-64. doi: 10.1158/0008-5472.CAN-08-1085.
• [941] Epidermal growth factor increases LRF/Pokemon expression in human prostate cancer cells.Exp Mol Pathol. 2011 Oct;91(2):496-501. doi: 10.1016/j.yexmp.2011.05.006. Epub 2011 May 27.
• [942] Intracranial Myxoid Variant of Angiomatoid Fibrous Histiocytoma: A Case Report and Literature Review.Cureus. 2019 Mar 18;11(3):e4261. doi: 10.7759/cureus.4261.
• [943] Thrombospondins and tumor angiogenesis.Trends Mol Med. 2001 Sep;7(9):401-7. doi: 10.1016/s1471-4914(01)02102-5.
• [944] Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.PLoS One. 2011;6(7):e22317. doi: 10.1371/journal.pone.0022317. Epub 2011 Jul 21.
• [945] Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.Mol Carcinog. 2013 Nov;52(11):890-9. doi: 10.1002/mc.21935. Epub 2012 Jun 29.
• [946] Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.Cancer Res. 2009 May 1;69(9):4036-42. doi: 10.1158/0008-5472.CAN-08-3913. Epub 2009 Apr 21.
• [947] Identification of AXUD1, a novel human gene induced by AXIN1 and its reduced expression in human carcinomas of the lung, liver, colon and kidney.Oncogene. 2001 Aug 16;20(36):5062-6. doi: 10.1038/sj.onc.1204603.
• [948] Cystatin M expression is reduced in gastric carcinoma and is associated with promoter hypermethylation.Biochem Biophys Res Commun. 2010 Jan 1;391(1):1070-4. doi: 10.1016/j.bbrc.2009.12.022. Epub 2009 Dec 10.
• [949] Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer.Anticancer Res. 2015 Jun;35(6):3575-9.
• [950] A two-step model for colon adenoma initiation and progression caused by APC loss.Cell. 2009 May 15;137(4):623-34. doi: 10.1016/j.cell.2009.02.037.
• [951] CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic.Oncogene. 2017 Jul 20;36(29):4100-4110. doi: 10.1038/onc.2017.25. Epub 2017 Mar 20.
• [952] Cthrc1 overexpression is an independent prognostic marker in gastric cancer.Hum Pathol. 2014 May;45(5):1031-8. doi: 10.1016/j.humpath.2013.12.020. Epub 2014 Jan 21.
• [953] Hereditary diffuse gastric cancer - pathophysiology and clinical management.Best Pract Res Clin Gastroenterol. 2014 Dec;28(6):1055-68. doi: 10.1016/j.bpg.2014.09.007. Epub 2014 Sep 28.
• [954] Cell-cell adhesion genes CTNNA2 and CTNNA3 are tumour suppressors frequently mutated in laryngeal carcinomas.Nat Commun. 2013;4:2531. doi: 10.1038/ncomms3531.
• [955] Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma.J Pathol. 1992 Sep;168(1):7-13. doi: 10.1002/path.1711680103.
• [956] Identification of E2F1 as a positive transcriptional regulator for delta-catenin.Biochem Biophys Res Commun. 2008 May 2;369(2):414-20. doi: 10.1016/j.bbrc.2008.02.069. Epub 2008 Feb 25.
• [957] DNA Adduct Assessment During Antihormonal Treatment of Perianal Gland Tumors With Tamoxifen in Male Dogs.In Vivo. 2019 May-Jun;33(3):731-735. doi: 10.21873/invivo.11532.
• [958] Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors.Int J Cancer. 2004 Nov 20;112(4):636. doi: 10.1002/ijc.20450.
• [959] Soluble chemokine (C-X-C motif) ligand 16 (CXCL16) in urine as a novel biomarker candidate to identify high grade and muscle invasive urothelial carcinomas.Oncotarget. 2017 Sep 8;8(62):104946-104959. doi: 10.18632/oncotarget.20737. eCollection 2017 Dec 1.
• [960] Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases.Pancreatology. 2008;8(4-5):488-97. doi: 10.1159/000151776. Epub 2008 Sep 3.
• [961] A comprehensive look at transcription factor gene expression changes in colorectal adenomas.BMC Cancer. 2014 Jan 29;14:46. doi: 10.1186/1471-2407-14-46.
• [962] Anterior tongue cancer with no history of tobacco and alcohol use may be a distinct molecular and clinical entity.J Oral Pathol Med. 2014 Sep;43(8):593-9. doi: 10.1111/jop.12175. Epub 2014 May 9.
• [963] Control of cell shape and plasticity during development and disease by the actin-binding protein Drebrin.Histol Histopathol. 2010 Apr;25(4):533-40. doi: 10.14670/HH-25.533.
• [964] SAGE mRNA expression in advanced-stage lung cancers.Eur J Surg Oncol. 2003 Dec;29(10):900-3. doi: 10.1016/j.ejso.2003.06.001.
• [965] Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas.Lab Invest. 2003 Apr;83(4):501-5. doi: 10.1097/01.lab.0000063929.61760.f6.
• [966] Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.Cancer Chemother Pharmacol. 2007 Apr;59(5):697-702. doi: 10.1007/s00280-006-0351-1. Epub 2006 Sep 29.
• [967] Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression.Genes Chromosomes Cancer. 2014 Apr;53(4):339-48. doi: 10.1002/gcc.22144. Epub 2014 Jan 29.
• [968] Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.Med Oncol. 2015 Apr;32(4):92. doi: 10.1007/s12032-015-0525-y. Epub 2015 Feb 27.
• [969] Evaluation of deleted in malignant brain tumors 1 (DMBT1) gene expression in bladder carcinoma cases: preliminary study.Biomarkers. 2011 Nov;16(7):610-5. doi: 10.3109/1354750X.2011.620627. Epub 2011 Oct 15.
• [970] Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.Cancer Cell. 2007 Oct;12(4):381-94. doi: 10.1016/j.ccr.2007.08.034.
• [971] DNAJB4 molecular chaperone distinguishes WT from mutant E-cadherin, determining their fate in vitro and in vivo.Hum Mol Genet. 2014 Apr 15;23(8):2094-105. doi: 10.1093/hmg/ddt602. Epub 2013 Nov 29.
• [972] Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma.Endocr Relat Cancer. 2013 Jul 4;20(4):551-64. doi: 10.1530/ERC-13-0098. Print 2013 Aug.
• [973] Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer.J Pathol. 2005 Oct;207(2):199-206. doi: 10.1002/path.1821.
• [974] NADPH oxidases and cancer.Clin Sci (Lond). 2015 Jun;128(12):863-75. doi: 10.1042/CS20140542.
• [975] Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma.Cancer Res. 2016 May 1;76(9):2612-25. doi: 10.1158/0008-5472.CAN-15-1846. Epub 2016 Mar 3.
• [976] Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer.Cancer Res. 2010 Aug 15;70(16):6629-38. doi: 10.1158/0008-5472.CAN-10-1616. Epub 2010 Jul 27.
• [977] cDNA cloning of a human dishevelled DVL-3 gene, mapping to 3q27, and expression in human breast and colon carcinomas.Biochem Biophys Res Commun. 1997 Oct 20;239(2):510-6. doi: 10.1006/bbrc.1997.7500.
• [978] DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells.Nature. 2018 Nov;563(7732):522-526. doi: 10.1038/s41586-018-0670-5. Epub 2018 Oct 31.
• [979] Accumulated frameshift mutations at coding nucleotide repeats during the progression of gastric carcinoma with microsatellite instability.Lab Invest. 1999 Sep;79(9):1113-20.
• [980] Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus.Br J Cancer. 2007 May 21;96(10):1613-20. doi: 10.1038/sj.bjc.6603748. Epub 2007 Apr 17.
• [981] LPA/PKD-1-FoxO1 Signaling Axis Mediates Endothelial Cell CD36 Transcriptional Repression and Proangiogenic and Proarteriogenic Reprogramming.Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1197-208. doi: 10.1161/ATVBAHA.116.307421. Epub 2016 Mar 24.
• [982] Carcinoma-associated eIF3i overexpression facilitates mTOR-dependent growth transformation.Mol Carcinog. 2006 Dec;45(12):957-67. doi: 10.1002/mc.20269.
• [983] Integrated genomic characterization of papillary thyroid carcinoma.Cell. 2014 Oct 23;159(3):676-90. doi: 10.1016/j.cell.2014.09.050.
• [984] Expression of translation initiation factor eIF-2alpha is increased in benign and malignant melanocytic and colonic epithelial neoplasms.Cancer. 2003 Sep 1;98(5):1080-8. doi: 10.1002/cncr.11619.
• [985] EIF3B correlates with advanced disease stages and poor prognosis, and it promotes proliferation and inhibits apoptosis in non-small cell lung cancer.Cancer Biomark. 2018;23(2):291-300. doi: 10.3233/CBM-181628.
• [986] Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays.Lab Invest. 2002 May;82(5):629-37. doi: 10.1038/labinvest.3780457.
• [987] Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma.Eur Arch Otorhinolaryngol. 1995;252(7):433-9. doi: 10.1007/BF00167315.
• [988] Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.Gynecol Oncol. 2006 Feb;100(2):264-70. doi: 10.1016/j.ygyno.2005.08.026. Epub 2005 Oct 19.
• [989] Senescence-associated protein p400 is a prognostic marker in renal cell carcinoma.Oncol Rep. 2013 Nov;30(5):2245-53. doi: 10.3892/or.2013.2698. Epub 2013 Aug 26.
• [990] Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas.Int J Cancer. 2011 Dec 15;129(12):2855-66. doi: 10.1002/ijc.25951. Epub 2011 Apr 1.
• [991] EPS8-mediated regulation of multiple myeloma cell growth and survival.Am J Cancer Res. 2019 Aug 1;9(8):1622-1634. eCollection 2019.
• [992] Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma.Am J Dermatopathol. 2006 Oct;28(5):410-2. doi: 10.1097/01.dad.0000211521.49810.ac.
• [993] t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.Am J Surg Pathol. 2014 May;38(5):604-14. doi: 10.1097/PAS.0000000000000203.
• [994] Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.Mod Pathol. 2009 Sep;22(9):1176-85. doi: 10.1038/modpathol.2009.79. Epub 2009 May 22.
• [995] Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I.Hum Gene Ther. 1997 Mar 20;8(5):513-21. doi: 10.1089/hum.1997.8.5-513.
• [996] Disruption of the FA/BRCA pathway in bladder cancer.Cytogenet Genome Res. 2007;118(2-4):166-76. doi: 10.1159/000108297.
• [997] Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis.Oncogene. 2010 Jan 21;29(3):442-50. doi: 10.1038/onc.2009.332. Epub 2009 Nov 2.
• [998] Establishment and characterization of primary lung cancer cell lines from Chinese population.Acta Pharmacol Sin. 2011 Mar;32(3):385-92. doi: 10.1038/aps.2010.214.
• [999] URP1: a member of a novel family of PH and FERM domain-containing membrane-associated proteins is significantly over-expressed in lung and colon carcinomas.Biochim Biophys Acta. 2003 Apr 17;1637(3):207-16. doi: 10.1016/s0925-4439(03)00035-8.
• [1000] Fez1/lzts1 alterations in gastric carcinoma.Clin Cancer Res. 2001 Jun;7(6):1546-52.
• [1001] Analysis of T-cell receptor V region gene usage of cytotoxic T-lymphocytes and tumor-infiltrating lymphocytes derived from human autologous gastric signet ring cell carcinomas.Cancer Res. 1993 Jul 1;53(13):3078-84.
• [1002] POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas.PLoS One. 2010 Nov 4;5(11):e13837. doi: 10.1371/journal.pone.0013837.
• [1003] Reduced expression of tocopherol-associated protein (TAP/Sec14L2) in human breast cancer.Cancer Invest. 2009 Dec;27(10):971-7. doi: 10.3109/07357900802392659.
• [1004] Comparative analysis of DNA methylation between primary and metastatic gastric carcinoma.Oncol Rep. 2009 May;21(5):1251-9. doi: 10.3892/or_00000348.
• [1005] SiRNA-mediated flotillin-2 (Flot2) downregulation inhibits cell proliferation, migration, and invasion in gastric carcinoma cells.Oncol Res. 2014;21(5):271-9. doi: 10.3727/096504014X13946737557031.
• [1006] miRNA expression in colon polyps provides evidence for a multihit model of colon cancer.PLoS One. 2011;6(6):e20465. doi: 10.1371/journal.pone.0020465. Epub 2011 Jun 9.
• [1007] The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases.Histopathology. 2018 Dec;73(6):943-952. doi: 10.1111/his.13706. Epub 2018 Sep 25.
• [1008] c-Fos mediates 1, 2-fucosyltransferase 1 and Lewisy expression in response to TGF-1 in ovarian cancer.Oncol Rep. 2017 Dec;38(6):3355-3366. doi: 10.3892/or.2017.6052. Epub 2017 Oct 23.
• [1009] Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells.Int J Oncol. 2004 Jan;24(1):97-105.
• [1010] Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5 (Dysadherin) gene.J Clin Endocrinol Metab. 2012 Nov;97(11):E2168-78. doi: 10.1210/jc.2012-1929. Epub 2012 Sep 10.
• [1011] Alteration of frizzled expression in renal cell carcinoma.Tumour Biol. 2004 Jul-Aug;25(4):161-71. doi: 10.1159/000081098.
• [1012] Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families.J Hum Genet. 2013 Feb;58(2):59-66. doi: 10.1038/jhg.2012.127. Epub 2012 Nov 15.
• [1013] Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis.Clin Cancer Res. 2018 Sep 15;24(18):4468-4481. doi: 10.1158/1078-0432.CCR-17-3533. Epub 2018 May 29.
• [1014] The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism.Oncogene. 2010 Apr 29;29(17):2577-84. doi: 10.1038/onc.2009.525. Epub 2010 Jan 25.
• [1015] Mutation analysis of replicative genes encoding the large subunits of DNA polymerase alpha and replication factors A and C in human sporadic colorectal cancers.Int J Cancer. 2000 May 1;86(3):318-24. doi: 10.1002/(sici)1097-0215(20000501)86:3<318::aid-ijc3>3.0.co;2-b.
• [1016] Expression and chromosomal localization of the gene for the human transcriptional repressor GCF.J Biol Chem. 1992 Jan 25;267(3):1689-94.
• [1017] Effects of polymorphisms in ERCC1, ASE-1 and RAI on the risk of colorectal carcinomas and adenomas: a case control study.BMC Cancer. 2006 Jul 3;6:175. doi: 10.1186/1471-2407-6-175.
• [1018] Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastoma.Acta Neuropathol Commun. 2014 Jul 25;2:85. doi: 10.1186/s40478-014-0085-y.
• [1019] Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells.Cancer Res. 2004 Oct 1;64(19):6874-82. doi: 10.1158/0008-5472.CAN-04-0633.
• [1020] The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors.Hum Pathol. 2017 Jun;64:164-170. doi: 10.1016/j.humpath.2017.03.026. Epub 2017 Apr 21.
• [1021] Clinicopathological significance of PSF3 expression in uterine endometrial carcinomas.Hum Pathol. 2018 Oct;80:104-112. doi: 10.1016/j.humpath.2018.06.010. Epub 2018 Jun 21.
• [1022] Inactivation of the Gastrokine 1 gene in gastric adenomas and carcinomas.J Pathol. 2011 Apr;223(5):618-25. doi: 10.1002/path.2838. Epub 2011 Feb 21.
• [1023] Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union.Cancer. 1998 Jul 15;83(2):267-75.
• [1024] GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma.Tumour Biol. 2017 Jun;39(6):1010428317700410. doi: 10.1177/1010428317700410.
• [1025] GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer.Oncogene. 2018 Nov;37(44):5873-5886. doi: 10.1038/s41388-018-0377-y. Epub 2018 Jul 4.
• [1026] Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum.Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3410-5. doi: 10.1073/pnas.0530278100. Epub 2003 Mar 6.
• [1027] Overexpression of goosecoid homeobox is associated with chemoresistance and poor prognosis in ovarian carcinoma.Oncol Rep. 2014 Jul;32(1):189-98. doi: 10.3892/or.2014.3203. Epub 2014 May 20.
• [1028] Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types.J Clin Pathol. 2005 Jun;58(6):621-5. doi: 10.1136/jcp.2004.021774.
• [1029] An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells.Mol Cancer Ther. 2003 Aug;2(8):773-82.
• [1030] Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure.Int J Mol Sci. 2012 Oct 10;13(10):12925-38. doi: 10.3390/ijms131012925.
• [1031] Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas.Cancer Res. 1998 Oct 15;58(20):4745-51.
• [1032] Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1.FASEB J. 2010 Nov;24(11):4443-58. doi: 10.1096/fj.10-159806. Epub 2010 Jul 12.
• [1033] Loss of HLTF function promotes intestinal carcinogenesis.Mol Cancer. 2012 Mar 27;11:18. doi: 10.1186/1476-4598-11-18.
• [1034] Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder.Oncol Rep. 2003 Jan-Feb;10(1):51-5.
• [1035] Napsin-A and AMACR are Superior to HNF-1 in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract.Appl Immunohistochem Mol Morphol. 2020 Sep;28(8):593-601. doi: 10.1097/PAI.0000000000000801.
• [1036] Comparative transcriptome analysis of sinonasal inverted papilloma and associated squamous cell carcinoma: Out-HOXing developmental genes.Head Neck. 2019 Sep;41(9):3090-3104. doi: 10.1002/hed.25795. Epub 2019 Apr 30.
• [1037] HOXB homeobox gene expression in cervical carcinoma.Int J Gynecol Cancer. 2006 Jan-Feb;16(1):329-35. doi: 10.1111/j.1525-1438.2006.00350.x.
• [1038] HOXB5 expression in oral squamous cell carcinoma.J Appl Oral Sci. 2011 Apr;19(2):125-9. doi: 10.1590/s1678-77572011000200008.
• [1039] Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.Cell Mol Immunol. 2011 Sep;8(5):424-32. doi: 10.1038/cmi.2011.21. Epub 2011 Jul 25.
• [1040] Expression of the RNA-binding protein CRD-BP in brain and non-small cell lung tumors.Cancer Lett. 2004 Jun 25;209(2):245-50. doi: 10.1016/j.canlet.2003.12.015.
• [1041] CCN6 regulates IGF2BP2and HMGA2 signaling in metaplastic carcinomas of the breast.Breast Cancer Res Treat. 2018 Dec;172(3):577-586. doi: 10.1007/s10549-018-4960-2. Epub 2018 Sep 15.
• [1042] Differential gene and protein expression in primary gastric carcinomas and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis.J Dig Dis. 2010 Jun;11(3):167-75. doi: 10.1111/j.1751-2980.2010.00432.x.
• [1043] Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes.Clin Cancer Res. 2007 Jul 15;13(14):4061-8. doi: 10.1158/1078-0432.CCR-06-3052.
• [1044] Comparative study of interleukin-17C (IL-17C) and IL-17D in large yellow croaker Larimichthys crocea reveals their similar but differential functional activity.Dev Comp Immunol. 2017 Nov;76:34-44. doi: 10.1016/j.dci.2017.05.014. Epub 2017 May 16.
• [1045] Genetic alterations of tumor suppressor ING1 in human non-small cell lung cancer.Oncol Rep. 2011 Apr;25(4):1073-81. doi: 10.3892/or.2011.1172. Epub 2011 Jan 31.
• [1046] Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm.J Endocrinol. 2000 May;165(2):223-9. doi: 10.1677/joe.0.1650223.
• [1047] INSL-3 is expressed in human hyperplastic and neoplastic thyrocytes.Int J Oncol. 2003 May;22(5):993-1001.
• [1048] Nucleotide variants within the IQGAP1 gene in diffuse-type gastric cancers.Genes Chromosomes Cancer. 2005 Mar;42(3):280-6. doi: 10.1002/gcc.20150.
• [1049] Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3598-605.
• [1050] Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.Cancer Res. 2000 Dec 15;60(24):7119-25.
• [1051] Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.Clin Cancer Res. 2009 Jul 15;15(14):4612-21. doi: 10.1158/1078-0432.CCR-08-3321. Epub 2009 Jul 7.
• [1052] The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.Oncogene. 2008 Jan 31;27(6):865-76. doi: 10.1038/sj.onc.1210669. Epub 2007 Jul 23.
• [1053] Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis.J Cancer Res Clin Oncol. 2012 Jan;138(1):163-72. doi: 10.1007/s00432-011-1088-8. Epub 2011 Nov 15.
• [1054] Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.Gynecol Oncol. 2016 Mar;140(3):545-53. doi: 10.1016/j.ygyno.2015.12.006. Epub 2015 Dec 12.
• [1055] AP-1 Expression and its Clinical Relevance in Immune Disorders and Cancer.Am J Med Sci. 2017 May;353(5):474-483. doi: 10.1016/j.amjms.2017.01.019. Epub 2017 Feb 1.
• [1056] Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.Nature. 2007 Aug 30;448(7157):1063-7. doi: 10.1038/nature06055.
• [1057] Histone acetyltransferase Hbo1: catalytic activity, cellular abundance, and links to primary cancers.Gene. 2009 May 1;436(1-2):108-14. doi: 10.1016/j.gene.2009.01.020. Epub 2009 Feb 10.
• [1058] Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines.J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62. doi: 10.1210/jcem.82.6.4013.
• [1059] KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.Oncol Rep. 2012 Oct;28(4):1187-92. doi: 10.3892/or.2012.1908. Epub 2012 Jul 13.
• [1060] Krpple-like factor 5 is essential for mammary gland development and tumorigenesis.J Pathol. 2018 Dec;246(4):497-507. doi: 10.1002/path.5153. Epub 2018 Nov 5.
• [1061] KLHL5 knockdown increases cellular sensitivity to anticancer drugs.Oncotarget. 2018 Dec 21;9(100):37429-37438. doi: 10.18632/oncotarget.26462. eCollection 2018 Dec 21.
• [1062] Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas.Clin Biochem. 2010 Oct;43(15):1205-11. doi: 10.1016/j.clinbiochem.2010.07.016. Epub 2010 Jul 30.
• [1063] Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas.PLoS One. 2013 Nov 18;8(11):e81167. doi: 10.1371/journal.pone.0081167. eCollection 2013.
• [1064] Evaluation of serum HGF and CK18 levels in patients with esophageal cancer.Genet Mol Res. 2016 Aug 29;15(3). doi: 10.4238/gmr.15038583.
• [1065] Genes of laminin B1 chain, alpha 1 (IV) chain of type IV collagen, and 72-kd type IV collagenase are mainly expressed by the stromal cells of lung carcinomas.Am J Pathol. 1993 May;142(5):1622-30.
• [1066] Prognostic significance of lactate dehydrogenase B according to histologic type of non-small-cell lung cancer and its association with serum lactate dehydrogenase.Pathol Res Pract. 2017 Sep;213(9):1134-1138. doi: 10.1016/j.prp.2017.07.006. Epub 2017 Jul 6.
• [1067] Epstein-Barr virus stably confers an invasive phenotype to epithelial cells through reprogramming of the WNT pathway.Oncotarget. 2018 Jan 2;9(12):10417-10435. doi: 10.18632/oncotarget.23824. eCollection 2018 Feb 13.
• [1068] Galectin-4 functions as a tumor suppressor of human colorectal cancer.Int J Cancer. 2011 Aug 15;129(4):799-809. doi: 10.1002/ijc.25750. Epub 2010 Dec 9.
• [1069] Galectin-7 in Epithelial Homeostasis and Carcinomas.Int J Mol Sci. 2017 Dec 19;18(12):2760. doi: 10.3390/ijms18122760.
• [1070] Galectin-8 induces endothelial hyperpermeability through the eNOS pathway involving S-nitrosylation-mediated adherens junction disassembly.Carcinogenesis. 2019 Apr 29;40(2):313-323. doi: 10.1093/carcin/bgz002.
• [1071] LHX6 is a sensitive methylation marker in head and neck carcinomas.Oncogene. 2006 Aug 17;25(36):5018-26. doi: 10.1038/sj.onc.1209509. Epub 2006 May 29.
• [1072] Detection of hypermethylated genes as markers for cervical screening in women living with HIV.J Int AIDS Soc. 2018 Aug;21(8):e25165. doi: 10.1002/jia2.25165.
• [1073] PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.Cytopathology. 2011 Feb;22(1):22-9. doi: 10.1111/j.1365-2303.2010.00757.x.
• [1074] High frequency of LMAN1 abnormalities in colorectal tumors with microsatellite instability.Cancer Res. 2009 Jan 1;69(1):292-9. doi: 10.1158/0008-5472.CAN-08-3314.
• [1075] The phosphatidic acid phosphatase lipin-1 facilitates inflammation-driven colon carcinogenesis.JCI Insight. 2018 Sep 20;3(18):e97506. doi: 10.1172/jci.insight.97506. eCollection 2018 Sep 20.
• [1076] Nuclear receptor CAR-regulated expression of the FAM84A gene during the development of mouse liver tumors.Int J Oncol. 2011 Jun;38(6):1511-20. doi: 10.3892/ijo.2011.980. Epub 2011 Mar 17.
• [1077] Latent transforming growth factor binding protein 4 (LTBP4) is downregulated in mouse and human DCIS and mammary carcinomas.Cell Oncol (Dordr). 2011 Oct;34(5):419-34. doi: 10.1007/s13402-011-0023-y. Epub 2011 Apr 6.
• [1078] Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression.PLoS One. 2017 May 8;12(5):e0174768. doi: 10.1371/journal.pone.0174768. eCollection 2017.
• [1079] Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential.BMC Cancer. 2011 Apr 6;11:121. doi: 10.1186/1471-2407-11-121.
• [1080] Relation between prognosis and expression of metastasis-associated protein 1 in stage I non-small cell lung cancer.Interact Cardiovasc Thorac Surg. 2011 Feb;12(2):166-9. doi: 10.1510/icvts.2010.243741. Epub 2010 Oct 8.
• [1081] LZTS2 and PTEN collaboratively regulate -catenin in prostatic tumorigenesis.PLoS One. 2017 Mar 21;12(3):e0174357. doi: 10.1371/journal.pone.0174357. eCollection 2017.
• [1082] MAGE Xp-2: a member of the MAGE gene family isolated from an expression library using systemic lupus erythematosus sera.Mol Genet Metab. 1998 Jan;63(1):3-13. doi: 10.1006/mgme.1997.2639.
• [1083] CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease.Int J Cancer. 2013 Sep 15;133(6):1293-9. doi: 10.1002/ijc.28138. Epub 2013 Apr 4.
• [1084] Expression and distribution of MAL2, an essential element of the machinery for basolateral-to-apical transcytosis, in human thyroid epithelial cells.Endocrinology. 2004 Feb;145(2):1011-6. doi: 10.1210/en.2003-0652. Epub 2003 Oct 23.
• [1085] Autophagy is upregulated during colorectal carcinogenesis, and in DNA microsatellite stable carcinomas.Oncol Rep. 2015 Dec;34(6):3222-30. doi: 10.3892/or.2015.4326.
• [1086] The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.Am J Surg Pathol. 2018 Sep;42(9):1190-1200. doi: 10.1097/PAS.0000000000001100.
• [1087] Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun.Oncotarget. 2015 Aug 21;6(24):20190-203. doi: 10.18632/oncotarget.4171.
• [1088] Expression and functional regulation of myoglobin in epithelial cancers.Am J Pathol. 2009 Jul;175(1):201-6. doi: 10.2353/ajpath.2009.081124. Epub 2009 Jun 18.
• [1089] Proteomic analysis of differential proteins in pancreatic carcinomas: Effects of MBD1 knock-down by stable RNA interference.BMC Cancer. 2008 Apr 29;8:121. doi: 10.1186/1471-2407-8-121.
• [1090] MBD4 mutations are rare in gastric carcinomas with microsatellite instability.Cancer Genet Cytogenet. 2003 Sep;145(2):103-7. doi: 10.1016/s0165-4608(03)00062-1.
• [1091] Loss of heterozygosity of APC/MCC gene in differentiated and undifferentiated gastric carcinomas in Taiwan.Cancer Lett. 1995 Sep 25;96(2):169-74. doi: 10.1016/0304-3835(95)03925-m.
• [1092] Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis.Clin Cancer Res. 2004 Dec 15;10(24):8386-95. doi: 10.1158/1078-0432.CCR-04-1029.
• [1093] Deregulation of microcephalin and ASPM expression are correlated with epithelial ovarian cancer progression.PLoS One. 2014 May 15;9(5):e97059. doi: 10.1371/journal.pone.0097059. eCollection 2014.
• [1094] DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours.Oncogene. 2007 Nov 22;26(53):7414-22. doi: 10.1038/sj.onc.1210553. Epub 2007 Jun 4.
• [1095] Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma.Am J Cancer Res. 2019 May 1;9(5):887-905. eCollection 2019.
• [1096] Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase.J Biol Chem. 2007 Jul 27;282(30):22150-62. doi: 10.1074/jbc.M611518200. Epub 2007 May 30.
• [1097] Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis.Genes Chromosomes Cancer. 2014 May;53(5):373-80. doi: 10.1002/gcc.22148. Epub 2014 Jan 30.
• [1098] Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.Cancer Res. 2000 Feb 15;60(4):877-82.
• [1099] Calcium regulates tertiary structure and enzymatic activity of human endometase/matrilysin-2 and its role in promoting human breast cancer cell invasion.Biochem J. 2007 Apr 1;403(1):31-42. doi: 10.1042/BJ20061390.
• [1100] MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors.Gene. 2001 Mar 7;265(1-2):87-93. doi: 10.1016/s0378-1119(01)00360-2.
• [1101] Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.Cancer Res. 2001 Jan 15;61(2):538-49.
• [1102] Altered expression of the DNA repair protein, N-methylpurine-DNA glycosylase (MPG) in human gonads.Anticancer Res. 2002 Mar-Apr;22(2A):793-8.
• [1103] Potential role of the 3-mercaptopyruvate sulfurtransferase (3-MST)-hydrogen sulfide (H(2)S) pathway in cancer cells.Pharmacol Res. 2020 Apr;154:104083. doi: 10.1016/j.phrs.2018.11.034. Epub 2018 Nov 27.
• [1104] Absence of association with cancer risk and low frequency of alterations at a p53 responsive PIG3 gene polymorphism in breast and lung carcinomas.Mutat Res. 2004 Nov 22;556(1-2):143-50. doi: 10.1016/j.mrfmmm.2004.07.008.
• [1105] Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias.Gastroenterology. 2010 Nov;139(5):1519-25. doi: 10.1053/j.gastro.2010.08.001. Epub 2010 Aug 11.
• [1106] Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.BMC Cancer. 2014 Mar 20;14:214. doi: 10.1186/1471-2407-14-214.
• [1107] Mucin 21 in esophageal squamous epithelia and carcinomas: analysis with glycoform-specific monoclonal antibodies.Glycobiology. 2012 Sep;22(9):1218-26. doi: 10.1093/glycob/cws082. Epub 2012 May 19.
• [1108] Promoter hypomethylation contributes to the expression of MUC3A in cancer cells.Biochem Biophys Res Commun. 2010 Jun 25;397(2):333-9. doi: 10.1016/j.bbrc.2010.05.124. Epub 2010 May 27.
• [1109] Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas.J Transl Med. 2018 Sep 20;16(1):259. doi: 10.1186/s12967-018-1632-2.
• [1110] Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.Mod Pathol. 2019 Jun;32(6):884-892. doi: 10.1038/s41379-018-0198-0. Epub 2019 Feb 1.
• [1111] Down-regulation of Mus81 as a potential marker for the malignancy of gastric cancer.Anticancer Res. 2010 Dec;30(12):5011-4.
• [1112] Increased expression of lung resistance-related protein in lower grade urothelial carcinoma of the renal pelvis and ureter.Int J Urol. 2004 Sep;11(9):721-7. doi: 10.1111/j.1442-2042.2004.00874.x.
• [1113] Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.Int J Gynecol Cancer. 2017 Nov;27(9):2006-2013. doi: 10.1097/IGC.0000000000001105.
• [1114] Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.Cancer Res. 1999 Oct 1;59(19):4834-42.
• [1115] High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S40-S63. doi: 10.1097/PGP.0000000000000491.
• [1116] Screening of genetic and expression alterations of SRC1 gene in prostate cancer.Prostate. 2006 Sep 15;66(13):1391-8. doi: 10.1002/pros.20427.
• [1117] B7-H6 protein expression has no prognostic significance in human gastric carcinoma.Pathol Oncol Res. 2014 Jan;20(1):203-7. doi: 10.1007/s12253-013-9686-1. Epub 2013 Nov 16.
• [1118] HGF and ligation of alphavbeta5 integrin induce a novel, cancer cell-specific gene expression required for cell scattering.Exp Cell Res. 2004 Jan 15;292(2):274-87. doi: 10.1016/j.yexcr.2003.09.016.
• [1119] Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation.Biol Pharm Bull. 2009 Jun;32(6):968-75. doi: 10.1248/bpb.32.968.
• [1120] NEIL1 p.Gln282Stop variant is predominantly localized in the cytoplasm and exhibits reduced activity in suppressing mutations.Gene. 2015 Oct 15;571(1):33-42. doi: 10.1016/j.gene.2015.06.043. Epub 2015 Jun 19.
• [1121] Roles of plasma membrane-associated sialidase NEU3 in human cancers.Biochim Biophys Acta. 2008 Mar;1780(3):532-7. doi: 10.1016/j.bbagen.2007.09.016. Epub 2007 Oct 2.
• [1122] Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1.Oncotarget. 2015 Jan 30;6(3):1582-93. doi: 10.18632/oncotarget.2750.
• [1123] Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18740-4. doi: 10.1073/pnas.0909114106. Epub 2009 Oct 19.
• [1124] Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas.Endocr Pathol. 2020 Mar;31(1):39-45. doi: 10.1007/s12022-019-09600-6.
• [1125] Increased nm23-H1 and nm23-H2 messenger RNA expression and absence of mutations in colon carcinomas of low and high metastatic potential.J Natl Cancer Inst. 1993 Jan 20;85(2):147-52. doi: 10.1093/jnci/85.2.147.
• [1126] Immunohistochemical investigation of new suppressor oncogene p130 in oral squamous cell carcinoma.Oral Oncol. 1999 May;35(3):321-5. doi: 10.1016/s1368-8375(98)00089-x.
• [1127] An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma.Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6516-20. doi: 10.1073/pnas.89.14.6516.
• [1128] Elevated NRD1 metalloprotease expression plays a role in breast cancer growth and proliferation.Genes Chromosomes Cancer. 2011 Oct;50(10):837-47. doi: 10.1002/gcc.20905. Epub 2011 Jul 18.
• [1129] The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.Biochem Biophys Res Commun. 2010 Jul 30;398(3):565-70. doi: 10.1016/j.bbrc.2010.06.119. Epub 2010 Jul 1.
• [1130] Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors.Diagn Cytopathol. 2011 Aug;39(8):562-6. doi: 10.1002/dc.21424. Epub 2010 Aug 20.
• [1131] Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions.Cancer Immunol Res. 2014 May;2(5):480-6. doi: 10.1158/2326-6066.CIR-13-0124. Epub 2013 Nov 11.
• [1132] Association between orosomucoid types and cancer.Oncology. 1995 Nov-Dec;52(6):498-500. doi: 10.1159/000227518.
• [1133] Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas.J Vis Exp. 2019 Feb 28;(144). doi: 10.3791/56880.
• [1134] OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.Gastroenterology. 2016 Mar;150(3):659-671.e16. doi: 10.1053/j.gastro.2015.11.041. Epub 2015 Nov 24.
• [1135] Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance.Br J Cancer. 2006 May 22;94(10):1516-23. doi: 10.1038/sj.bjc.6603108.
• [1136] Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of mllerian origin?.Appl Immunohistochem Mol Morphol. 2012 May;20(3):272-6. doi: 10.1097/PAI.0b013e3182366531.
• [1137] Poly (C)-binding protein 2 (PCBP2) promotes the progression of esophageal squamous cell carcinoma (ESCC) through regulating cellular proliferation and apoptosis.Pathol Res Pract. 2016 Aug;212(8):717-25. doi: 10.1016/j.prp.2016.05.008. Epub 2016 May 27.
• [1138] Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer.J Am Coll Surg. 2014 Nov;219(5):904-13. doi: 10.1016/j.jamcollsurg.2014.06.014. Epub 2014 Jun 26.
• [1139] Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways.Oncogene. 2012 Oct 4;31(40):4409-19. doi: 10.1038/onc.2011.609. Epub 2012 Jan 16.
• [1140] Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line.J Immunol. 2004 May 15;172(10):6330-5. doi: 10.4049/jimmunol.172.10.6330.
• [1141] Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers.Oncogene. 2004 Jul 22;23(33):5697-702. doi: 10.1038/sj.onc.1207740.
• [1142] miR-21 increases the programmed cell death 4 gene-regulated cell proliferation in head and neck squamous carcinoma cell lines.Oncol Rep. 2014 Nov;32(5):2283-9. doi: 10.3892/or.2014.3456. Epub 2014 Sep 1.
• [1143] Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene.Oncogene. 1995 Mar 2;10(5):891-5.
• [1144] PDIA3 and PDIA6 gene expression as an aggressiveness marker in primary ductal breast cancer.Genet Mol Res. 2015 Jun 26;14(2):6960-7. doi: 10.4238/2015.June.26.4.
• [1145] SCC-112, a novel cell cycle-regulated molecule, exhibits reduced expression in human renal carcinomas.Gene. 2004 Mar 17;328:187-96. doi: 10.1016/j.gene.2003.12.013.
• [1146] The effects of Curcumin on HCT-116 cells proliferation and apoptosis via the miR-491/PEG10 pathway.J Cell Biochem. 2018 Apr;119(4):3091-3098. doi: 10.1002/jcb.26449. Epub 2018 Jan 15.
• [1147] Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets.Hum Pathol. 2005 Jun;36(6):670-5. doi: 10.1016/j.humpath.2005.03.016.
• [1148] Loss of circadian clock gene expression is associated with tumor progression in breast cancer.Cell Cycle. 2014;13(20):3282-91. doi: 10.4161/15384101.2014.954454.
• [1149] Phosphofructokinase type 1 kinetics, isoform expression, and gene polymorphisms in cancer cells.J Cell Biochem. 2012 May;113(5):1692-703. doi: 10.1002/jcb.24039.
• [1150] PGK1 a potential marker for peritoneal dissemination in gastric cancer.Cell Physiol Biochem. 2008;21(5-6):429-36. doi: 10.1159/000129635. Epub 2008 Apr 24.
• [1151] Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level.Cancer Res. 1995 Jun 15;55(12):2537-41.
• [1152] Differential DNA methylation status between breast carcinomatous and normal tissues.Biomed Pharmacother. 2014 Jul;68(6):699-707. doi: 10.1016/j.biopha.2014.07.014. Epub 2014 Jul 17.
• [1153] Differential roles for the p101 and p84 regulatory subunits of PI3K in tumor growth and metastasis.Oncogene. 2012 May 3;31(18):2350-61. doi: 10.1038/onc.2011.414. Epub 2011 Sep 26.
• [1154] TCF21/POD-1, a Transcritional Regulator of SF-1/NR5A1, as a Potential Prognosis Marker in Adult and Pediatric Adrenocortical Tumors.Front Endocrinol (Lausanne). 2018 Feb 22;9:38. doi: 10.3389/fendo.2018.00038. eCollection 2018.
• [1155] Prolactin-induced protein (PIP)-characterization and role in breast cancer progression.Am J Cancer Res. 2018 Nov 1;8(11):2150-2164. eCollection 2018.
• [1156] Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2.Cancer Res. 2010 Jun 1;70(11):4569-79. doi: 10.1158/0008-5472.CAN-09-2670. Epub 2010 May 11.
• [1157] Loss of constitutional heterozygosity in colon carcinoma from patients with familial polyposis coli.Nature. 1988 Jan 21;331(6153):273-7. doi: 10.1038/331273a0.
• [1158] An alternative promoter of the human plakophilin-3 gene controls the expression of the new isoform PKP3b.Cell Tissue Res. 2014 Jan;355(1):143-62. doi: 10.1007/s00441-013-1736-1. Epub 2013 Nov 1.
• [1159] Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency.Mod Pathol. 2013 Jan;26(1):131-8. doi: 10.1038/modpathol.2012.138. Epub 2012 Aug 24.
• [1160] Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas.Int J Cancer. 2015 Jul 15;137(2):320-31. doi: 10.1002/ijc.29396. Epub 2015 Jan 20.
• [1161] Overexpression of DNA polymerase iota (Pol) in esophageal squamous cell carcinoma.Cancer Sci. 2012 Aug;103(8):1574-9. doi: 10.1111/j.1349-7006.2012.02309.x. Epub 2012 May 30.
• [1162] Quantitative analysis of TGF-alpha and EGFR mRNA in laryngeal carcinoma tissues.Chin Med J (Engl). 1999 Dec;112(12):1088-92.
• [1163] Amplification of the PPFIA1 gene region on 11q13 in oral squamous cell carcinomas (OSCC).J Craniomaxillofac Surg. 2013 Dec;41(8):845-9. doi: 10.1016/j.jcms.2013.01.040. Epub 2013 Feb 26.
• [1164] Loss of periplakin expression is associated with the tumorigenesis of colorectal carcinoma.Biomed Pharmacother. 2017 Mar;87:366-374. doi: 10.1016/j.biopha.2016.12.103. Epub 2017 Jan 6.
• [1165] Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res. 2005 Aug 1;65(15):6583-92. doi: 10.1158/0008-5472.CAN-05-1433.
• [1166] Somatic mutations and genetic polymorphisms of the PPP1R3 gene in patients with several types of cancers.Oncogene. 2000 Feb 10;19(6):836-40. doi: 10.1038/sj.onc.1203388.
• [1167] Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway.Sci Rep. 2016 Jun 7;6:27391. doi: 10.1038/srep27391.
• [1168] Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.BMC Cancer. 2015 Apr 15;15:285. doi: 10.1186/s12885-015-1266-1.
• [1169] Activation of ERK/IER3/PP2A-B56-positive feedback loop in lung adenocarcinoma by allelic deletion of B56 gene.Oncol Rep. 2016 May;35(5):2635-42. doi: 10.3892/or.2016.4677. Epub 2016 Mar 16.
• [1170] Clinicoprognostic significance of pRb1 pathway alterations in uterine endometrial adenocarcinoma.Cancer Genet Cytogenet. 2004 Oct 15;154(2):186-9. doi: 10.1016/j.cancergencyto.2004.05.016.
• [1171] Epidermal Snail expression drives skin cancer initiation and progression through enhanced cytoprotection, epidermal stem/progenitor cell expansion and enhanced metastatic potential.Cell Death Differ. 2014 Feb;21(2):310-20. doi: 10.1038/cdd.2013.148. Epub 2013 Oct 25.
• [1172] Frequent frameshift mutations of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability.Cancer Res. 2000 Sep 1;60(17):4701-4.
• [1173] Prospero-related homeobox 1 (PROX1) is frequently inactivated by genomic deletions and epigenetic silencing in carcinomas of the bilary system.J Hepatol. 2007 Jan;46(1):89-97. doi: 10.1016/j.jhep.2006.07.033. Epub 2006 Sep 27.
• [1174] Mutational analysis of proapoptotic ARTS P-loop domain in common human cancers.Pathol Res Pract. 2006;202(2):67-70. doi: 10.1016/j.prp.2005.11.001. Epub 2005 Dec 22.
• [1175] Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.Am J Surg Pathol. 2007 Feb;31(2):161-9. doi: 10.1097/01.pas.0000213335.40358.47.
• [1176] Lung carcinoma progression and survival versus amino- and carboxyl-parathyroid hormone-related protein expression.J Cancer Res Clin Oncol. 2017 Aug;143(8):1395-1407. doi: 10.1007/s00432-017-2396-4. Epub 2017 Mar 25.
• [1177] Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?.Neoplasma. 2007;54(1):57-62.
• [1178] PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle.Am J Pathol. 2003 Mar;162(3):897-905. doi: 10.1016/S0002-9440(10)63885-0.
• [1179] PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker.Med Oncol. 2013;30(3):618. doi: 10.1007/s12032-013-0618-4. Epub 2013 Jun 4.
• [1180] Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.Cancer Res. 1993 May 15;53(10 Suppl):2272-8.
• [1181] Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.Sci Rep. 2015 Apr 24;5:9633. doi: 10.1038/srep09633.
• [1182] Mutational analysis of PTPRT phosphatase domains in common human cancers.APMIS. 2007 Jan;115(1):47-51. doi: 10.1111/j.1600-0463.2007.apm_554.x.
• [1183] Contribution of the PI3K/MMPs/Ln-52 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas.Int J Oncol. 2013 Jun;42(6):2103-15. doi: 10.3892/ijo.2013.1897. Epub 2013 Apr 15.
• [1184] Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.Breast Cancer Res. 2018 Aug 2;20(1):83. doi: 10.1186/s13058-018-1018-7.
• [1185] Genomic instability and oncogene amplifications in colorectal adenomas predict recurrence and synchronous carcinoma.Mod Pathol. 2011 Apr;24(4):542-55. doi: 10.1038/modpathol.2010.217. Epub 2010 Nov 19.
• [1186] Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses.Eur J Endocrinol. 2004 Apr;150(4):547-56. doi: 10.1530/eje.0.1500547.
• [1187] HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma.Cancer Res. 1999 May 1;59(9):2023-8.
• [1188] Implications of a RAD54L polymorphism (2290C/T) in human meningiomas as a risk factor and/or a genetic marker.BMC Cancer. 2003 Mar 4;3:6. doi: 10.1186/1471-2407-3-6. Epub 2003 Mar 4.
• [1189] Rap2B promotes migration and invasion of human suprarenal epithelioma.Tumour Biol. 2014 Sep;35(9):9387-94. doi: 10.1007/s13277-014-2174-8. Epub 2014 Jun 21.
• [1190] Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma.Mod Pathol. 2015 Aug;28(8):1023-32. doi: 10.1038/modpathol.2015.60. Epub 2015 May 29.
• [1191] RbAp48 is a target of nuclear factor-kappaB activity in thyroid cancer.J Clin Endocrinol Metab. 2007 Apr;92(4):1458-66. doi: 10.1210/jc.2006-2199. Epub 2007 Jan 23.
• [1192] Expression and function of retinoblastoma binding protein 6 (RBBP6) in human lung cancer.Immunobiology. 2011 Oct;216(10):1065-73. doi: 10.1016/j.imbio.2011.05.004. Epub 2011 May 17.
• [1193] miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.Mol Cancer Res. 2013 Nov;11(11):1314-25. doi: 10.1158/1541-7786.MCR-13-0131. Epub 2013 Sep 17.
• [1194] Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells.Am J Pathol. 2003 Nov;163(5):1781-90. doi: 10.1016/S0002-9440(10)63538-9.
• [1195] Mammary carcinoma suppression by cellular retinoic acid binding protein-II.Cancer Res. 2003 Aug 1;63(15):4426-33.
• [1196] Regulator of chromatin condensation 1 abrogates the G1 cell cycle checkpoint via Cdk1 in human papillomavirus E7-expressing epithelium and cervical cancer cells.Cell Death Dis. 2018 May 22;9(6):583. doi: 10.1038/s41419-018-0584-z.
• [1197] Regulation of p27 by ubiquitin ligases and its pathological significance in human lung carcinomas.Hum Pathol. 2017 Aug;66:67-78. doi: 10.1016/j.humpath.2017.05.022. Epub 2017 Jun 7.
• [1198] Deletions of N33, STK11 and TP53 are involved in the development of lymph node metastasis in larynx and pharynx carcinomas.Cell Oncol. 2007;29(4):327-34. doi: 10.1155/2007/635962.
• [1199] The roles of JK-1 (FAM134B) expressions in colorectal cancer.Exp Cell Res. 2014 Aug 1;326(1):166-73. doi: 10.1016/j.yexcr.2014.06.013. Epub 2014 Jun 25.
• [1200] Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol zeta.Oncogene. 2008 Oct 16;27(47):6093-101. doi: 10.1038/onc.2008.212. Epub 2008 Jul 14.
• [1201] Genetic alterations of the p16 gene in urothelial carcinoma in Taiwanese patients.BJU Int. 2000 Jan;85(1):143-9. doi: 10.1046/j.1464-410x.2000.00323.x.
• [1202] RHOBTB3 promotes proteasomal degradation of HIF through facilitating hydroxylation and suppresses the Warburg effect.Cell Res. 2015 Sep;25(9):1025-42. doi: 10.1038/cr.2015.90. Epub 2015 Jul 28.
• [1203] Mina53, a novel molecular marker for the diagnosis and prognosis of gastric adenocarcinoma.Oncol Rep. 2014 Feb;31(2):634-40. doi: 10.3892/or.2013.2918. Epub 2013 Dec 12.
• [1204] Improvement of tissue preparation for laser capture microdissection: application for cell type-specific miRNA expression profiling in colorectal tumors.BMC Genomics. 2010 Mar 10;11:163. doi: 10.1186/1471-2164-11-163.
• [1205] The novel protein PTPIP51 is expressed in human keratinocyte carcinomas and their surrounding stroma.J Cell Mol Med. 2008 Oct;12(5B):2083-95. doi: 10.1111/j.1582-4934.2008.00198.x.
• [1206] Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas.Dig Dis Sci. 1996 Jun;41(6):1069-75. doi: 10.1007/BF02088221.
• [1207] A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling.Cancers (Basel). 2019 Feb 22;11(2):255. doi: 10.3390/cancers11020255.
• [1208] Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.BMC Cancer. 2018 Oct 26;18(1):1045. doi: 10.1186/s12885-018-4917-1.
• [1209] Ribosomal protein l19 is a prognostic marker for human prostate cancer.Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2061-5. doi: 10.1158/1078-0432.CCR-05-2445.
• [1210] Ubiquitin fusion proteins are overexpressed in colon cancer but not in gastric cancer.Biochim Biophys Acta. 1995 Dec 12;1272(3):147-53. doi: 10.1016/0925-4439(95)00079-8.
• [1211] Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.Hum Pathol. 2011 Feb;42(2):214-26. doi: 10.1016/j.humpath.2010.05.025. Epub 2010 Oct 30.
• [1212] RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma.Diagn Pathol. 2019 Jan 26;14(1):7. doi: 10.1186/s13000-019-0784-6.
• [1213] Restricted expression of calcium-binding protein S100A5 in human kidney.Biochem Biophys Res Commun. 2002 Mar 1;291(3):623-7. doi: 10.1006/bbrc.2002.6494.
• [1214] Psoriasin (S100A7) up-regulation in oral squamous cell carcinoma and its relation to clinicopathologic features.Oral Oncol. 2009 Aug;45(8):731-6. doi: 10.1016/j.oraloncology.2008.11.012. Epub 2009 Jan 14.
• [1215] MiR-34a inhibits the proliferation, migration, and invasion of oral squamous cell carcinoma by directly targeting SATB2.J Cell Physiol. 2020 May;235(5):4856-4864. doi: 10.1002/jcp.29363. Epub 2019 Oct 29.
• [1216] Genetic detection for micrometastasis in lymph node of biliary tract carcinoma.Clin Cancer Res. 2000 Jun;6(6):2326-32.
• [1217] The SNAIL family member SCRATCH1 is not expressed in human tumors.Oncol Rep. 2010 Feb;23(2):523-9.
• [1218] Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease.Br J Cancer. 2009 May 19;100(10):1534-9. doi: 10.1038/sj.bjc.6605045. Epub 2009 Apr 21.
• [1219] Sec62/Ki67 and p16/Ki67 dual-staining immunocytochemistry in vulvar cytology for the identification of vulvar intraepithelial neoplasia and vulvar cancer: a pilot study.Arch Gynecol Obstet. 2019 Mar;299(3):825-833. doi: 10.1007/s00404-018-5021-0. Epub 2019 Jan 4.
• [1220] Identification of a novel role of Septin 10 in paclitaxel-resistance in cancers through a functional genomics screen.Cancer Sci. 2012 Apr;103(4):821-7. doi: 10.1111/j.1349-7006.2012.02221.x. Epub 2012 Mar 4.
• [1221] Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression.Breast Cancer Res. 2011 Aug 10;13(4):R76. doi: 10.1186/bcr2924.
• [1222] Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.Gynecol Oncol. 2000 Nov;79(2):244-50. doi: 10.1006/gyno.2000.5959.
• [1223] The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types.Radiother Oncol. 2015 Sep;116(3):346-51. doi: 10.1016/j.radonc.2015.06.028. Epub 2015 Jul 10.
• [1224] Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.Asian J Androl. 2014 Mar-Apr;16(2):319-24. doi: 10.4103/1008-682X.122812.
• [1225] Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.Int J Mol Med. 2006 Oct;18(4):547-57.
• [1226] Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.Mol Cancer. 2008 Nov 6;7:83. doi: 10.1186/1476-4598-7-83.
• [1227] Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas.Pathology. 2006 Aug;38(4):312-5. doi: 10.1080/00313020600820880.
• [1228] SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas.J Biol Chem. 2011 Jul 1;286(26):23003-11. doi: 10.1074/jbc.M111.244152. Epub 2011 May 9.
• [1229] Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14211-6. doi: 10.1073/pnas.1409580111. Epub 2014 Sep 15.
• [1230] Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors.Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4760-5. doi: 10.1073/pnas.0831000100. Epub 2003 Apr 3.
• [1231] The pluripotent renal stem cell regulator SIX2 is activated in renal neoplasms and influences cellular proliferation and migration.Hum Pathol. 2013 Mar;44(3):336-45. doi: 10.1016/j.humpath.2012.05.021. Epub 2012 Sep 17.
• [1232] Decreased expression of the mitochondrial solute carrier SLC25A43 in basal cell carcinoma compared with healthy skin.Oncol Lett. 2017 Aug;14(2):2218-2222. doi: 10.3892/ol.2017.6452. Epub 2017 Jun 21.
• [1233] Heme and FLVCR-related transporter families SLC48 and SLC49. Mol Aspects Med. 2013 Apr-Jun;34(2-3):669-82.
• [1234] The cohesin SMC3 is a target the for beta-catenin/TCF4 transactivation pathway.J Biol Chem. 2003 May 30;278(22):20259-67. doi: 10.1074/jbc.M209511200. Epub 2003 Mar 21.
• [1235] The miR-203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK-3/-CATENIN signal pathway.IUBMB Life. 2018 Mar;70(3):224-236. doi: 10.1002/iub.1720. Epub 2018 Feb 1.
• [1236] Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.Cancer Res. 1996 Apr 15;56(8):1823-7.
• [1237] Sorting nexin 1 down-regulation promotes colon tumorigenesis.Clin Cancer Res. 2006 Dec 1;12(23):6952-9. doi: 10.1158/1078-0432.CCR-06-0317.
• [1238] Favorable prognostic value of SOCS2 and IGF-I in breast cancer.BMC Cancer. 2007 Jul 25;7:136. doi: 10.1186/1471-2407-7-136.
• [1239] A human bone morphogenetic protein antagonist is down-regulated in renal cancer.Mol Biol Cell. 2008 Feb;19(2):457-64. doi: 10.1091/mbc.e07-05-0433. Epub 2007 Nov 21.
• [1240] SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue.Virchows Arch. 2019 Jun;474(6):667-672. doi: 10.1007/s00428-019-02557-1. Epub 2019 Mar 23.
• [1241] SOX11: a potentially useful marker in surgical pathology: a systematic analysis of SOX11 expression in epithelial and non-epithelial tumours.Histopathology. 2019 Feb;74(3):391-405. doi: 10.1111/his.13757. Epub 2018 Dec 2.
• [1242] Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy.Cancer Lett. 2018 May 1;421:161-169. doi: 10.1016/j.canlet.2018.02.017. Epub 2018 Feb 13.
• [1243] Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years.J Clin Endocrinol Metab. 2006 Feb;91(2):607-13. doi: 10.1210/jc.2005-1967. Epub 2005 Nov 22.
• [1244] Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma.Int J Mol Sci. 2019 Apr 3;20(7):1653. doi: 10.3390/ijms20071653.
• [1245] Drosophila split ends homologue SHARP functions as a positive regulator of Wnt/beta-catenin/T-cell factor signaling in neoplastic transformation.Cancer Res. 2007 Jan 15;67(2):482-91. doi: 10.1158/0008-5472.CAN-06-2314.
• [1246] Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.Cancer Res. 2000 Nov 1;60(21):6148-59.
• [1247] Loss of heterozygosity on chromosome 1q in human breast cancer.Proc Natl Acad Sci U S A. 1989 Sep;86(18):7204-7. doi: 10.1073/pnas.86.18.7204.
• [1248] Expression of serum response factor in gastric carcinoma and its molecular mechanisms involved in the regulation of the invasion and migration of SGC-7901 cells.Cancer Biother Radiopharm. 2013 Mar;28(2):146-52. doi: 10.1089/cbr.2012.1265. Epub 2012 Nov 7.
• [1249] -Galactoside 2,6-sialyltranferase 1 promotes transforming growth factor--mediated epithelial-mesenchymal transition.J Biol Chem. 2014 Dec 12;289(50):34627-41. doi: 10.1074/jbc.M114.593392. Epub 2014 Oct 24.
• [1250] Somatic mutation analysis of p53 and ST7 tumor suppressor genes in gastric carcinoma by DHPLC.World J Gastroenterol. 2003 Dec;9(12):2662-5. doi: 10.3748/wjg.v9.i12.2662.
• [1251] STAG2 loss of expression is rare in aneuploid malignant salivary gland neoplasms.J Oral Pathol Med. 2014 Apr;43(4):273-5. doi: 10.1111/jop.12127.
• [1252] Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth.Oncogene. 2007 Jul 5;26(31):4580-9. doi: 10.1038/sj.onc.1210244. Epub 2007 Feb 5.
• [1253] Expression and transcriptional profiling of the LKB1 tumor suppressor in cervical cancer cells.Gynecol Oncol. 2014 Aug;134(2):372-8. doi: 10.1016/j.ygyno.2014.04.050. Epub 2014 May 2.
• [1254] Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.Am J Pathol. 2010 Aug;177(2):930-42. doi: 10.2353/ajpath.2010.090769. Epub 2010 Jun 17.
• [1255] Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions.Cancer Prev Res (Phila). 2014 Dec;7(12):1251-7. doi: 10.1158/1940-6207.CAPR-14-0237. Epub 2014 Oct 3.
• [1256] Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival.Clin Cancer Res. 2008 Mar 1;14(5):1494-501. doi: 10.1158/1078-0432.CCR-07-1066.
• [1257] Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.Front Oncol. 2018 May 3;8:143. doi: 10.3389/fonc.2018.00143. eCollection 2018.
• [1258] Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.Hepatology. 2007 Jan;45(1):42-52. doi: 10.1002/hep.21467.
• [1259] Expression of TDRD9 in a subset of lung carcinomas by CpG island hypomethylation protects from DNA damage.Oncotarget. 2017 Nov 27;9(11):9618-9631. doi: 10.18632/oncotarget.22709. eCollection 2018 Feb 9.
• [1260] STT3A, C1orf24, TFF3: putative markers for characterization of follicular thyroid neoplasms from fine-needle aspirates.Laryngoscope. 2011 May;121(5):983-9. doi: 10.1002/lary.21736.
• [1261] The expression of TLR pathway molecules in peripheral blood mononuclear cells and their relationship with tumor invasion and cytokine secretion in laryngeal carcinoma.Adv Med Sci. 2012 Jun 1;57(1):124-35. doi: 10.2478/v10039-011-0058-3.
• [1262] Methylation of the TFPI2 gene is frequently detected in advanced gastric carcinoma.Anticancer Res. 2010 Oct;30(10):4131-3.
• [1263] zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells.Int J Cancer. 1999 Oct 29;83(3):349-58. doi: 10.1002/(sici)1097-0215(19991029)83:3<349::aid-ijc10>3.0.co;2-c.
• [1264] Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours.J Pathol. 2008 Jan;214(1):46-57. doi: 10.1002/path.2252.
• [1265] Lack of rearranged Tpr-met mRNA expression in human gastric cancer cell lines and gastric mucosa and carcinoma.Anticancer Res. 1996 Sep-Oct;16(5A):2881-4.
• [1266] Tumor suppressor NGX6 inhibits the growth and metastasis of multiple cancers.Tumour Biol. 2016 May;37(5):5751-60. doi: 10.1007/s13277-016-4966-5. Epub 2016 Feb 15.
• [1267] Thymopoietin Beta and Gamma Isoforms as a Potential Diagnostic Molecular Marker for Breast Cancer: Preliminary Data.Pathol Oncol Res. 2015 Sep;21(4):1045-50. doi: 10.1007/s12253-015-9907-x. Epub 2015 Apr 4.
• [1268] Ovarian tumor cells express a novel multi-domain cell surface serine protease.Biochim Biophys Acta. 2000 Nov 15;1502(3):337-50. doi: 10.1016/s0925-4439(00)00058-2.
• [1269] Hypomethylation of the thymosin (10) gene is not associated with its overexpression in non-small cell lung cancer.Mol Cells. 2011 Oct;32(4):343-8. doi: 10.1007/s10059-011-0073-z. Epub 2011 Oct 17.
• [1270] Clinical significance of expression and amplification of the DcR3 gene in pancreatic carcinomas.Asian Pac J Cancer Prev. 2012;13(2):719-24. doi: 10.7314/apjcp.2012.13.2.719.
• [1271] Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage.J Ovarian Res. 2019 Mar 27;12(1):30. doi: 10.1186/s13048-019-0498-0.
• [1272] TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection.Hum Pathol. 2018 Sep;79:93-101. doi: 10.1016/j.humpath.2018.05.008. Epub 2018 May 21.
• [1273] Expression of p53 family genes in urinary bladder cancer: correlation with disease aggressiveness and recurrence.Tumour Biol. 2014 Mar;35(3):2481-9. doi: 10.1007/s13277-013-1328-4. Epub 2013 Nov 11.
• [1274] Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: clinical and sample considerations.Leuk Res. 2006 Nov;30(11):1355-63. doi: 10.1016/j.leukres.2006.03.009. Epub 2006 Apr 18.
• [1275] Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma.Anal Cell Pathol. 2000;21(1):1-9. doi: 10.1155/2000/351963.
• [1276] TRAF4 overexpression is a common characteristic of human carcinomas.Oncogene. 2007 Jan 4;26(1):142-7. doi: 10.1038/sj.onc.1209762. Epub 2006 Jun 26.
• [1277] A human tRNA methyltransferase 9-like protein prevents tumour growth by regulating LIN9 and HIF1-.EMBO Mol Med. 2013 Mar;5(3):366-83. doi: 10.1002/emmm.201201161. Epub 2013 Feb 4.
• [1278] Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.Mod Pathol. 1999 Dec;12(12):1083-9.
• [1279] E-cadherin/p120-catenin and tetraspanin Co-029 cooperate for cell motility control in human colon carcinoma.Cancer Res. 2010 Oct 1;70(19):7674-83. doi: 10.1158/0008-5472.CAN-09-4482. Epub 2010 Sep 21.
• [1280] E3B1/ABI-1 isoforms are down-regulated in cancers of human gastrointestinal tract.Dis Markers. 2012;32(4):273-9. doi: 10.3233/DMA-2011-0881.
• [1281] ALKBH3 contributes to survival and angiogenesis of human urothelial carcinoma cells through NADPH oxidase and tweak/Fn14/VEGF signals.Clin Cancer Res. 2012 Oct 1;18(19):5247-55. doi: 10.1158/1078-0432.CCR-12-0955. Epub 2012 Jul 31.
• [1282] Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma.Hum Pathol. 2014 Jun;45(6):1285-93. doi: 10.1016/j.humpath.2014.02.008. Epub 2014 Feb 28.
• [1283] Ezrin Is Associated with Disease Progression in Ovarian Carcinoma.PLoS One. 2016 Sep 13;11(9):e0162502. doi: 10.1371/journal.pone.0162502. eCollection 2016.
• [1284] Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma.Int J Colorectal Dis. 2012 Nov;27(11):1391-9. doi: 10.1007/s00384-012-1460-4. Epub 2012 Mar 23.
• [1285] The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance.Oncotarget. 2016 Dec 13;7(50):82783-82797. doi: 10.18632/oncotarget.12635.
• [1286] Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors.Am J Pathol. 1998 Nov;153(5):1579-88. doi: 10.1016/S0002-9440(10)65746-X.
• [1287] Downregulated inhibitor of growth 3 (ING3) expression during colorectal carcinogenesis.Indian J Med Res. 2014 Apr;139(4):561-7.
• [1288] Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.J Clin Endocrinol Metab. 2013 Mar;98(3):E586-94. doi: 10.1210/jc.2012-3490. Epub 2013 Feb 5.
• [1289] MPP3 inactivation by promoter CpG islands hypermethylation in colorectal carcinogenesis.Cancer Biomark. 2012;11(2-3):99-106. doi: 10.3233/CBM-2012-0264.
• [1290] Microsatellite instability in multifocal urothelial carcinoma and effect on BAX and AXIN2.Can J Urol. 2003 Oct;10(5):2000-6.
• [1291] Potential role of a navigator gene NAV3 in colorectal cancer.Br J Cancer. 2012 Jan 31;106(3):517-24. doi: 10.1038/bjc.2011.553. Epub 2011 Dec 15.
• [1292] Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.Eur J Cancer. 2011 May;47(7):1106-14. doi: 10.1016/j.ejca.2010.12.025. Epub 2011 Jan 25.
• [1293] PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer.Genes Chromosomes Cancer. 2000 Mar;27(3):332-6. doi: 10.1002/(sici)1098-2264(200003)27:3<332::aid-gcc15>3.0.co;2-k.
• [1294] CRBP-1 expression in ovarian cancer: a potential therapeutic target.Anticancer Res. 2014 Jul;34(7):3303-12.
• [1295] MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/-catenin pathway and interaction with SNAIL promoter.Cancer Lett. 2014 May 1;346(2):225-36. doi: 10.1016/j.canlet.2013.12.029. Epub 2013 Dec 30.
• [1296] DNA methylation biomarker candidates for early detection of colon cancer.Tumour Biol. 2012 Apr;33(2):363-72. doi: 10.1007/s13277-011-0302-2. Epub 2012 Jan 12.
• [1297] Frequent TLE1 Expression in Cutaneous Neoplasms.Am J Dermatopathol. 2019 Jan;41(1):1-6. doi: 10.1097/DAD.0000000000001186.
• [1298] Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.Anticancer Res. 2004 Sep-Oct;24(5A):2745-56.